
<html lang="en"     class="pb-page"  data-request-id="b4f4f41c-d5d1-4977-96c2-f460a880c164"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2012.55.issue-8;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm300042x;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of the Novel Potent and Selective FLT3 Inhibitor 1-{5-[7-(3- Morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and Its Anti-Acute Myeloid Leukemia (AML) Activities in Vitro and in Vivo" /></meta><meta name="dc.Creator" content="Wei-Wei  Li" /></meta><meta name="dc.Creator" content="Xiao-Yan  Wang" /></meta><meta name="dc.Creator" content="Ren-Lin  Zheng" /></meta><meta name="dc.Creator" content="Heng-Xiu  Yan" /></meta><meta name="dc.Creator" content="Zhi-Xing  Cao" /></meta><meta name="dc.Creator" content="Lei  Zhong" /></meta><meta name="dc.Creator" content="Ze-Rong  Wang" /></meta><meta name="dc.Creator" content="Pan  Ji" /></meta><meta name="dc.Creator" content="Ling-Ling  Yang" /></meta><meta name="dc.Creator" content="Li-Jiao  Wang" /></meta><meta name="dc.Creator" content="Yong  Xu" /></meta><meta name="dc.Creator" content="Jing-Jing  Liu" /></meta><meta name="dc.Creator" content="Jiao  Yang" /></meta><meta name="dc.Creator" content="Chun-Hui  Zhang" /></meta><meta name="dc.Creator" content="Shuang  Ma" /></meta><meta name="dc.Creator" content="Shan  Feng" /></meta><meta name="dc.Creator" content="Qi-Zheng  Sun" /></meta><meta name="dc.Creator" content="Yu-Quan  Wei" /></meta><meta name="dc.Creator" content="Sheng-Yong  Yang" /></meta><meta name="dc.Description" content="Structure–activity relationship (SAR) studies of 2-(quinazolin-4-ylthio)thiazole derivatives, which are for optimizing the in vitro and in vivo antiacute myeloid leukemia (AML) activity of a previo..." /></meta><meta name="Description" content="Structure–activity relationship (SAR) studies of 2-(quinazolin-4-ylthio)thiazole derivatives, which are for optimizing the in vitro and in vivo antiacute myeloid leukemia (AML) activity of a previo..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 6, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm300042x" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm300042x" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm300042x" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm300042x" /></link>
        
    
    

<title>Discovery of the Novel Potent and Selective FLT3 Inhibitor 1-{5-[7-(3- Morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and Its Anti-Acute Myeloid Leukemia (AML) Activities in Vitro and in Vivo | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm300042x" /></meta><meta property="og:title" content="Discovery of the Novel Potent and Selective FLT3 Inhibitor 1-{5-[7-(3- Morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and Its Anti-Acute Myeloid Leukemia (AML) Activities in Vitro and in Vivo" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0009.jpeg" /></meta><meta property="og:description" content="Structure–activity relationship (SAR) studies of 2-(quinazolin-4-ylthio)thiazole derivatives, which are for optimizing the in vitro and in vivo antiacute myeloid leukemia (AML) activity of a previously identified FLT3 inhibitor 2-(6,7-dimethoxyquinazolin-4-ylthio)thiazole (1), are described. SAR studies centering around the head (thiazole) and tails (6- and 7-positions) of the quinazoline moiety of 1 led to the discovery of a series of compounds that exhibited significantly increased potency against FLT3-driven AML MV4-11 cells. Preliminary in vivo assays were carried out on three highly active compounds, whose results showed that 1-{5-[7-(3-morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea (20c) had the highest in vivo activity. Further in vitro and in vivo anti-AML studies were then performed on 20c; in an MV4-11 xenograft mouse model, a once-daily dose of 20c at 100 mg/kg for 18 days led to complete tumor regression without obvious toxicity. Western blot and immunohistochemical analysis were carried out to illustrate the mechanism of action of 20c." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm300042x"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm300042x">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm300042x&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm300042x&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm300042x&amp;href=/doi/10.1021/jm300042x" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 3852-3866</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm300037x" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm300070h" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of the Novel Potent and Selective FLT3 Inhibitor 1-{5-[7-(3- Morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-<i>p</i>-tolylurea and Its Anti-Acute Myeloid Leukemia (AML) Activities <i>in Vitro</i> and <i>in Vivo</i></span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei-Wei++Li">Wei-Wei Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiao-Yan++Wang">Xiao-Yan Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ren-Lin++Zheng">Ren-Lin Zheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Heng-Xiu++Yan">Heng-Xiu Yan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhi-Xing++Cao">Zhi-Xing Cao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Zhong">Lei Zhong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ze-Rong++Wang">Ze-Rong Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pan++Ji">Pan Ji</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ling-Ling++Yang">Ling-Ling Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li-Jiao++Wang">Li-Jiao Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Xu">Yong Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing-Jing++Liu">Jing-Jing Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiao++Yang">Jiao Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chun-Hui++Zhang">Chun-Hui Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shuang++Ma">Shuang Ma</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shan++Feng">Shan Feng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qi-Zheng++Sun">Qi-Zheng Sun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yu-Quan++Wei">Yu-Quan Wei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sheng-Yong++Yang">Sheng-Yong Yang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">College of Chemical Engineering, Sichuan University, Sichuan 610041, China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">West China School of Pharmacy, Sichuan University, Sichuan 610041, China</span></div><div class="corresp-info"><strong>*</strong>Tel: +86-28-85164063. Fax: +86-28-85164060. E-mail: <a href="/cdn-cgi/l/email-protection#750c141b12060c350616005b1011005b161b"><span class="__cf_email__" data-cfemail="a5dcc4cbc2d6dce5d6c6d08bc0c1d08bc6cb">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm300042x&amp;href=/doi/10.1021%2Fjm300042x" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 3852–3866</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 27, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 January 2012</li><li><span class="item_label"><b>Published</b> online</span>6 April 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 April 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm300042x" title="DOI URL">https://doi.org/10.1021/jm300042x</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3852%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWei-Wei%2BLi%252C%2BXiao-Yan%2BWang%252C%2BRen-Lin%2BZheng%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D8%26contentID%3Djm300042x%26title%3DDiscovery%2Bof%2Bthe%2BNovel%2BPotent%2Band%2BSelective%2BFLT3%2BInhibitor%2B1-%257B5-%255B7-%25283-%2BMorpholinopropoxy%2529quinazolin-4-ylthio%255D-%255B1%252C3%252C4%255Dthiadiazol-2-yl%257D-3-p-tolylurea%2Band%2BIts%2BAnti-Acute%2BMyeloid%2BLeukemia%2B%2528AML%2529%2BActivities%2Bin%2BVitro%2Band%2Bin%2BVivo%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3866%26publicationDate%3DApril%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm300042x"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2722</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">29</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm300042x" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of the Novel Potent and Selective FLT3 Inhibitor 1-{5-[7-(3- Morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and Its Anti-Acute Myeloid Leukemia (AML) Activities in Vitro and in Vivo&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Wei-Wei&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Xiao-Yan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Ren-Lin&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Heng-Xiu&quot;,&quot;last_name&quot;:&quot;Yan&quot;},{&quot;first_name&quot;:&quot;Zhi-Xing&quot;,&quot;last_name&quot;:&quot;Cao&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Zhong&quot;},{&quot;first_name&quot;:&quot;Ze-Rong&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Pan&quot;,&quot;last_name&quot;:&quot;Ji&quot;},{&quot;first_name&quot;:&quot;Ling-Ling&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Li-Jiao&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Jing-Jing&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Jiao&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Chun-Hui&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Shuang&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Shan&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Qi-Zheng&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Yu-Quan&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Sheng-Yong&quot;,&quot;last_name&quot;:&quot;Yang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;06&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;3852-3866&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm300042x&quot;},&quot;abstract&quot;:&quot;Structure–activity relationship (SAR) studies of 2-(quinazolin-4-ylthio)thiazole derivatives, which are for optimizing the in vitro and in vivo antiacute myeloid leukemia (AML) activity of a previously identified FLT3 inhibitor 2-(6,7-dimethoxyquinazolin-4-ylthio)thiazole (1), are described. SAR studies centering around the head (thiazole) and tails (6- and 7-positions) of the quinazoline moiety of 1 led to the discovery of a series of compounds that exhibited significantly increased potency against FLT3-driven AML MV4-11 cells. Preliminary in vivo assays were carried out on three highly active compounds, whose results showed that 1-{5-[7-(3-morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea (20c) had the highest in vivo activity. Further in vitro and in vivo anti-AML studies were then performed on 20c; in an MV4-11 xenograft mouse model, a once-daily dose of 20c at 100 mg/kg for 18 days led to complete tumor regression without obvious toxicity. Western blot and immunohistochemical a&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300042x&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300042x" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300042x&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300042x" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300042x&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300042x" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm300042x&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300042x&amp;href=/doi/10.1021/jm300042x" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm300042x" /></input><a href="/doi/pdf/10.1021/jm300042x" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm300042x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm300042x%26sid%3Dliteratum%253Aachs%26pmid%3D22452518%26genre%3Darticle%26aulast%3DLi%26date%3D2012%26atitle%3DDiscovery%2Bof%2Bthe%2BNovel%2BPotent%2Band%2BSelective%2BFLT3%2BInhibitor%2B1-%257B5-%255B7-%25283-%2BMorpholinopropoxy%2529quinazolin-4-ylthio%255D-%255B1%252C3%252C4%255Dthiadiazol-2-yl%257D-3-p-tolylurea%2Band%2BIts%2BAnti-Acute%2BMyeloid%2BLeukemia%2B%2528AML%2529%2BActivities%2Bin%2BVitro%2Band%2Bin%2BVivo%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D8%26spage%3D3852%26epage%3D3866%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jmcmar.2012.55.issue-8/production/jmcmar.2012.55.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Structure–activity relationship (SAR) studies of 2-(quinazolin-4-ylthio)thiazole derivatives, which are for optimizing the <i>in vitro</i> and <i>in vivo</i> antiacute myeloid leukemia (AML) activity of a previously identified FLT3 inhibitor 2-(6,7-dimethoxyquinazolin-4-ylthio)thiazole (<b>1</b>), are described. SAR studies centering around the head (thiazole) and tails (6- and 7-positions) of the quinazoline moiety of <b>1</b> led to the discovery of a series of compounds that exhibited significantly increased potency against FLT3-driven AML MV4-11 cells. Preliminary <i>in vivo</i> assays were carried out on three highly active compounds, whose results showed that 1-{5-[7-(3-morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-<i>p</i>-tolylurea (<b>20c</b>) had the highest <i>in vivo</i> activity. Further <i>in vitro</i> and <i>in vivo</i> anti-AML studies were then performed on <b>20c</b>; in an MV4-11 xenograft mouse model, a once-daily dose of <b>20c</b> at 100 mg/kg for 18 days led to complete tumor regression without obvious toxicity. Western blot and immunohistochemical analysis were carried out to illustrate the mechanism of action of <b>20c</b>.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote"><h4><span>∥</span> Author Contributions</h4><p class="last">These authors contributed equally to this work.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68555" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68555" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">FMS-like tyrosine kinase 3 (FLT3), a member of the class III receptor tyrosine kinase family, has been demonstrated to play an important role in the proliferation, differentiation, and apoptosis of hematopoietic cells.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> Typically, FLT3 is activated upon the binding of the FLT3 ligand, which subsequently activates multiple downstream signaling pathways, including signal transducer and activator of transcription 5 (STAT5), Ras/mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase (PI3K)/AKT pathways. Activating mutations in FLT3 kinase are found in up to 1/3 of acute myeloid leukemia (AML) cases.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> The most prevalent activating mutation is “internal tandem duplications” (ITD) in the juxtamembrane domain that leads to constitutive, ligand-independent activation of the kinase. The prognosis for AML patients with FLT3-ITD mutations is significantly worse than that for patients with wt-FLT3 (wild-type FLT3) when treated with standard therapy.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6-8)</a> In addition, activating point mutations in the kinase activation loop of FLT3 are found in another subset of AML patients,<a onclick="showRef(event, 'ref6 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref6 ref9 ref10 ref11">(6, 9-11)</a> which are also associated with a poor prognosis for overall survival. Thus, FLT3 has been considered as a potential molecular target in the treatment of AML.</div><div class="NLM_p">Because of the therapeutic values in AML, the discovery of FLT3 inhibitors has increasingly attracted much attention in recent years. To date, several FLT3 inhibitors including SU-5416,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> SU-11248,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> CHIR-258,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> PKC-412,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> CEP-701,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> MLN-518,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> BAY-43-9006,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> KW-2449,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and AC220<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> have been advanced to clinical trials. However, except for very few of them, such as AC220, the clinical efficacy of most of these FLT3 inhibitors in patients with AML seems unimpressive, mainly because of their potency and/or adverse events that stem from their poor target selectivity. A survey analysis of FLT3 inhibitors that are currently in clinical trials made by us indicated that most of these inhibitors were not initially screened for sensitivity and selectivity against the FLT3 kinase but found an extra inhibitory potency against FLT3 in addition to the targeting of their designated kinases (see Table S1 in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>).<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21-23)</a> Therefore, the discovery and development of the next generation of novel FLT3 inhibitors with higher potency and better selectivity are strongly demanded at the present time.</div><div class="NLM_p">As a part of the efforts in discovering more potent and selective FLT3 inhibitors for the treatment of AML, we recently found a new lead compound, namely, 2-(6,7-dimethoxyquinazolin-4-ylthio)thiazole (<b>1</b>), with the aid of a restricted <i>de novo</i> design strategy proposed by us.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Compound <b>1</b> has a considerable inhibitory potency against FLT3 kinase with a half maximal inhibitory concentration (IC<sub>50</sub>) of 0.007 μM. In addition, compound <b>1</b> also displayed a good selectivity for FLT3 against a panel of selected human kinases (see Table S2 in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>). Unfortunately, <b>1</b> showed poor antitumor activities <i>in vitro</i> and <i>in vivo</i> in models of FLT3-driven AML; the IC<sub>50</sub> value against the human AML cell line MV4-11, which is a typical FLT3-ITD-expressing and a FLT3-driven AML cell line, is 1.14 μM, and the tumor inhibitory rate is less than 50% in its maximum dose in an MV4-11 xenograft model. The purpose here is to carry out a structural modification to optimize the <i>in vitro</i> and <i>in vivo</i> anti-AML activity of <b>1</b>. A series of novel 2-(quinazolin-4-ylthio)thiazole derivatives were synthesized and tested for their <i>in vitro</i> anti-AML activity. The most potent derivatives were then subjected to an <i>in vivo</i> assay in a mouse xenograft model of AML. Finally, a drug candidate, <b>20c</b>, which shows considerable <i>in vitro</i> and <i>in vivo</i> efficacy in models of FLT3-driven AML, was identified. In this account, we report the chemical synthesis, and the structure–activity relationship (SAR) of these novel series of compounds as well as <i>in vitro</i> and <i>in vivo</i> anti-AML activities of <b>20c</b>.</div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0011.gif" alt="" id="fx1" /></img></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84764" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84764" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As depicted in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, compounds <b>1</b>, <b>1a</b>–<b>1d</b>, which have identical side chains at the C-6 and C-7 positions of the quinazoline, were prepared by treatment of the commercially available 4-chloro-6,7-dimethoxyquinazoline (<b>2</b>) or 4-chloro-6,7- bis(2-methoxyethoxy)quinazoline (<b>3</b>) with thiazole-2-thiol or its analogues ([1,3,4]thiadiazole-2-thiol and 4-methylthiazole-2-thiol).</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) thiazole-2-thiol, [1,3,4]thiadiazole-2-thiol, or 4-methylthiazole-2-thiol, K<sub>2</sub>CO<sub>3</sub>, 2-butanone, 80 °C, 2–4 h.</p></p></figure><div class="NLM_p">Synthetic routes of 2-(quinazolin-4-ylthio)thiazole derivatives with nonidentical 6- and 7-position side chains are illustrated in Schemes <a class="ref internalNav" href="#sch2" aria-label="2">2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. The production of 6-alkyloxy-7-methyoxyquinazoline analogues <b>8a</b>–<b>e</b> was started from the reaction of commercially available 7-methoxy-4-oxo-3,4-dihydroquinazolin-6-yl acetate (<b>4</b>) with phosphorus oxychloride in the presence of <i>N,N-</i>diethylaniline, which gave 4-chloro-7-methoxyquinazolin-6-yl acetate (<b>5</b>). Substitution of 4-chloride in <b>5</b> by thiazole-2-thiol in basic conditions afforded intermediate 7-methoxy-4-(thiazol-2-ylthio)quinazolin-6-yl acetate (<b>6</b>). Then intermediate <b>6</b> was cleanly hydrolyzed by NH<sub>3</sub>·H<sub>2</sub>O in methanol to obtain 7-methoxy-4-(thiazol-2-ylthio)quinazolin-6-ol (<b>7</b>), which was alkylated with various chloralkanes in the presence of K<sub>2</sub>CO<sub>3</sub> to provide 6-alkyloxy-7-methyoxy analogues <b>8a</b>–<b>e</b>. The synthesis of 6-methoxy-7-alkyloxy analogues <b>13a</b>–<b>d</b> (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>) was commenced with commercially available 6-methoxy-4-oxo-3,4- dihydroquinazolin-7-yl acetate (<b>9</b>) using conditions similar to those for the preparation of <b>8a</b>–<b>e</b> to afford the desired compounds.</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0013.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) phosphorus oxychloride, toluene, <i>N,N-</i>diethylaniline, reflux, 3 h; (b) thiazole-2-thiol, K<sub>2</sub>CO<sub>3</sub>, 2-butanone, 80 °C, 2–4 h; (c) NH<sub>3</sub>·H<sub>2</sub>O, MeOH, rt, 5 h; (d) alkyl halides, K<sub>2</sub>CO<sub>3</sub>, 2-butanone, 85 °C, 6 h.</p></p></figure><figure id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0015.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) phosphorus oxychloride, chloroform, Et<sub>3</sub>N, reflux, overnight; (b) thiazole-2-thiol, K<sub>2</sub>CO<sub>3</sub>, 2-butanone, 80 °C, 4 h; (c) NH<sub>3</sub>·H<sub>2</sub>O, MeOH, rt, 5 h; (d) alkyl halides, K<sub>2</sub>CO<sub>3</sub>, 2-butanone, 85 °C, 6 h.</p></p></figure><div class="NLM_p">The synthesis of analogues <b>15a</b>–<b>o</b> with substitutive groups in the 4- and 5-positions of the thiazole ring is accomplished in a two-step process outlined in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. Commercially available <b>2</b> and <b>3</b> were reacted with 2-(2-mercapto-4-methylthiazol-5-yl)acetic acid or 2-(2-mercaptothiazol-4-yl)acetic acid at reflux under basic conditions in butanone overnight to afford intermediates 4-substitutive-quinazolines <b>14a</b>, <b>14b</b>, and <b>14c</b>. Then, an amidation reaction of intermediates <b>14a</b>, <b>14b</b>, and <b>14c</b> with varieties of substitutive anilines was carried out in the presence of 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and <i>N,N</i>-diisopropylethylamine at reflux for 12–24 h in CH<sub>2</sub>Cl<sub>2</sub> to provide the compounds shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>.</div><figure id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0014.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-(2-mercapto-4-methylthiazol-5-yl)acetic acid or 2-(2-mercaptothiazol-4-yl)acetic acid, 2-butanone, K<sub>2</sub>CO<sub>3</sub>, reflux, overnight; (b) anilines or amines, HOBT, EDCI, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, reflux, 12–24 h.</p></p></figure><div class="NLM_p">Finally, we synthesized a series of the 2-(quinazolin-4-ylthio)-[1,3,4]thiadiazole analogues <b>17a</b>–<b>h</b> and <b>20a</b>–<b>e</b> with the original thiazole ring replaced by the thiadiazole ring (see Schemes <a class="ref internalNav" href="#sch5" aria-label="5">5</a> and <a class="ref internalNav" href="#sch6" aria-label="6">6</a>). The intermediate <b>16a</b> was achieved by reaction of 5-amino-[1,3,4]thiadiazole-2-thiol with acetic anhydride under reflux utilizing the synthetic method as described in ref <a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">25</a>. The intermediate <b>16b</b> was synthesized by an amidation reaction of 5-amino-[1,3,4]thiadiazole-2-thiol with acrylyl chloride in the presence of organic base using the synthetic procedure as described in ref <a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">26</a>. The intermediates <b>16c</b>–<b>i</b> were achieved by the reaction of 5-amino-[1,3,4]thiadiazole-2-thiol with substituent phenyl isocyanates under reflux in an appropriate solvent overnight using the methods described in refs <a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">27</a> and <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">28</a>. Then, intermediates <b>16a</b>–<b>h</b> were reacted with commercially available <b>3</b> in the presence of K<sub>2</sub>CO<sub>3</sub> at 100 °C in <i>N,N-</i>dimethylformamide overnight to provide the 6,7-bis(2-methoxyethoxy) quinazoline analogues <b>17a</b>–<b>h</b> (see Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>). The synthesis of 6-<i>H</i>-7-(3-morpholinopropoxy)quinazoline analogues <b>20a</b>–<b>e</b> was achieved via the intermediate <b>19</b>, which was synthesized starting from commercially available 7-fluoro-3<i>H</i>-quinazolin-4-one (<b>18</b>) (see Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>). The fluoro group of 7-fluoro-3<i>H</i>-quinazolin-4-one was displaced with the anion of 3-morpholinopropan-1-ol at 100 °C in <i>N,N</i>-dimethylformamide overnight to give intermediate quinazolin-4-one (<b>19</b>). The intermediate <b>19</b> was then chlorinated by phosphorus oxychloride in the presence of <i>N,N</i>-diethylaniline followed by substitution with the intermediates <b>16b</b>, <b>c</b>, <b>g</b>, <b>f</b>, and <b>i</b> using the same conditions as those for the preparation of <b>17</b> described in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a> to afford the final products <b>20a</b>–<b>e</b>.</div><figure id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0016.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>N,N</i>-dimethylformamide, K<sub>2</sub>CO<sub>3</sub>, 100 °C, overnight.</p></p></figure><figure id="sch6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0017.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3-morpholinopropan-1-ol, NaH (60%), <i>N,N</i>-dimethylformamide, 100 °C, overnight; (b) (i) phosphorus oxychloride, <i>N,N-</i>diethylaniline, reflux, 3 h; (ii) <b>16</b>, <i>N,N</i>-dimethylformamide, K<sub>2</sub>CO<sub>3</sub>, 100 °C, overnight.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70321" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70321" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Since our intention here is to optimize the functional activities of compound <b>1</b> both <i>in vitro</i> and <i>in vivo</i>, cell-based assays will be used to evaluate the bioactivity of synthesized compounds in the SAR studies.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a> Two cell lines including FLT3-driven MV4-11 and FLT3-independent HCT116 were chosen here; the involvement of HCT116 is for ruling out activity due to non-FLT3 mediated effects (“off target” or cellular toxic effects). Compounds are likely better FLT3 inhibitors if they have high potency against MV4-11 cells but low or no activity against HCT116. It should be pointed out from the start that the SAR obtained from such cell-based assays potentially report a combination of intrinsic activity of compounds against the kinase target modulated by the ability of compounds to permeate the cell wall during the assay. The enzymatic assays were also performed but just on compounds with higher potency at the cellular level. The most active compounds in both enzymatic and cellular levels will be selected for further <i>in vivo</i> experiments to evaluate their anti-AML activity.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Modifications of 6- and 7-Positions of Quinazoline</h3><div class="NLM_p">As previously indicated,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> the 6- and 7-substituents of the quinazoline ring in <b>1</b> extend toward the solvent. The modifications of these positions were thus expected to help to improve the absorption ability of the cells.<a onclick="showRef(event, 'ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31 ref32">(29-32)</a> Our attempts for the modifications of 6- and 7-substituents include increasing the chain length and varying the polarity of the tail. Various derivatives of <b>1</b> together with their bioactivities are presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. Obviously, the modifications of 6- and 7-substituents of the quinazoline ring in <b>1</b> did not bring an increase in inhibitory activities against both MV4-11 and HCT116 cells. We thus started to modify the thiazole head.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. 2-(Quinazolin-4-ylthio)thiazole Derivatives with Different Substituents at the 6- and 7-Positions of Quinazoline Together with Their Antiviability Activity against FLT3-ITD-Expressing MV4-11 Cells and FLT3-Independent HCT116 Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0001.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0002.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div></div><div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Substitutions of 4- and 5-Positions of Thiazole</h3><div class="NLM_p">The modification toward the thiazole head was initiated to substitute the 4- and 5-positions of thiazole with different groups. At first, a single methyl group was introduced to the 4-position of thiazole. The resulting compound <b>1a</b> showed a similar antiproliferative activity against MV4-11 cells and no activity against HCT116 (unless it is necessary, we shall, later on, not mention the activity against HCT116 if there is no activity). We next explored the SAR of 5-position of thiazole; the methyl group was kept at the 4-position of thiazole due to the synthetic accessibility. The different substituents on the 5-position of thiazole (see <b>15a</b>–<b>15e</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) have considerable influence on the antiproliferative activity against MV4-11. The most active compound <b>15c</b>, in which the 5-position substituent is <i>N-</i>[3-(trifluoromethyl)phenyl]propionamide, has an IC<sub>50</sub> value of 0.02 μM against MV4-11. The cellular activity increases more than 50 times relative to that of compound <b>1</b>. We then replaced the methoxy groups at the 6- and 7-positions of the quinazoline ring with longer methoxyethoxy groups, leading to compounds <b>15f</b>–<b>15k</b>. The bioactivities of the series of compounds were not improved, which is consistent with the above result that the modifications of 6- and 7-substituents of the quinazoline ring did not bring an increase in bioactivity. In the series of compounds, the most active compounds <b>15g</b> (IC<sub>50</sub>: 0.025 μM) and <b>15h</b> (IC<sub>50</sub>: 0.027 μM) again correspond to the 5-position substitution of <i>N-</i>[3-(trifluoromethyl)phenyl]propionamide (<b>15g</b>) and its isomer <i>N-</i>[4-(trifluoromethyl)phenyl]propionamide (<b>15h</b>). Lastly, in order to explore the substitution effect of 4-position of thiazole, we synthesized compounds <b>15l</b>–<b>15o</b> that contain different substituents at the 4-position of thiazole. The bioactivity of <b>15l</b>–<b>15o</b> at the cellular level is clearly decreased relative to those of their counterparts <b>15f</b>–<b>15i</b> (see Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). From here, we can conclude that a bulkier substituent on the 5-position of thiazole is of benefit to increasing the bioactivity against MV4-11.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. 2-(Quinazolin-4-ylthio)thiazole Derivatives with Different Substituents at the 4- and 5-Positions of the Thiazole Ring Together with Their Antiviability Activity against FLT3-ITD-Expressing MV4-11 Cells and FLT3-Independent HCT116 Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0003.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0004.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div></div><div></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Replacement of Thiazole with Thiadiazole</h3><div class="NLM_p">In order to further improve the potency, we replaced the thiazole ring with the thiadizole ring based on the bioisosterism.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The first compound (<b>1c</b>) obtained contains a thiadizole head and two methyoxy groups at the 6- and 7-positions of quinazoline. Compound <b>1c</b> has FLT3 kinase inhibitory potency (IC<sub>50</sub> = 0.009 μM) very similar to that of <b>1</b>. The antiproliferative activity (IC<sub>50</sub>) of <b>1c</b> against MV4-11 is 1.20 μM, which is also similar to that of <b>1</b>. We then replaced methyoxy groups at the 6- and 7-positions of quinazoline with methoxyethoxy groups. The resulting compound <b>1d</b> has almost the same bioactivity as <b>1c</b>, which is again consistent with previous observations. We next optimized the thiadiazole head by replacing the 5-position with different substituents containing an amide or urea. We obtained a series of compounds <b>17a</b>–<b>h</b>, of which, <b>17f</b> that contains 3-ethynylphenylurea is the most active compound (IC<sub>50</sub> = 0.005 μM). In order to further optimize the physicochemical properties, we introduced the polar group 4-(3-methoxypropyl) morpholine at the 7-position of quinazoline, which led to <b>20a</b>–<b>e</b> (see Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Obviously, the introduction of a polar group considerably improves the bioactivity at the cellular level. Of special note are <b>20c</b> and <b>20e</b>, whose IC<sub>50</sub> values against MV4-11 are 0.006 μM and 0.0003 μM, respectively (the kinase inhibitory potency against FLT3 is 0.01 μM for <b>20c</b> and 0.006 μM for <b>20e</b>, showing the consistency between cellular and enzymatic activities).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. 2-(Quinazolin-4-ylthio)-1,3,4-thiadiazole Derivatives with Different Substituents at C-6 and C-7 of Quinazoline and the 5-Position of the Thiadiazole Ring Together with Their Anti-vViability Activity against FLT3-ITD-Expressing MV4-11 Cells and FLT3-Independent HCT116 Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0005.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0006.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div></div><div></div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Kinase Inhibition Profile of <b>20c</b></h3><div class="NLM_p">The chemical modifications toward compound <b>1</b> resulted in three compounds (<b>17f</b>, <b>20c</b>, and <b>20e)</b>, which potently inhibited the proliferation of AML MV4-11 cells with IC<sub>50</sub> values less than 0.01 μM but displayed very weak or no inhibitory activity against HCT116, implying that these compounds could possibly have a potential value in the treatment of AML. Thus, the three compounds were selected to carry out preliminary <i>in vivo</i> anti-AML experiments using the MV4-11 tumor xenograft model. Compound <b>20c</b> displayed significant anti-AML potency (see Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>a), while <b>17f</b> and <b>20e</b> just showed very weak tumor inhibitory activity (the tumor inhibition rate is less than 50% at their maximum dose, namely, 50 mg/kg/d, for both of them by intraperitoneal administration). A plausible explanation for this is that <b>20c</b> has better bioavailability relative to <b>17f</b> and <b>20e</b>. Indeed, a comparison of pharmacokinetic profiles of <b>20c</b> and <b>20e</b> showed that <b>20c</b> has much better absorption than <b>20e</b> (<i>C</i><sub>max</sub> values are 5.31 μg/mL for <b>20c</b> and 2.74 μg/mL for <b>20e</b> at a dose of 40 mg/kg by intraperitoneal administration. For details, see Table S3 and Figure S1 in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>). Therefore, further studies on the kinase inhibition profile and anti-AML activity of <b>20c</b> both <i>in vitro</i> and <i>in vivo</i> will be carried out subsequently.</div><div class="NLM_p">Kinase inhibition profiles of <b>20c</b> against a panel of recombinant human protein kinases are shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. Compound <b>20c</b> potently inhibited FLT3 with an IC<sub>50</sub> value of 0.01 μM (see Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>a). It just weakly inhibited Aurora A, FMS, FLT4, and c-Kit (IC<sub>50</sub>s: 1.5 μM, 2.8 μM, 3.7 μM, and 6.8 μM, respectively). Compound <b>20c</b> displayed almost no inhibitory activity against the other 13 selected protein kinases. All of these demonstrate that <b>20c</b> is a potent FLT3 inhibitor with good kinase selectivity.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Kinase Inhibition Profile for <b>20c</b> against Human FLT3 and a Panel of Other Selected Protein Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT3</td><td class="colsep0 rowsep0" align="left">0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Kit</td><td class="colsep0 rowsep0" align="left">6.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FMS</td><td class="colsep0 rowsep0" align="left">2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT1</td><td class="colsep0 rowsep0" align="left">>1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KDR</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT4</td><td class="colsep0 rowsep0" align="left">3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora A</td><td class="colsep0 rowsep0" align="left">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IGF-1R</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Met</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pim-1</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PLK1</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ret</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Syk</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Raf</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK3</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Lck</td><td class="colsep0 rowsep0" align="left">>10</td></tr></tbody></table></div></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <i>In Vitro</i> Growth Inhibitory Activities of <b>20c</b> against Leukemia and Other Cancer Cells</h3><div class="NLM_p">The growth inhibitory potencies of <b>20c</b> against various cell lines, including leukemia and solid tumor cell lines, were examined, and the results are presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Compound <b>20c</b> potently inhibited the growth of MV4-11 cells that express FLT3-ITD, with an IC<sub>50</sub> value of 0.006 μM. It just exhibited very weak inhibitory activity against human T lymphoma Jurkat cells, human Burkitt’s lymphoma Ramos cells, human lung cancer PC-9 and H292 cells, and human epithelial carcinoma A431 cells (IC<sub>50</sub>: 3.05 μM, 6.25 μM, 3.72 μM, 6.94 μM, and 8.91 μM, respectively). For other leukemia and solid tumor cell lines, including K562, U937, Karpas299, HCC827, A549, H2228, H820, MDA-MB-231, BT474, MCF-7, HCT116, SW480, LoVo, HeLa, SKOV-3, SK, DU145, PC-3, A431, and SH-SY5Y, <b>20c</b> did not exhibit an obvious growth inhibition effect at the concentration of 10 μM (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Antiproliferative Activities of <b>20c</b> against Various Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell lines</th><th class="colsep0 rowsep0" align="center">tumor type</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MV4–11</td><td class="colsep0 rowsep0" align="left">human acute myeloid leukemia</td><td class="colsep0 rowsep0" align="left">0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">K562</td><td class="colsep0 rowsep0" align="left">human chronic myelogenous leukemia</td><td class="colsep0 rowsep0" align="left">12.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U937</td><td class="colsep0 rowsep0" align="left">human leukemic monocyte lymphoma</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Jurkat</td><td class="colsep0 rowsep0" align="left">human T lymphoma</td><td class="colsep0 rowsep0" align="left">3.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ramos</td><td class="colsep0 rowsep0" align="left">human Burkitt’s lymphoma</td><td class="colsep0 rowsep0" align="left">6.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Karpas299</td><td class="colsep0 rowsep0" align="left">human anaplastic large cell lymphoma</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCC827</td><td class="colsep0 rowsep0" align="left">human lung cancer</td><td class="colsep0 rowsep0" align="left">12.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549</td><td class="colsep0 rowsep0" align="left">human lung cancer</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H2228</td><td class="colsep0 rowsep0" align="left">human lung cancer</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H820</td><td class="colsep0 rowsep0" align="left">human lung cancer</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PC-9</td><td class="colsep0 rowsep0" align="left">human lung cancer</td><td class="colsep0 rowsep0" align="left">3.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H292</td><td class="colsep0 rowsep0" align="left">human lung cancer</td><td class="colsep0 rowsep0" align="left">6.94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-231</td><td class="colsep0 rowsep0" align="left">human breast cancer</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BT474</td><td class="colsep0 rowsep0" align="left">human breast cancer</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MCF-7</td><td class="colsep0 rowsep0" align="left">human breast cancer</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCT116</td><td class="colsep0 rowsep0" align="left">human colorectal carcinoma</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SW480</td><td class="colsep0 rowsep0" align="left">human colorectal carcinoma</td><td class="colsep0 rowsep0" align="left">11.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LoVo</td><td class="colsep0 rowsep0" align="left">human colorectal carcinoma</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HeLa</td><td class="colsep0 rowsep0" align="left">human cervical carcinoma</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SKOV-3</td><td class="colsep0 rowsep0" align="left">human ovarian carcinoma</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SK</td><td class="colsep0 rowsep0" align="left">human ovarian carcinoma</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DU145</td><td class="colsep0 rowsep0" align="left">human prostate cancer</td><td class="colsep0 rowsep0" align="left">18.60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PC-3</td><td class="colsep0 rowsep0" align="left">human prostate cancer</td><td class="colsep0 rowsep0" align="left">15.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A431</td><td class="colsep0 rowsep0" align="left">human epithelial carcinoma</td><td class="colsep0 rowsep0" align="left">8.91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SH-SY5Y</td><td class="colsep0 rowsep0" align="left">human neurobfastoma</td><td class="colsep0 rowsep0" align="left">>20</td></tr></tbody></table></div></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Signaling Inhibition in Intact MV4-11 Cells</h3><div class="NLM_p">The ability of <b>20c</b> to inhibit the activation of FLT3 and downstream signaling proteins in intact cells was assessed using Western blot analysis. After a 5 h treatment with increasing concentrations of <b>20c</b>, MV4-11 cells were harvested and lysed for an IP/wt assay. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>b, <b>20c</b> inhibited FLT3 phosphorylation in a dose-dependent manner. Consistent with the downregulation of the phosphorylation of FLT3, the phosphorylation of the downstream signaling proteins STAT5 and ERK1/2 was also significantly inhibited at concentrations >0.1 μM (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>b). We also observed that <b>20c</b> did not modulate the expression of these proteins during the drug treatment period.</div><figure id="fig1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Dose–response relationship of <b>20c</b> inhibition against the human FLT3 kinase (ATP concentration: 200 μM). (b) Western blot analysis showing that <b>20c</b> inhibits FLT3 autophosphorylation and the phosphorylation of downstream signaling proteins STAT5 and ERK1/2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> <i>In Vivo</i> Effects of <i>20c</i> against s.c. MV4-11 Tumor Xenografts</h3><div class="NLM_p">The <i>in vivo</i> antileukemia activity of <b>20c</b> was evaluated using an MV4-11 xenograft model. In the MV4-11 model, when the tumor grew to a volume of 300–500 mm<sup>3</sup>, the mice were grouped and treated intraperitoneally once daily with 20, 40, or 100 mg/kg/d <b>20c</b> for 21 days. The tumor volumes were measured every 3 days. Treatment with <b>20c</b> at 100 mg/kg/d resulted in rapid and complete tumor regression in all mice of this group (see Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>a). Compound <b>20c</b> treatment at 20 mg/kg/d and 40 mg/kg/d significantly slowed down the tumor growth; the tumor inhibition rates are 66% and 84%, respectively. Moreover, during the whole experiment, no significant weight loss (see Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>b) or any other obvious signs of toxicity were observed for all of the <b>20c</b>-treated mice.</div><figure id="fig2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Antitumor efficacy of <b>20c</b> at different doses in an <i>in vivo</i> MV4-11 xenograft model. (b) Average body weights for <b>20c</b>-treated mice groups at different doses (20 mg/kg, 40 mg/kg, and 100 mg/kg) and vehicle group in an <i>in vivo</i> MV4-11 xenograft model. (c) Ki67 and TUNEL staining of tumor tissues showing the inhibition of cell proliferation and the induction of apoptosis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>20c</b> was also evaluated for its effects on the tumor mitotic index (Ki67) and apoptosis using histological and immunohistochemical techniques. Similar to the tumor xenograft model, a dose of 20 mg/kg/d of <b>20c</b> was administered in the MV4-11 model. After treatment for 2 or 3 days, tumors were collected and analyzed. Tumor tissues from the vehicle group were stained strongly with Ki67, indicating a large number of highly proliferative cells (see Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>c). Conversely, the tumor tissues from the <b>20c</b>-treated groups showed significantly fewer Ki67-positive cells. Furthermore, the TUNEL data showed an obvious increase in the percentage of apoptotic cells in a time-dependent manner. Hematoxylin staining also showed a significant regression of MV4-11 tumors (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>c).</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85160" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85160" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have described the optimization of the FLT3 inhibitor 2-(6,7-dimethoxyquinazolin-4-ylthio)thiazole (<b>1</b>) that showed considerable enzymatic potency but very low anti-AML activity <i>in vitro</i> and <i>in vivo.</i> SAR studies centering around the head (thiazole) and tails (6- and 7-positions) of the quinazoline moiety led to the discovery of compounds displaying significantly increased potency against FLT3-driven MV4-11 cells but not active against HCT116 that is FLT3-independent. In-depth <i>in vitro</i> and <i>in vivo</i> assays were then carried out on one of the most active compounds, <b>20c</b>, which exhibited a higher potency against MV4-11 with IC<sub>50</sub> = 0.006 μM and the maximum tumor inhibition rate in an <i>in vivo</i> MV4-11 xenograft model. Compound <b>20c</b> displayed very good FLT3 kinase selectivity against a panel of selected kinases and considerable sensitivity against FLT3-driven MV4-11 cells. Western blot and immunohistochemical analysis were carried out to illustrate the mechanism of action of <b>20c</b>, which showed that <b>20c</b> down-regulated the phosphorylation of FLT3/STAT5/ERK, blocked cell proliferation, and induced apoptosis in tumor tissue.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81454" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81454" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemistry Methods</h3><div class="NLM_p">Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. The synthesis of compounds <b>1</b>, <b>8</b>, <b>13</b>, <b>15</b>, <b>17</b>, and <b>20</b> was as previously reported. All final compounds were purified to >95% purity, as determined by high-performance liquid chromatography (HPLC). HPLC analysis was carried out on a Waters 2695 HPLC system with the use of a Kromasil C18 column (4.6 mm × 250 mm, 5 um). <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker AV-400 spectrometer at 400 and 100 MHz, respectively. Chemical shifts are reported in ppm (δ) relative to tetramethylsilane (TMS) as an internal standard. Multiplicities are given as s (singlet), d (doublet), dd (double–doublet), t (triplet), q (quadruplet), m (multiplet), and br s (broad signal). Low-resolution and high-resolution mass spectral (HRMS) data were obtained on an Agilent 1100 series LCMS with UV detection at 254 nm using electrospray ionization. Thin layer chromatography (TLC) was conducted on aluminum sheet silica gel Merck 60F254. The spots were visualized using ultraviolet light.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 6,7-Dimethoxy-4-(thiazol-2-ylthio)quinazoline (<b>1</b>)</h4><div class="NLM_p last">A solution of 4-chloro-6,7-dimethoxy-quinazoline (<b>2</b>, 600 mg, 2.67 mmol), thiazole-2-thiol (330 mg, 2.8 mmol), and K<sub>2</sub>CO<sub>3</sub> (1.1 g, 7.98 mmol) in 2-butanone was heated under reflux for 3 h. The reaction mixture was evaporated under reduced pressure. The residue was extracted with CH<sub>2</sub>Cl<sub>2</sub> and water. The organic layer was collected, washed with brine, and dried over MgSO<sub>4</sub>. The solvent was evaporated under reduced pressure. The residue was decolorized by active carbon and purified by recrystallization from ethanol yielding 653 mg (80%, 99% HPLC purity) of <b>1</b> as fine white crystals. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.88(s, 1H), 8.06(d, <i>J</i> = 3.2 Hz, 1H), 8.03(d, <i>J</i> = 3.2 Hz, 1H), 7.40(s, 1H), 7.29(s, 1H), 4.00(s, 6H) ppm. <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 162.4, 156.1, 153.8, 151.6, 150.5, 146.0, 143.0, 125.3, 117.4, 107.1, 100.7, 56.3, 56.1 ppm. MS (ESI, positive ion) <i>m</i>/<i>z</i>: 306.10 [M + H].</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 6,7-Dimethoxy-4-(4-methylthiazol-2-ylthio)quinazoline (<b>1a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>2</b> and 4-methylthiazole-2-thiol using the procedure previously described for compound <b>1</b> and was purified by column chromatography eluting with 30–50% EtOAc in petroleum ether to provide <b>1a</b> (300 mg, 82% yield, 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.88(s, 1H), 7.29(s, 1H), 7.24(s, 1H), 7.15(d, <i>J</i> = 1.2 Hz, 1H), 4.05(s, 6H), 2.53(d, <i>J</i> = 0.8 Hz, 3H) ppm. MS (ESI, negative ion) <i>m</i>/<i>z</i>: 318.30 [M – H].</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 6,7-Bis(2-methoxyethoxy)-4-(thiazol-2-ylthio)quinazoline (<b>1b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>3</b> and thiazole-2-thiol using the procedure previously described for compound <b>1</b> and was purified by column chromatography eluting with 30–50% EtOAc in petroleum ether to provide <b>1b</b> (200 mg, 75% yield, 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.89(s, 1H), 7.97(d, <i>J</i> = 3.2 Hz, 1H), 7.61(d, <i>J</i> = 3.2 Hz, 1H), 7.33(s, 1H), 4.33(m, 4H), 3.89(m, 4H), 3.50(d, <i>J</i> = 7.6 Hz, 6H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub> [M + H] <sup>+</sup> 394.0895; found, 393.8950.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 4-([1,3,4]Thiadiazol-2-ylthio)-6,7-dimethoxyquinazoline (<b>1c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>2</b> and [1,3,4]thiadiazole-2-thiol using the procedure previously described for compound <b>1</b> and was purified by column chromatography eluting with 30–50% EtOAc in petroleum ether to provide <b>1c</b> (350 mg, 86% yield, 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.33(s, 1H), 8.97(s, 1H), 7.37(s, 1H), 7.23(s, 1H), 4.09(d, <i>J</i> = 5.6 Hz, 6H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>12</sub>H<sub>10</sub>N<sub>4</sub>O<sub>2</sub>S<sub>2</sub> [M + H]<sup>+</sup> 307.0323; found, 307.2012.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 4-([1,3,4]Thiadiazol-2-ylthio)-6,7-bis(2-methoxyethoxy)quinazoline (<b>1d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>3</b> and [1,3,4]thiadiazole-2-thiol using the procedure previously described for compound <b>1</b> and was purified by column chromatography eluting with 30–50% EtOAc in petroleum ether to provide <b>1d</b> (300 mg, 79% yield, 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.86(s, 1H), 8.94(s, 1H), 7.46(s, 1H), 7.40(s, 1H), 4.38(q, 4H), 3.78(q, 4H), 3.37(d, <i>J</i> = 7.6 Hz, 6H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>16</sub>H<sub>18</sub>N<sub>4</sub>O<sub>4</sub>S<sub>2</sub> [M + Na]<sup>+</sup> 417.0667; found, 417.0803.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 7-Methoxy-6-[2-(piperidin-1-yl)ethoxy]-4-(thiazol-2-ylthio)quinazoline (<b>8a</b>)</h4><div class="NLM_p">Phosphorus oxychloride (6.0 mL) was added to a solution of 7-methoxy-4-oxo-3,4-dihydro-quinazolin-6-yl acetate (<b>4</b>, 3.0 g, 12.8 mmol) and <i>N,N-</i>diethylaniline (2.5 mL, 15.4 mmol) in toluene at room temperature. Then the mixture was stirred in a preheated oil bath (100 °C) and refluxed for 3 h. The solvent was removed under reduced pressure. Ice water (50 mL) was added and the light brown precipitate filtered and washed with ice water (100 mL). The brownish precipitate was dried to give <b>5</b> (2.85 g, 88%). MS (ESI, positive ion) <i>m</i>/<i>z</i>: 253.03 [M + H].</div><div class="NLM_p">A solution of <b>5</b> (2.0 g, 7.9 mmol), thiazole-2-thiol (927.6 mg, 7.9 mmol), and K<sub>2</sub>CO<sub>3</sub> (3.27 g, 23.7 mmol) in 2-butanone was heated under reflux for 2 h. The reaction mixture was evaporated under reduced pressure. The residue was extracted with CH<sub>2</sub>Cl<sub>2</sub> and water. The organic layer was collected, washed with brine, and dried over MgSO<sub>4</sub>. The solvent was evaporated under reduced pressure. The residue was purified by column chromatography eluting with 30–50% EtOAc in petroleum ether to provide <b>6</b> (2.35 g, 89% yield) as an orange yellow powder. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.95(s, 1H), 7.99(d, <i>J</i> = 3.2 Hz, 1H), 7.79(s, 1H), 7.63(d, <i>J</i> = 3.2 Hz, 1H), 7.43(s, 1H), 4.02(s, 3H), 2.41(s, 3H) ppm.</div><div class="NLM_p">A solution of 7-methoxy-4-(thiazol-2-ylthio)quinazolin-6-yl acetate (<b>6</b>, 250 mg, 0.75 mmol) in NH<sub>3</sub>·H<sub>2</sub>O/MeOH (10 mL, 1.5 N solution) was stirred at room temperature for 5 h. The reaction mixture was monitored by TLC. The solvent was evaporated under reduced pressure to give the crude intermediate <b>7</b> (yield by 100%). The residue was not further purified and directly used for the next step reaction.</div><div class="NLM_p last">A solution of 7-methoxy-4-(thiazol-2-ylthio)quinazolin-6-ol (<b>7</b>, 218.5 mg, 0.75 mmol) and K<sub>2</sub>CO<sub>3</sub> (310.4 mg, 2.25 mmol) in 2-butanone (10 mL) was stirred at room temperature for 15 min, and then 2-piperidinoethylchloride hydrochloride (207 mg, 1.13 mmol) was added. This reaction mixture was heated under reflux for 7 h. The solvent was evaporated under reduced pressure. The residue was extracted with CH<sub>2</sub>Cl<sub>2</sub> and water. The organic layer was collected, washed with brine, and dried over MgSO<sub>4</sub>. The solvent was evaporated under reduced pressure. The residue was recrystallized from ethyl ether yielding 153 mg (50%, 96% HPLC purity) of <b>8a</b> as a white powder. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.88(s, 1H), 8.06(d, <i>J</i> = 3.2 Hz, 1H), 8.03(d, <i>J</i> = 3.2 Hz, 1H), 7.40(s, 1H), 7.38(s, 1H), 4.31(t, <i>J</i> = 6.0 Hz, 2H), 4.00 (s, 3H), 2.75(t, <i>J</i> = 5.8 Hz, 2H), 2.48(br s, 3H), 1.84(s, 1H), 1.50–1.55(m, 4H), 1.39–1.40(m, 2H) ppm. MS (ESI, positive ion) <i>m</i>/<i>z</i>: 403.03 [M + H].</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-Chloro-6-methoxyquinazolin-7-yl acetate (<b>10</b>)</h4><div class="NLM_p last">Phosphorus oxychloride (3.0 mL) was added to a solution of 6-methoxy-4-oxo-3,4-dihydro-quinazolin-7-yl acetate (<b>9</b>, 3.0 g, 12.8 mmol) in chloroform at room temperature. Then the mixture was stirred in a preheated oil bath (70 °C) and refluxed for 1 h, and then triethylamine (4.8 mL) was added dropwise. The reaction mixture was refluxed for 12 h. The solvent was removed under reduced pressure. Ice water (50 mL) was added, and the aqueous solution was neutralized with saturated sodium carbonate solution. The aqueous solution was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was collected, washed with brine, and dried over MgSO<sub>4</sub>. The solvent was evaporated under reduced pressure to afford <b>10</b> (3.18 g, 98%) without further purification. MS (ESI, positive ion) <i>m</i>/<i>z</i>: 253.03 [M + H].</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 7-Methoxy-6-(2-morpholinoethoxy)-4-(thiazol-2-ylthio)quinazoline (<b>8b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>7</b> and 4-(2-chloroethyl)morpholine hydrochloride using the procedure previously described for compound <b>8a</b> and was purified by recrystallization from ethyl ether. Yield: 100 mg (37%, 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.88(s, 1H), 8.06(d, <i>J</i> = 3.6 Hz, 1H), 8.03(d, <i>J</i> = 3.2 Hz, 1H), 7.40(s, 1H), 7.36(s, 1H), 4.33(t, <i>J</i> = 5.8 Hz, 2H), 4.00(s, 3H), 3.61(t, <i>J</i> = 4.4 Hz, 4H), 2.80(t, <i>J</i> = 5.8 Hz, 2H), 2.51(t, <i>J</i> = 1.8 Hz, 4H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>S<sub>2</sub> [M + H]<sup>+</sup> 405.1055; found, 405.0109.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 7-Methoxy-6-(2-(pyrrolidin-1-yl)ethoxy)-4-(thiazol-2-ylthio)quinazoline (<b>8c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>7</b> and 1-(2-chloroethyl)pyrrolidine hydrochloride using the procedure previously described for compound <b>8c</b> and was purified by recrystallization from ethyl ether. Yield: 92 mg (42%, 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.88(s, 1H), 8.06(d, <i>J</i> = 3.2 Hz, 1H), 8.03(d, <i>J</i> = 3.2 Hz, 1H), 7.41(s, 1H), 7.36(s, 1H), 4.31(t, <i>J</i> = 5.6 Hz, 2H), 4.01(s, 3H), 2.91(t, <i>J</i> = 5.6 Hz, 2H), 2.59(s, 4H), 1.71(s, 4H) ppm. MS (ESI, positive ion) <i>m</i>/<i>z</i>: 388.99 [M + H].</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 3-[7-Methoxy-4-(thiazol-2-ylthio)quinazolin-6-yloxy]-<i>N,N</i>-dimethylpropan-1-amine (<b>8d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>7</b> and 3-chloro-<i>N,N</i>-dimethylpropan-1-amine hydrochloride using the procedure previously described for compound <b>8d</b> and was purified by recrystallization from ethyl ether. Yield: 90 mg (46%, 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.87(s, 1H), 8.06(d, <i>J</i> = 3.2 Hz, 1H), 8.03(d, <i>J</i> = 3.2 Hz, 1H), 7.39(s, 1H), 7.28(s, 1H), 4.22(t, <i>J</i> = 6.6 Hz, 2H), 4.01(s, 3H), 2.41(t, <i>J</i> = 7.0 Hz, 2H), 2.18(s, 6H), 1.96(m, 2H) ppm. MS (ESI, positive ion) <i>m</i>/<i>z</i>: 376.99 [M + H].</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 7-Methoxy-6-(3-morpholinopropoxy)-4-(thiazol-2-ylthio)quinazoline (<b>8e</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>7</b> and 4-(3-chloropropyl)morpholine using the procedure previously described for compound <b>8e</b> and was purified by recrystallization from ethyl ether. Yield: 150 mg (54%, 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.90(s, 1H), 7.97(d, <i>J</i> = 3.2 Hz, 1H), 7.60(d, <i>J</i> = 3.6 Hz, 1H), 7.30(s, 1H), 4.26(t, <i>J</i> = 6.4 Hz, 2H), 4.04(s, 3H), 3.75(s, 4H), 2.60(br s, 2H), 2.51(br s, 4H), 2.15(br s, 2H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>S<sub>2</sub> [M + H]<sup>+</sup> 419.1212; found, 419.1217.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 6-Methoxy-7-[2-(piperidin-1-yl)ethoxy]-4-(thiazol-2-ylthio)quinazoline (<b>13a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12</b> and 1-(2-chloroethyl)piperidine hydrochloride using the procedure previously described for compound <b>8a</b> and was purified by recrystallization from ethyl ether. Yield: 211 mg (36%, 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.89(s, 1H), 7.97(d, <i>J</i> = 3.6 Hz, 1H), 7.60(d, <i>J</i> = 3.2 Hz, 1H), 7.30(d, <i>J</i> = 6.0 Hz, 2H), 4.34(br s, 2H), 4.04(s, 3H), 2.95(br s, 2H), 2.60(br s, 4H), 1.67(br s, 4H), 1.48(br s, 2H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>S<sub>2</sub> [M + H]<sup>+</sup> 403.1262; found, 403.1256.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 6-Methoxy-7-(2-morpholinoethoxy)-4-(thiazol-2-ylthio)quinazoline (<b>13b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12</b> and 4-(2-chloroethyl)morpholine hydrochloride using the procedure previously described for compound <b>8a</b> and was purified by recrystallization from ethyl ether. Yield: 112 mg (29%, 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.90(s, 1H), 7.97(d, <i>J</i> = 3.6 Hz, 1H), 7.60(d, <i>J</i> = 3.2 Hz, 1H), 7.30(d, <i>J</i> = 2.0 Hz, 2H), 4.35(t, <i>J</i> = 6.4 Hz, 2H), 4.04(s, 3H), 3.78(t, <i>J</i> = 4.4 Hz, 4H), 2.96(t, <i>J</i> = 5.8 Hz, 2H), 2.67(br s, 4H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>S<sub>2</sub> [M + H]<sup>+</sup> 405.1055; found, 405.1059.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 6-Methoxy-7-[2-(pyrrolidin-1-yl)ethoxy]-4-(thiazol-2-ylthio)quinazoline (<b>13c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12</b> and 1-(2-chloroethyl)pyrrolidine hydrochloride using the procedure previously described for compound <b>8a</b> and was purified by recrystallization from ethyl ether. Yield: 124 mg (38%, 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.89(s, 1H), 7.97(d, <i>J</i> = 3.6 Hz, 1H), 7.60(d, <i>J</i> = 3.2 Hz, 1H), 7.30(d, <i>J</i> = 2.8 Hz, 2H), 4.32(t, <i>J</i> = 6.0 Hz, 2H), 4.05(s, 3H), 3.07(t, <i>J</i> = 6.0 Hz, 2H), 2.70(br s, 4H), 1.85(br s, 4H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>S<sub>2</sub> [M + H]<sup>+</sup> 389.1106; found, 389.1101.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 6-Methoxy-7-(3-morpholinopropoxy)-4-(thiazol-2-ylthio)quinazoline (<b>13d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>12</b> and 4-(3-chloropropyl)morpholine using the procedure previously described for compound <b>8a</b> and was purified by recrystallization from ethyl ether. Yield: 150 mg (40%, 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.90(s, 1H), 7.97(d, <i>J</i> = 3.2 Hz, 1H), 7.61(d, <i>J</i> = 3.2 Hz, 1H), 7.30(s, 1H), 7.27(s, 1H), 4.27(t, <i>J</i> = 6.6 Hz, 2H), 4.04(s, 3H), 3.76(br s, 4H), 2.62(br s, 2H), 2.53(br s, 4H), 2.16(br s, 2H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>S<sub>2</sub> [M + H]<sup>+</sup> 419.1212; found, 419.1221.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N-</i>(3-Chlorophenyl)-2-[2-(6,7-dimethoxyquinazolin-4-ylthio)-4-methylthiazol-5-yl]acetamide (<b>15a</b>)</h4><div class="NLM_p">A solution of 4-chloro-6,7-dimethoxyquinazoline (<b>2</b>, 500 mg, 2.22 mmol), 2-(2-mercapto-4-methylthiazol-5-yl)acetic acid (420 mg, 2.22 mmol), and K<sub>2</sub>CO<sub>3</sub> (920 mg, 6.66 mmol) in 2-butanone was refluxed overnight. The reaction mixture was evaporated under reduced pressure. Ice water (100 mL) was added and the light yellow precipitate filtered and washed with ice water (100 mL) and CH<sub>2</sub>Cl<sub>2</sub>. The light yellow precipitate was dried to give <b>14a</b> (655 mg, 78%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.77(s, 1H), 8.87(s, 1H), 7.39(s, 1H), 7.28(s, 1H), 4.00(s, 6H), 3.92(s, 2H), 2.34(s, 3H) ppm.</div><div class="NLM_p last">2-[2-(6,7-Dimethoxyquinazolin-4-ylthio)-4-methylthiazol-5-yl]acetic acid <b>14a</b> (250 mg, 0.66 mmol) was reacted with 3-chlorobenzenamine (0.1 mL, 0.99 mmol) in the presence of 1-hydroxybenzotriazole (HOBT, 107.4 mg, 0.79 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 152.4 mg, 0.79 mmol), and <i>N,N</i>-diisopropylethylamine (DIEA, 0.13 mL, 0.79 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL). The mixture was heated under reflux for 24 h. Then, the mixture was cooled to room temperature, water (5 mL) added, and the precipitate filtered and washed with ice water and CH<sub>2</sub>Cl<sub>2</sub> to obtain <b>15a</b> (194 mg, 60%). The light white precipitate was purified by recrystallization from ethanol (>98% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.52(s, 1H), 8.86(s, 1H), 7.82(s, 1H), 7.45(d, <i>J</i> = 8.4 Hz, 1H), 7.34–7.39(m, 2H), 7.29(s, 1H), 7.13(d, <i>J</i> = 7.6 Hz, 1H), 4.00(s, 8H), 2.39(s, 3H) ppm. MS (ESI, negative ion) <i>m</i>/<i>z</i>: 485.00 [M – H].</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N-</i>(3,5-Dichlorophenyl)-2-[2-(6,7-dimethoxyquinazolin-4-ylthio)-4-methylthiazol-5-yl]acetamide (<b>15b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14a</b> and 3,5-dichlorobenzenamine using the procedure previously described for compound <b>15a</b> and was purified by recrystallization from ethanol. Yield: 110 mg (33%, > 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.68(s, 1H), 8.87(s, 1H), 7.67(s, 2H), 7.40(s, 1H), 7.30(d, <i>J</i> = 8.4 Hz, 2H), 4.01(d, <i>J</i> = 7.6 Hz, 6H), 3.96(s, 2H), 2.39(s, 3H) ppm. MS (ESI, positive ion) <i>m</i>/<i>z</i>: 520.91 [M + H].</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-[2-(6,7-Dimethoxyquinazolin-4-ylthio)-4-methylthiazol-5-yl]-<i>N-</i>[3-(trifluoromethyl)phenyl]acetamide (<b>15c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14a</b> and 3-(trifluoromethyl)benzenamine using the procedure previously described for compound <b>15a</b> and was purified by recrystallization from ethanol. Yield: 153 mg (45%, > 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.67(s, 1H), 8.87(s, 1H), 8.11(s, 1H), 7.78(d, <i>J</i> = 7.6 Hz, 1H), 7.58(t, <i>J</i> = 8.0 Hz, 1H), 7.40–7.44(m, 2H), 7.29(s, 1H), 4.04(s, 2H), 4.00(s, 6H), 2.40(s, 3H) ppm. MS (ESI, negative ion) <i>m</i>/<i>z</i>: 519.00 [M – H].</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N-</i>(4-Acetamidephenyl)-2-[2-(6,7-dimethoxyquinazolin-4-ylthio)-4-methylthiazol-5-yl]acetamide (<b>15d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14a</b> and <i>N-</i>(4-aminophenyl)acetamide using the procedure previously described for compound <b>15a</b> and was purified by recrystallization from ethanol. Yield: 232 mg (57%, > 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.27(s, 1H), 9.90(s, 1H), 8.86(s, 1H), 7.51(s, 4H), 7.39(s, 1H), 7.28(s, 1H), 4.00(s, 6H), 3.96(s, 2H), 2.40(s, 3H), 2.02(s, 3H) ppm. MS (ESI, negative ion) <i>m</i>/<i>z</i>: 508.00 [M – H].</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N-</i>(4-Chlorobenzyl)-2-[2-(6,7-dimethoxyquinazolin-4-ylthio)-4-methylthiazol-5-yl]acetamide (<b>15e</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14a</b> and (4-chlorophenyl)methanamine using the procedure previously described for compound <b>15a</b> and was purified by recrystallization from ethanol. Yield: 153 mg (48%, > 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.85(s, 1H), 8.77(s, 1H), 7.39(d, <i>J</i> = 7.2 Hz, 3H), 7.30(d, <i>J</i> = 8.0 Hz, 3H), 4.30(d, <i>J</i> = 4.8 Hz, 2H), 4.00(s, 6H), 3.81(s, 2H), 2.35(s, 3H) ppm. MS (ESI, positive ion) <i>m</i>/<i>z</i>: 500.96 [M + H].</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-{2-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]-4-methylthiazol-5-yl}-<i>N-</i>(3-chlorophenyl)acetamide (<b>15f</b>)</h4><div class="NLM_p">A solution of 4-chloro-6,7-bis(2-methoxyethoxy) quinazoline (<b>3</b>, 500 mg, 1.60 mmol), 2-(2-mercapto-4-methylthiazol-5-yl)acetic acid (302.6 mg, 1.60 mmol), and K<sub>2</sub>CO<sub>3</sub> (662 mg, 4.80 mmol) in 2-butanone was refluxed overnight. The reaction mixture was evaporated under reduced pressure. Ice water (100 mL) was added and the light yellow precipitate filtered and washed with ice water (100 mL). The light yellow precipitate was recrystallized from ethanol to give <b>14b</b> (655 mg, 78%).</div><div class="NLM_p last">2-{2-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]-4-methylthiazol-5-yl}acetic acid (<b>14b</b>) (250 mg, 0.54 mmol) was reacted with the 3-chlorobenzenamine (0.1 mL, 0.80 mmol) in the presence of 1-hydroxybenzotriazole (HOBT, 87.0 mg, 0.65 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 123.4 mg, 0.65 mmol), and <i>N,N</i>-diisopropylethylamine (DIEA, 0.11 mL, 0.65 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL). The mixture was heated under reflux for 24 h. Then the clear solution was evaporated under reduced pressure, the residue was chromatographed on a silica gel column (eluting system: EtOAc) to obtain <b>15f</b> (200 mg, 62%) as a white powder, which was purified by recrystallization from ethanol (>98% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.52(s, 1H), 8.85(s, 1H), 7.82(t, <i>J</i> = 1.8 Hz, 1H), 7.42–7.46(m, 2H), 7.38(s, 1H), 7.34–7.36(m, 1H), 7.13(dd, <i>J</i> = 0.8 Hz, 0.8 Hz, 1H), 4.35(m, 4H), 4.01(s, 2H), 3.77(m, 4H), 3.36(d, <i>J</i> = 6.0 Hz, 6H), 2.39(s, 3H) ppm. MS (ESI, negative ion) <i>m</i>/<i>z</i>: 573.02 [M – H].</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 2-{2-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]-4-methylthiazol-5-yl}-<i>N-</i>[3-(trifluoromethyl)phenyl]acetamide (<b>15g</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14b</b> and 3-(trifluoromethyl)benzenamine using the procedure previously described for compound <b>15f</b> and was purified by column chromatography (eluting system: EtOAc) and recrystallization from ethanol. Yield: 119 mg (37%, > 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.67(s, 1H), 8.86(s, 1H), 8.11(s, 1H), 7.78(d, <i>J</i> = 8.0 Hz, 1H), 7.58(t, <i>J</i> = 8.0 Hz, 1H), 7.43(d, <i>J</i> = 6.8 Hz, 2H), 7.35(s, 1H), 4.36(t, <i>J</i> = 2.2 Hz, 4H), 4.03(s, 2H), 3.77(t, <i>J</i> = 2.2 Hz, 4H), 3.36(d, <i>J</i> = 5.6 Hz, 6H), 2.40(s, 3H) ppm. MS (ESI, negative ion) <i>m</i>/<i>z</i>: 607.22 [M – H].</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-{2-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]-4-methylthiazol-5-yl}-<i>N-</i>[4-(trifluoromethyl)phenyl]acetamide (<b>15h</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14b</b> and 4-(trifluoromethyl)benzenamine using the procedure previously described for compound <b>15f</b> and was purified by column chromatography (eluting system: EtOAc) and recrystallization from ethanol. Yield: 160 mg (49%, > 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.69(s, 1H), 8.85(s, 1H), 7.82(d, <i>J</i> = 8.4 Hz, 2H), 7.70(d, <i>J</i> = 8.8 Hz, 2H), 7.42(s, 1H), 7.35(s, 1H), 4.36(m, 4H), 4.05(s, 2H), 3.77(m, 4H), 3.36(d, <i>J</i> = 6.0 Hz, 6H), 2.40(s, 3H) ppm. MS (ESI, negative ion) <i>m</i>/<i>z</i>: 607.22 [M – H].</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-{2-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]-4-methylthiazol-5-yl}-<i>N-</i>(3,5-dimethylphenyl)acetamide (<b>15i</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14b</b> and 3,5-dimethylbenzenamine using the procedure previously described for compound <b>15f</b> and was purified by column chromatography (eluting system: EtOAc) and recrystallization from ethanol. Yield: 210 mg (69%, > 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.17(s, 1H), 8.85(s, 1H), 7.42 (s, 2H), 7.35(s, 1H), 7.22(s, 1H), 6.71(s, 1H), 4.36(m, 4H), 3.96(s, 2H), 3.77(m, 4H), 3.36(d, <i>J</i> = 6.0 Hz, 6H), 2.39(s, 3H), 2.23(s, 6H) ppm. MS (ESI, negative ion) <i>m</i>/<i>z</i>: 567.02 [M – H].</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 2-{2-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]-4-methylthiazol-5-yl}-<i>N-</i>cyclopropylacetamide (<b>15j</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14b</b> and cyclopropanamine using the procedure previously described for compound <b>15f</b> and was purified by column chromatography (eluting system: EtOAc) and recrystallization from ethanol. Yield: 90 mg (33%, > 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.88(s, 1H), 7.33(s, 1H), 7.30(s, 1H), 5.73(s, 1H), 4.32(t, <i>J</i> = 4.0 Hz, 4H), 3.89(t, <i>J</i> = 4.0 Hz, 4H), 3.71(s, 2H), 3.50(d, <i>J</i> = 6.4 Hz, 6H), 2.72(m, 1H), 2.42(s, 3H), 0.79(m, 2H), 0.50(m, 2H) ppm. MS (ESI, positive ion) <i>m</i>/<i>z</i>: 505.00 [M + H].</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-{2-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]-4-methylthiazol-5-yl}-<i>N-</i>(6-methoxybenzo[<i>d</i>]thiazol-2-yl)acetamide (<b>15k</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14b</b> and 6-methoxybenzo[d]thiazol-2-amine using the procedure previously described for compound <b>15f</b> and was purified by column chromatography (eluting system: EtOAc) and recrystallization from ethanol. Yield: 102 mg (30%, > 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.60(s, 1H), 8.88(s, 1H), 7.66(d, <i>J</i> = 8.8 Hz, 1H), 7.58(s, 1H), 7.43(s, 1H), 7.35(s, 1H), 7.04(d, <i>J</i> = 7.2 Hz, 1H), 4.36(br s, 4H), 4.17(s, 2H), 3.81(s, 3H), 3.77(br s, 4H), 3.37(br s, 6H), 2.40(s, 3H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>28</sub>H<sub>29</sub>N<sub>5</sub>O<sub>6</sub>S<sub>3</sub> [M + H]<sup>+</sup> 628.1358; found, 628.0308.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-{2-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]thiazol-4-yl}-<i>N-</i>(3-chlorophenyl)acetamide (<b>15l</b>)</h4><div class="NLM_p">A solution of 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline (<b>3</b>, 1.0 g, 3.20 mmol), 2-(2-mercaptothiazol-4-yl)acetic acid (561.0 mg, 3.20 mmol), and K<sub>2</sub>CO<sub>3</sub> (1.32 g, 9.60 mmol) in 2-butanone was refluxed overnight. The reaction mixture was evaporated under reduced pressure. Ice water (100 mL) was added and the light yellow precipitate filtered and washed with ice water (100 mL). The light yellow precipitate was recrystallized from ethanol to give <b>14c</b> (1.1 g, 76%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.53(s, 1H), 8.89(s, 1H), 7.77(s, 1H), 7.43(s, 1H), 7.34(s, 1H), 4.36(br s, 4H), 3.81(s, 2H), 3.78(br s, 4H), 3.36(br s, 6H) ppm. MS (ESI, negative ion) <i>m</i>/<i>z</i>: 450.10 [M – H].</div><div class="NLM_p last">2-{2-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]thiazol-4-yl}acetic acid (<b>14c</b>, 450.0 mg, 1.0 mmol) was reacted with the 3-chlorobenzenamine (0.2 mL, 1.6 mmol) in the presence of 1-hydroxybenzotriazole (HOBT, 162.2 mg, 1.2 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 230.0 mg, 1.2 mmol), and <i>N,N</i>-diisopropylethylamine (DIEA, 0.2 mL, 1.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL). The mixture was heated under reflux for 24 h. Then the clear solution was evaporated under reduced pressure, and the residue was chromatographed on a silica gel column (eluting system: EtOAc) to obtain <b>15l</b> (360 mg, 64%, > 96% HPLC purity) as a white powder. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.47(s, 1H), 8.89(s, 1H), 7.85(s, 1H), 7.81(s, 1H), 7.48–7.44(m, 2H), 7.37–7.33(m, 2H), 7.12(d, <i>J</i> = 8.0 Hz, 1H), 4.36(br s, 4H), 3.91(s, 2H), 3.77(br s, 4H), 3.36(br s, 6H) ppm. MS (ESI, negative ion) <i>m</i>/<i>z</i>: 559.16 [M – H].</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 2-{2-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]thiazol-4-yl}-<i>N</i>[3-(trifluoromethyl)phenyl]acetamide (<b>15m</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14c</b> and 3-(trifluoromethyl)benzenamine using the procedure previously described for compound <b>15l</b> and was purified by column chromatography (eluting system: EtOAc) and recrystallization from ethanol. Yield: 276 mg (47%, > 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.62(s, 1H), 8.89(s, 1H), 8.14(s, 1H), 7.83(s, 1H), 7.79(d, <i>J</i> = 8.4 Hz, 1H), 7.57(t, <i>J</i> = 7.8 Hz, 1H), 7.44–7.41(m, 2H), 7.35(s, 1H), 4.36(br s, 4H), 3.93(s, 2H), 3.76(br s, 4H), 3.36(br s, 6H) ppm. MS (ESI, negative ion) <i>m</i>/<i>z</i>: 593.22 [M – H].</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 2-{2-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]thiazol-4-yl}-<i>N-</i>[4-(trifluoromethyl)phenyl]acetamide (<b>15n</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14c</b> and 4-(trifluoromethyl)benzenamine using the procedure previously described for compound <b>15l</b> and was purified by column chromatography (eluting system: EtOAc) and recrystallization from ethanol. Yield: 334 mg (56%, > 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.64(s, 1H), 8.89(s, 1H), 7.83(d, <i>J</i> = 9.2 Hz, 3H), 7.69(d, <i>J</i> = 8.4 Hz, 2H), 7.44(s, 1H), 7.35(s, 1H), 4.36(br s, 4H), 3.94(s, 2H), 3.76(br s, 4H), 3.36(br s, 6H) ppm. MS (ESI, negative ion) <i>m</i>/<i>z</i>: 593.22 [M – H].</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 2-{2-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]thiazol-4-yl}-<i>N-</i>(3,5-dimethylphenyl)acetamide (<b>15o</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>14c</b> and 4-(trifluoromethyl)benzenamine using the procedure previously described for compound <b>15l</b> and was purified by column chromatography (eluting system: EtOAc) and recrystallization from ethanol. Yield: 355 mg (64%, > 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.10(s, 1H), 8.90(s, 1H), 7.79(s, 1H), 7.44(s, 1H), 7.36(s, 1H), 7.24(s, 2H), 6.70(s, 1H), 4.36(br s, 4H), 3.86(s, 2H), 3.76(br s, 4H), 3.36(br s, 6H), 2.23(s, 6H) ppm. MS (ESI, negative ion) <i>m</i>/<i>z</i>: 553.24 [M – H].</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N-</i>{5-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}acetamide (<b>17a</b>)</h4><div class="NLM_p last">A solution of 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline (<b>3</b>, 300 mg, 0.96 mmol), <i>N-</i>(5-mercapto-[1,3,4]thiadiazol-2-yl)acetamide (<b>16a</b>, 185 mg, 1.05 mmol), and K<sub>2</sub>CO<sub>3</sub> (397 mg, 2.88 mmol) in <i>N,N-</i>dimethylformamide (10 mL) was heated overnight at 100 °C. The reaction mixture was evaporated under reduced pressure. Ice water (20 mL) was added and the white precipitate filtered and washed with ice water (50 mL), which was recrystallized from ethanol to give <b>17a</b> (205 mg, 46%, 96% HPLC purity) as a white powder. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.82(s, 1H), 8.86(s, 1H), 7.44(s, 1H), 7.38(s, 1H), 4.38(br s, 4H), 3.78(br s, 4H), 3.37(d, <i>J</i> = 7.6 Hz, 6H), 2.24(s, 3H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>18</sub>H<sub>21</sub>N<sub>5</sub>O<sub>5</sub>S<sub>2</sub> [M + H]<sup>+</sup> 452.1062; found, 452.1068.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N-</i>{5-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}acrylamide (<b>17b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>3</b> and <i>N-</i>(5-mercapto-[1,3,4]thiadiazol-2-yl)acrylamide (<b>16b</b>) using the procedure previously described for compound <b>17a</b> and was purified by recrystallization from ethanol. Yield: 144 mg (31%, 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.07(s, 1H), 8.89(s, 1H), 7.46(s, 1H), 7.40(s, 1H), 6.60(dd, <i>J</i> = 10.0 Hz, 10.0 Hz, 1H), 6.49(d, <i>J</i> = 16.8 Hz, 1H), 6.02(d, <i>J</i> = 10.0 Hz, 1H), 4.38(br s, 4H), 3.78(br s, 4H), 3.36(d, <i>J</i> = 7.6 Hz, 6H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>19</sub>H<sub>21</sub>N<sub>5</sub>O<sub>5</sub>S<sub>2</sub> [M + H]<sup>+</sup> 464.1062; found, 464.1071.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 1-{5-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-(3-chlorophenyl)urea (<b>17c</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>3</b> and 1-(3-chlorophenyl)-3-(5-mercapto-[1,3,4]thiadiazol-2-yl)urea (<b>16c</b>) using the procedure previously described for compound <b>17a</b> and was purified by recrystallization from ethanol. Yield: 440 mg (60%, 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.41(s, 1H), 9.34(s, 1H), 8.89 (s, 1H), 7.73(s, 1H), 7.45(s, 1H), 7.38(br s, 3H), 7.14 (s, 1H), 4.38(m, 4H), 3.78(m, 4H), 3.37(d, <i>J</i> = 7.6 Hz, 6H) ppm. MS (ESI, negative ion) <i>m</i>/<i>z</i>: 563.00 [M – H].</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 1-{5-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-(3-fluorophenyl)urea (<b>17d</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>3</b> and 1-(3-fluorophenyl)-3-(5-mercapto-[1,3,4]thiadiazol-2-yl)urea (<b>16d</b>) using the procedure previously described for compound <b>17a</b> and was purified by recrystallization from ethanol. Yield: 118 mg (46%, 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.47(s, 1H), 9.66(s, 1H), 8.89(s, 1H), 7.35–7.51(m, 4H), 7.24(d, <i>J</i> = 8.0 Hz, 1H), 6.90(t, <i>J</i> = 7.6 Hz, 1H), 4.37(t, <i>J</i> = 4.2 Hz, 4H), 3.78(t, <i>J</i> = 6.2 Hz, 4H), 3.37(d, <i>J</i> = 7.2 Hz, 6H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>23</sub>FN<sub>6</sub>O<sub>5</sub>S<sub>2</sub> [M + H]<sup>+</sup> 547.1234; found, 547.1238.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-{5-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-(3-bromophenyl)urea (<b>17e</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>3</b> and 1-(3-bromophenyl)-3-(5-mercapto-[1,3,4]thiadiazol-2-yl)urea (<b>16e</b>) using the procedure previously described for compound <b>17a</b> and was purified by recrystallization from ethanol. Yield: 188 mg (45%, 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.60(s, 1H), 9.84(s, 1H), 8.90(s, 1H), 7.86(s, 1H), 7.20–7.48(m, 5H), 4.38(br s, 4H), 3.72(br s, 4H), 3.36(d, <i>J</i> = 7.6 Hz, 6H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>23</sub>BrN<sub>6</sub>O<sub>5</sub>S<sub>2</sub> [M + H]<sup>+</sup> 607.0433; found, 607.0424.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 1-{5-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-(3-ethynylphenyl)urea (<b>17f</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>3</b> and 1-(3-ethynylphenyl)-3-(5-mercapto-[1,3,4]thiadiazol-2-yl)urea (<b>16f</b>) using the procedure previously described for compound <b>17a</b> and was purified by recrystallization from ethanol. Yield: 420 mg (67%, 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.78(s, 1H), 9.47(s, 1H), 8.82(s, 1H), 7.80(s, 1H), 7.58(s, 1H), 7.24–7.43(m, 3H), 7.04(d, <i>J</i> = 5.6 Hz, 1H), 4.41(br s, 4H), 4.24(s, 1H), 3.77(br s, 4H), 3.36(d, <i>J</i> = 6.4 Hz, 6H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>25</sub>H<sub>24</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub> [M + H]<sup>+</sup> 553.1328; found, 553.1024.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 1-{5-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-<i>p</i>-tolylurea (<b>17g</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>3</b> and 1-(5-mercapto-[1,3,4]thiadiazol-2-yl)-3-<i>p</i>-tolylurea (<b>16g</b>) using the procedure previously described for compound <b>17a</b> and was purified by recrystallization from ethanol. Yield: 90 mg (42%, 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.21(s, 1H), 9.05(s, 1H), 8.88(s, 1H), 7.58(s, 1H), 7.45(s, 1H), 7.40(d, <i>J</i> = 7.6 Hz, 2H), 7.15(d, <i>J</i> = 8.4 Hz, 2H), 4.38(br s, 4H), 3.78(br s, 4H), 3.37(d, <i>J</i> = 7.6 Hz, 6H), 2.27(s, 3H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>24</sub>H<sub>26</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub> [M + H]<sup>+</sup> 543.1484; found, 543.1220.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 1-{5-[6,7-Bis(2-methoxyethoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-[4-(trifluoromethyl)phenyl]urea (<b>17h</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>3</b> and 1-(5-mercapto-[1,3,4]thiadiazol-2-yl)-3-[4-(trifluoromethyl)phenyl]urea (<b>16h</b>) using the procedure previously described for compound <b>17a</b> and was purified by recrystallization from ethanol. Yield: 220 mg (40%, 96% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.90(s, 1H), 10.89(s, 1H), 8.89(s, 1H), 7.71–7.74(m, 4H), 7.45(s, 1H), 7.39(s, 1H), 4.38(br s, 4H), 3.78(br s, 4H), 3.36(d, <i>J</i> = 7.2 Hz, 6H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>24</sub>H<sub>23</sub>F<sub>3</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub> [M + Na]<sup>+</sup> 619.1021; found, 619.1024.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N-</i>{5-[7-(3-Morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}acrylamide (<b>20a</b>)</h4><div class="NLM_p">To a <i>N,N</i>-dimethylformamide solution (5 mL) of 3-morpholinopropan-1-ol (2.5 mL, 18.3 mmol) at 0 °C was added 60% NaH (744 mg, 18.6 mmol), and the mixture was stirred for 30 min. To this cold solution was added a <i>N,N</i>-dimethylformamide solution (3 mL) of 7-fluoroquinazolin-4(3<i>H</i>)-one (<b>18</b>, 1.0 g, 6.1 mmol), and the mixture was heated at 100 °C overnight. The solvent was evaporated, and the residue was purified by ethyl ether to afford desired product <b>19</b> (1.43 g, 81%) as a white powder. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.11(s, 1H), 8.05(s, 1H), 8.00–8.02(m, 1H), 7.07–7.10(m, 2H), 4.15(t, <i>J</i> = 6.4 Hz, 2H), 3.58(t, <i>J</i> = 4.4 Hz, 4H), 2.43(t, <i>J</i> = 7.2 Hz, 2H), 2.37(br s, 4H), 1.92(m, 2H) ppm.</div><div class="NLM_p">Phosphorus oxychloride (8.0 mL) was added dropwise to <i>N,N</i>-diethylaniline (1.0 mL) with magnetic stirring followed by the addition of 7-(3-morpholinopropoxy)quinazolin-4(3<i>H</i>)-one (<b>19</b>, 1.0 g, 3.45 mmol), and the reaction flask was immersed in a preheated oil bath (70 °C). The temperature was increased to 90 °C and kept at 90 °C for another 3 h. Most of the excess of phosphorus oxychloride was then removed under reduced pressure and the resulting dark oil triturated with toluene (3 × 40 mL). The residue was dissolved in water (20 mL) and extracted with EtOAc (2 × 15 mL). The pH of the aqueous phase was adjusted to 9–10 with Na<sub>2</sub>CO<sub>3</sub>, and it was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 150 mL) and dried over Na<sub>2</sub>SO<sub>4</sub>, and the organic solvent was removed to afford the product as yellowish oil (900 mg, 84%) without further purification to use for the next step.</div><div class="NLM_p last">A solution of the yellowish oil (300 mg, 0.97 mmol), <i>N-</i>(5-mercapto-[1,3,4]thiadiazol-2-yl)acrylamide (<b>16b</b>, 220 mg, 1.18 mmol), and K<sub>2</sub>CO<sub>3</sub> (404 mg, 2.93 mmol) in <i>N,N</i>-dimethylformamide (8 mL) was heated at 100 °C overnight. The reaction mixture was evaporated under reduced pressure. Ice water (20 mL) was added and the white precipitate filtered and washed with ice water (50 mL), which was recrystallized from ethanol to give <b>20a</b> (225 mg, 50%, 95% HPLC purity) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.02(s, 1H), 8.95(s, 1H), 8.15(d, <i>J</i> = 9.2 Hz, 1H), 6.60(dd, <i>J</i> = 10.0 Hz, 10.0 Hz, 1H), 6.49(dd, <i>J</i> = 1.6 Hz, 1.6 Hz, 1H), 6.02(dd, <i>J</i> = 2.0 Hz, 2.0 Hz, 1H), 4.27(t, <i>J</i> = 6.2 Hz, 2H), 3.59(t, <i>J</i> = 4.4 Hz, 4H), 2.48(br s, 2H), 2.40(br s, 4H), 1.97(m, 2H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>22</sub>N<sub>6</sub>O<sub>3</sub>S<sub>2</sub> [M + H]<sup>+</sup> 459.1273; found, 459.1270.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 1-{5-[7-(3-Morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-phenylurea (<b>20b</b>)</h4><div class="NLM_p last">The title compound was prepared from the intermediate yellowish oil and 1-(5-mercapto-[1,3,4]thiadiazol-2-yl)-3-phenylurea (<b>16i</b>) using the procedure previously described for compound <b>20a</b> and was purified by recrystallization from ethanol. Yield: 180 mg (70%, 95% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.43(s, 1H), 9.31(s, 1H), 8.94(s, 1H), 8.14(d, <i>J</i> = 9.2 Hz, 1H), 7.53(d, <i>J</i> = 8.0 Hz, 2H), 7.32–7.44(m, 4H), 7.07(t, <i>J</i> = 7.4 Hz, 1H), 4.27(t, <i>J</i> = 6.4 Hz, 2H), 3.59(t, <i>J</i> = 4.4 Hz, 4H), 2.48(br s, 2H), 2.42(br s, 4H), 1.98(m, 2H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>24</sub>H<sub>25</sub>N<sub>7</sub>O<sub>3</sub>S<sub>2</sub> [M + H]<sup>+</sup> 524.1539; found, 524.1553.</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 1-{5-[7-(3-Morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-<i>p</i>-tolylurea (<b>20c</b>)</h4><div class="NLM_p last">The title compound was prepared from the intermediate yellowish oil and 1-(5-mercapto-[1,3,4]thiadiazol-2-yl)-3-<i>p</i>-tolylurea (<b>16g</b>) using the procedure previously described for compound <b>20a</b> and was purified by recrystallization from ethanol. Yield: 210 mg (59%, 95% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.40(s, 1H), 9.17(s, 1H), 8.95(s, 1H), 8.15(d, <i>J</i> = 9.2 Hz, 1H), 7.40–7.44(m, 4H), 7.15(d, <i>J</i> = 8.4 Hz, 2H), 4.27(t, <i>J</i> = 6.0 Hz, 2H), 3.60(br s, 4H), 2.48(br s, 2H), 2.42(br s, 4H), 2.27(s, 3H), 1.98(m, 2H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>25</sub>H<sub>27</sub>N<sub>7</sub>O<sub>3</sub>S<sub>2</sub> [M + H]<sup>+</sup> 538.1695; found, 538.1685.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 1-(3-Chlorophenyl)-3-{5-[7-(3-morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}urea (<b>20d</b>)</h4><div class="NLM_p last">The title compound was prepared from the intermediate yellowish oil and 1-(3-chlorophenyl)-3-(5-mercapto-[1,3,4]thiadiazol-2-yl)urea (<b>16c</b>) using the procedure previously described for compound <b>20a</b> and was purified by recrystallization from ethanol. Yield: 355 mg (72%, 95% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.45(s, 1H), 10.19(s, 1H), 8.95(s, 1H), 8.15(d, <i>J</i> = 8.8 Hz, 1H), 7.77(s, 1H), 7.34–7.44(m, 4H), 7.10(d, <i>J</i> = 7.2 Hz, 1H), 4.27(t, <i>J</i> = 5.8 Hz, 2H), 3.61(br s, 4H), 2.55(br s, 2H), 2.48(br s, 4H), 2.00(m, 2H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>24</sub>H<sub>24</sub>ClN<sub>7</sub>O<sub>3</sub>S<sub>2</sub> [M + H]<sup>+</sup> 558.1149; found, 558.1156.</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 1-(3-Ethynylphenyl)-3-{5-[7-(3-morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}urea (<b>20e</b>)</h4><div class="NLM_p last">The title compound was prepared from the intermediate yellowish oil and 1-(3-ethynylphenyl)-3-(5-mercapto-[1,3,4]thiadiazol-2-yl)urea (<b>16f</b>) using the procedure previously described for compound <b>20a</b> and was purified by recrystallization from ethanol. Yield: 368 mg (77%, 95% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.85(s, 1H), 9.83(s, 1H), 8.94(s, 1H), 8.14(d, <i>J</i> = 8.8 Hz, 1H), 7.57(d, <i>J</i> = 8.0 Hz, 1H), 7.32–7.43(m, 3H), 7.15(d, <i>J</i> = 7.6 Hz, 2H), 4.26(t, <i>J</i> = 6.0 Hz, 2H), 4.19(s, 1H), 3.59(br s, 4H), 2.47(br s, 2H), 2.41(br s, 4H), 1.97(m, 2H) ppm. HRMS (<i>m</i>/<i>z</i>): calcd for C<sub>26</sub>H<sub>25</sub>N<sub>7</sub>O<sub>3</sub>S<sub>2</sub> [M + H]<sup>+</sup> 548.1539; found, 548.1553.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Kinase Inhibitory Assays</h3><div class="NLM_p last">The kinase inhibitory assays were performed according to the KinaseProfiler assay protocols of Upstate Biotechnology (Millipore).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Cell Culture</h3><div class="NLM_p last">Unless specifically mentioned, the cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were grown in RPMI 1640 or DMEM culture medium containing 10% fetal bovine serum (v/v) in 5% CO<sub>2</sub> at 37 °C, except for MV4-11 cells, which were cultured in IMDM culture medium.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Cell Viability Assays</h3><div class="NLM_p last">The viability of cells was determined using the MTT assay method. The leukemia cells were seeded in a 96-well plate at 1–4 × 10<sup>4</sup> cells per well, and an equal volume of medium containing increasing concentrations of inhibitors was added to each well. At the end of the incubation period (72 h at 37 °C), 20 μL of 5 mg/mL MTT reagent was added per well for 2–4 h of incubation, and 50 μL of 20% acidified SDS per well was used to lyse the cells. The other cell lines were seeded in 96-well plates at a density of 2–5 × 10<sup>3</sup> cells/well for 24 h followed by replacement of the medium with serial dilutions of inhibitors in culture medium. Following a 72-h incubation, the MTT reagent was added for a 2–4-h incubation, and 100% DMSO was used to dissolve the cells. Finally, the light absorption (OD) of the dissolved cells was measured at 570 nm using a SpectraMAX M5 microplate spectrophotometer (Molecular Devices). All experiments were performed in triplicate. The percentage of viability was calculated and compared with that of the control cells treated with DMSO (0.1%).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Immunoprecipitation and Western Blot Assays</h3><div class="NLM_p last">Immunoprecipitation and immunoblotting were performed for the analysis of FLT3 autophosphorylation. After treatment with a series of concentrations of <b>20c</b> for 24 h at 37 °C, MV4-11 cells were harvested, washed in ice-cold PBS, and lysed with RIPA buffer (10 mM Tris-HCl (pH 7.8), 1% NP40, 0.15 M NaCl, 1 mM EDTA, 10 μM aprotinin, 1 mM NaF, and 1 mM Na<sub>3</sub>VO<sub>4</sub>). Samples were incubated overnight at 4 °C with the anti-FLT3 antibody, and immune complexes were precipitated with protein A agarose (Roche Applied Science) at 4 °C. The precipitated samples were subjected to immunoblot analysis to detect FLT3 phosphorylation by probing with the antiphosphotyrosine antibody (Upstate Biotechnology, Lake Placid, NY). Total FLT3 was measured with an anti-FLT3 antibody after the PVDF membrane had been incubated with stripping buffer. STAT5 and Erk1/2 phosphorylation was detected through immunoblot analysis. Briefly, after 20 h of <b>20c</b> treatment, MV4-11 cells were harvested and lysed with RIPA buffer. Samples were analyzed by immunoblotting as outlined above using antiphospho-STAT5, anti-STAT5, anti-p44/42 MAPK, and antiphospho-p44/42 MAPK antibodies.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> <i>In Vivo</i> Models</h3><div class="NLM_p last">MV4-11 cells were harvested during the exponential-growth phase, washed twice with serum-free medium, and resuspended at the concentration of 1 × 10<sup>8</sup>/mL. One hundred microliters of cell suspensions was injected subcutaneously into the hind flank of each female NOD-SCID mouse (6–7 weeks old). The tumors were allowed to grow to 300–500 mm<sup>3</sup> at which point the mice were randomized into 4 groups (6 mice for each group) and dosed with <b>20c</b> (20, 40, or 100 mg/kg/d) or vehicle. The compounds were dissolved in 25% (v/v) PEG400 plus 5% DMSO and administered intraperitoneally at a dose of 5 mL/kg. Tumor growth was measured every 3 days using Vernier calipers for the duration of the treatment. The volume was calculated as follows: tumor volume = <i>a</i> × <i>b</i><sup>2</sup>/2 (<i>a</i>, long diameter; <i>b</i>, short diameter).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Histopathology and IHC</h3><div class="NLM_p last">NOD-SCID mice bearing tumors or having undergone bone marrow engraftment were treated with <b>20c</b> at a dose of 20 mg/kg/d (ip). At the indicated time after dosing, individual mice were sacrificed. The tumors or femoral bones were fixed with formalin and embedded in paraffin (femoral bones were decalcified). Sections measuring 4–8 μm in thickness were prepared for histological and immunohistochemical analysis. Proliferation was detected using immunostaining with the Ki67 antibody (Thermo Fisher Scientific, Fremont, CA). Apoptosis was determined using transferase-mediated dUTP nick-end labeling (TUNEL) and staining (Roche Applied Science). Finally, images were captured with an Olympus digital camera attached to a light microscope.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Pharmacokinetic Analysis</h3><div class="NLM_p last">Male Sprague–Dawley rats (200–250 g) were used and randomly divided into two groups (<i>n</i> = 3 in each group). A catheter was surgically placed into the femoral vein for collection of blood samples. Rats were fasted overnight before dosing. Compounds <b>20c</b> and <b>20e</b> were administered intraperitoneally (ip) at a dose of 40 mg/kg. Plasma concentrations of each compound were determined by LC-MS/MS (a 3200 QTRAP system, Applied Biosystems/MDS Sciex).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70"><a href="/doi/suppl/10.1021/jm300042x">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43043" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43043" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">IC<sub>50</sub> values of <b>1</b> against human FLT3 and pharmacokinetic properties of <b>20c</b> and <b>20e</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300042x/suppl_file/jm300042x_si_001.pdf">jm300042x_si_001.pdf (210.07 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm300042x" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02513" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02513" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheng-Yong Yang</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#eb928a858c9892ab98889ec58e8f9ec58885"><span class="__cf_email__" data-cfemail="552c343b32262c152636207b3031207b363b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei-Wei Li</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span>; 
    <span class="hlFld-Affiliation affiliation">College of Chemical Engineering, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiao-Yan Wang</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span>; 
    <span class="hlFld-Affiliation affiliation">West China School of Pharmacy, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ren-Lin Zheng</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heng-Xiu Yan</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhi-Xing Cao</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Zhong</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ze-Rong Wang</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pan Ji</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ling-Ling Yang</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li-Jiao Wang</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Xu</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing-Jing Liu</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiao Yang</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chun-Hui Zhang</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuang Ma</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shan Feng</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qi-Zheng Sun</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu-Quan Wei</span> - <span class="hlFld-Affiliation affiliation">State Key
Laboratory of Biotherapy
and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Sichuan 610041, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d130e4354-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31214" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31214" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation of China (81172987), the National S&T Major Project (2012ZX09102-101-002), and the 863 Hi-Tech Program (2012AA020301 and 2012AA020308).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i72" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i72"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i73" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i73"> Abbreviations Used</h2><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">FMS-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">STAT5</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 5</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3-kinase</p></td></tr><tr><td class="NLM_term">ITD</td><td class="NLM_def"><p class="first last">internal tandem duplications</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">HOBT</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24418" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24418" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 33 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Lyman, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zappone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleath, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckmann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bird, T.</span><span> </span><span class="NLM_article-title">Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">815</span><span class="NLM_x">–</span> <span class="NLM_lpage">822</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1993&pages=815-822&author=S.+D.+Lymanauthor=L.+Jamesauthor=J.+Zapponeauthor=P.+R.+Sleathauthor=M.+P.+Beckmannauthor=T.+Bird&title=Characterization+of+the+protein+encoded+by+the+flt3+%28flk2%29+receptor-like+tyrosine+kinase+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLyman%26aufirst%3DS.%2BD.%26aulast%3DJames%26aufirst%3DL.%26aulast%3DZappone%26aufirst%3DJ.%26aulast%3DSleath%26aufirst%3DP.%2BR.%26aulast%3DBeckmann%26aufirst%3DM.%2BP.%26aulast%3DBird%26aufirst%3DT.%26atitle%3DCharacterization%2520of%2520the%2520protein%2520encoded%2520by%2520the%2520flt3%2520%2528flk2%2529%2520receptor-like%2520tyrosine%2520kinase%2520gene%26jtitle%3DOncogene%26date%3D1993%26volume%3D8%26spage%3D815%26epage%3D822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Rosnet, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pebusque, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchetto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonnelle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toiron, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnbaum, D.</span><span> </span><span class="NLM_article-title">Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">1110</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1993&pages=1110-1119&author=O.+Rosnetauthor=C.+Schiffauthor=M.+J.+Pebusqueauthor=S.+Marchettoauthor=C.+Tonnelleauthor=Y.+Toironauthor=F.+Birgauthor=D.+Birnbaum&title=Human+FLT3%2FFLK2+gene%3A+cDNA+cloning+and+expression+in+hematopoietic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosnet%26aufirst%3DO.%26aulast%3DSchiff%26aufirst%3DC.%26aulast%3DPebusque%26aufirst%3DM.%2BJ.%26aulast%3DMarchetto%26aufirst%3DS.%26aulast%3DTonnelle%26aufirst%3DC.%26aulast%3DToiron%26aufirst%3DY.%26aulast%3DBirg%26aufirst%3DF.%26aulast%3DBirnbaum%26aufirst%3DD.%26atitle%3DHuman%2520FLT3%252FFLK2%2520gene%253A%2520cDNA%2520cloning%2520and%2520expression%2520in%2520hematopoietic%2520cells%26jtitle%3DBlood%26date%3D1993%26volume%3D82%26spage%3D1110%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Lyman, S. D.</span><span> </span><span class="NLM_article-title">Biology of Xt3 ligand and receptor</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1016%2F0925-5710%2895%2900389-A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=8590775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADyaK2MXptl2qsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1995&pages=63-73&author=S.+D.+Lyman&title=Biology+of+Xt3+ligand+and+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Biology of flt3 ligand and receptor</span></div><div class="casAuthors">Lyman, Stewart D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">63-73</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review, with 42 refs., on the discovery of the flt3 ligand and its receptor, its biol. activities, and some potential clin. uses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouQkW9M_ml7rVg90H21EOLACvtfcHk0lig02ciybs9ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptl2qsLs%253D&md5=18590831d0db14fe9b6f5767db528a40</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2F0925-5710%2895%2900389-A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0925-5710%252895%252900389-A%26sid%3Dliteratum%253Aachs%26aulast%3DLyman%26aufirst%3DS.%2BD.%26atitle%3DBiology%2520of%2520Xt3%2520ligand%2520and%2520receptor%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D1995%26volume%3D62%26spage%3D63%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">The roles of FLT3 in hematopoiesis and leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1532</span><span class="NLM_x">–</span> <span class="NLM_lpage">1542</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1182%2Fblood-2002-02-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=12176867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=1532-1542&author=D.+G.+Gillilandauthor=J.+D.+Griffin&title=The+roles+of+FLT3+in+hematopoiesis+and+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of FLT3 in hematopoiesis and leukemia</span></div><div class="casAuthors">Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1532-1542</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system.  The ligand for FLT3 is expressed by marrow stromal cells and other cells and synergized with other growth factors to stimulate proliferation of stem cells, progenitor cells, dendritic cells, and natural killer cells.  Mutations of FLT3 have been detected in about 30% of patients with acute myelogenous leukemia and a small no. of patients with acute lymphocytic leukemia or myelodysplastic syndrome.  Patients with FLT3 mutations tend to have a poor prognosis.  The mutations most often involve small tandem duplications of amino acids within the juxtamembrane domain of the receptor and result in constitutive tyrosine kinase activity.  Expression of a mutant FLT3 receptor in murine marrow cells results in a lethal myeloproliferative syndrome and preliminary studies suggest that mutant FLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype.  Taken together, these results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQc2WkC8EQbVg90H21EOLACvtfcHk0lig02ciybs9ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D&md5=f6d04b227f5c5baf5c22cfba6e693ff1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-02-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-02-0492%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520roles%2520of%2520FLT3%2520in%2520hematopoiesis%2520and%2520leukemia%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D1532%26epage%3D1542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">FLT3 tyrosine kinase inhibitors</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1532%2FIJH97.05079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=16146839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2005&pages=100-107&author=M.+Levisauthor=D.+Small&title=FLT3+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 tyrosine kinase inhibitors</span></div><div class="casAuthors">Levis, Mark; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">100-107</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Carden Jennings Publishing</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase FLT3 is an important regulatory mol. in hematopoiesis and is expressed on the blasts in most cases of acute leukemia.  Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are assocd. with a distinctly worse clin. outcome.  Efforts to target this mutation and improve outcomes in this subgroup of AML patients have led to the investigation of several novel small-mol. FLT3 tyrosine kinase inhibitors.  These compds. derive from a wide variety of chem. classes and differ significantly, both in their potency and in their selectivity.  In this review, we discuss the results of preclin., clin., and correlative lab. studies of FLT3 inhibitors in demonstrating how this field represents a truly translational enterprise with multiple ongoing interactions between the lab. and the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF4BnW93Jv2rVg90H21EOLACvtfcHk0lig02ciybs9ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN&md5=75bdd31913d422c3a42551ee048e4f1e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1532%2FIJH97.05079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1532%252FIJH97.05079%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DFLT3%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2005%26volume%3D82%26spage%3D100%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Cloos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goemans, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, C. J.</span><span> </span><span class="NLM_article-title">Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1217</span><span class="NLM_x">–</span> <span class="NLM_lpage">1220</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=1217-1220&author=J.+Cloosauthor=B.+F.+Goemansauthor=C.+J.+Hess&title=Stability+and+prognostic+influence+of+FLT3+mutations+in+paired+initial+and+relapsed+AML+samples"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3DGoemans%26aufirst%3DB.%2BF.%26aulast%3DHess%26aufirst%3DC.%2BJ.%26atitle%3DStability%2520and%2520prognostic%2520influence%2520of%2520FLT3%2520mutations%2520in%2520paired%2520initial%2520and%2520relapsed%2520AML%2520samples%26jtitle%3DLeukemia%26date%3D2006%26volume%3D20%26spage%3D1217%26epage%3D1220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Gale, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, C.</span><span> </span><span class="NLM_article-title">The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">2776</span><span class="NLM_x">–</span> <span class="NLM_lpage">2784</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=2776-2784&author=R.+E.+Galeauthor=C.+Greenauthor=C.+Allen&title=The+impact+of+FLT3+internal+tandem+duplication+mutant+level%2C+number%2C+size%2C+and+interaction+with+NPM1+mutations+in+a+large+cohort+of+young+adult+patients+with+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGale%26aufirst%3DR.%2BE.%26aulast%3DGreen%26aufirst%3DC.%26aulast%3DAllen%26aufirst%3DC.%26atitle%3DThe%2520impact%2520of%2520FLT3%2520internal%2520tandem%2520duplication%2520mutant%2520level%252C%2520number%252C%2520size%252C%2520and%2520interaction%2520with%2520NPM1%2520mutations%2520in%2520a%2520large%2520cohort%2520of%2520young%2520adult%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D2776%26epage%3D2784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Meshinchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonzo, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirewalt, D. L.</span><span> </span><span class="NLM_article-title">Clinical implications of FLT3 mutations in pediatric AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3654</span><span class="NLM_x">–</span> <span class="NLM_lpage">3661</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3654-3661&author=S.+Meshinchiauthor=T.+A.+Alonzoauthor=D.+L.+Stirewalt&title=Clinical+implications+of+FLT3+mutations+in+pediatric+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeshinchi%26aufirst%3DS.%26aulast%3DAlonzo%26aufirst%3DT.%2BA.%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26atitle%3DClinical%2520implications%2520of%2520FLT3%2520mutations%2520in%2520pediatric%2520AML%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3654%26epage%3D3661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozekia, K.</span><span> </span><span class="NLM_article-title">Clinical significance of FLT3 in leukemia</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1532%2FIJH97.05066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=16146837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2005&pages=85-92&author=H.+Kiyoiauthor=M.+Yanadaauthor=K.+Ozekia&title=Clinical+significance+of+FLT3+in+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of FLT3 in leukemia</span></div><div class="casAuthors">Kiyoi, Hitoshi; Yanada, Masamitsu; Ozeki, Kazutaka</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-92</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Carden Jennings Publishing</span>)
        </div><div class="casAbstract">A review.  FLT3 is a class III receptor tyrosine kinase together with KIT, FMS and PDGFR.  FLT3 mutations were first reported as internal tandem duplication (FLT3/ITD) of the juxtamembrane domain-coding sequence, and subsequently as a missense mutation of D835 (FLT3/KDM) within a kinase domain.  Furthermore, point mutations, deletions, and insertions in the codons surrounding D835 have also been found.  FLT3/ITD and FLT3/KDM occur in 15% to 35% and 5% to 10%, resp., of patients with AML.  FLT3 mutations are, therefore, the most frequent genetic alterations so far reported in AML.  Several large-scale studies have confirmed that FLT3/ITD is strongly assocd. with leukocytosis and a poor prognosis.  Although the clin. significance of FLT3/KDM is controversial, the meta-anal. suggests its adverse effect on the outcome.  FLT3/ITD is far less common in patients with ALL, whereas FLT3/KDM is recurrently found in patients with ALL, esp. in those harboring an MLL gene rearrangement or hyperdiploidy.  The overexpression of FLT3 transcripts has been demonstrated in a proportion of the AML patients without FLT3 mutations, which are assocd. with a poor prognosis for overall survival.  Routine screening of FLT3 mutations is recommended to stratify the patients into distinct risk groups, while the optimal treatment strategy for patients with FLT3 mutations should be further evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8m_krDfgYdbVg90H21EOLACvtfcHk0li4ZJfQTOc5Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL7E&md5=f7a532cc6aa951bb754f64bd3163cb1f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1532%2FIJH97.05066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1532%252FIJH97.05066%26sid%3Dliteratum%253Aachs%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DYanada%26aufirst%3DM.%26aulast%3DOzekia%26aufirst%3DK.%26atitle%3DClinical%2520significance%2520of%2520FLT3%2520in%2520leukemia%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2005%26volume%3D82%26spage%3D85%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Meshinchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonzo, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirewalt, D. L.</span><span> </span><span class="NLM_article-title">Clinical implications of FLT3 mutations in pediatric AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3654</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3654-366&author=S.+Meshinchiauthor=T.+A.+Alonzoauthor=D.+L.+Stirewalt&title=Clinical+implications+of+FLT3+mutations+in+pediatric+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeshinchi%26aufirst%3DS.%26aulast%3DAlonzo%26aufirst%3DT.%2BA.%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26atitle%3DClinical%2520implications%2520of%2520FLT3%2520mutations%2520in%2520pediatric%2520AML%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3654%26epage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Schlenk, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauter, J.</span><span> </span><span class="NLM_article-title">Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">1909</span><span class="NLM_x">–</span> <span class="NLM_lpage">1918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1056%2FNEJMoa074306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=18450602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ggu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1909-1918&author=R.+F.+Schlenkauthor=K.+Dohnerauthor=J.+Krauter&title=Mutations+and+treatment+outcome+in+cytogenetically+normal+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia</span></div><div class="casAuthors">Schlenk, Richard F.; Doehner, Konstanze; Krauter, Jurgen; Frohling, Stefan; Corbacioglu, Andrea; Bullinger, Lars; Habdank, Marianne; Spith, Daniela; Morgan, Michael; Benner, Axel; Schlegelberger, Brigitte; Heil, Gerhard; Ganser, Arnold; Doehner, Hartmut; Schlimok, G.; Arnold, R.; Pezzutto, A.; Glasmacher, A.; Germing, U.; Heit, W.; Hoelzer, D.; Derigs, H. G.; Luebbert, M.; Pralle, H.; Runde, V.; Griesinger, F.; Fiedler, W.; Salwender, H.; Kirchner, H.; Hensel, M.; Hartmann, F.; Fischer, J. T.; Kneba, M.; Hinke, A.; Kremers, S.; Goetze, K.; Waterhouse, C.; del Valle, F.; Matzdorff, A.; Grimminger, W.; Mergenthaler, H. G.; Kirchen, H.; Brossart, P.; Bergmann, L.; Raghavachar, Aruna; Petzer, A.; Koller, E.; Neons, L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1909-1918</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations occur in several genes in cytogenetically normal acute myeloid leukemia (AML) cells: the nucleophosmin gene (NPM1), the fms-related tyrosine kinase 3 gene (FLT3), the CCAAT/enhancer binding protein a gene (CEPBA), the myeloid-lymphoid or mixed-lineage leukemia gene (MLL), and the neuroblastoma RAS viral oncogene homolog (NRAS).  We evaluated the assocns. of these mutations with clin. outcomes in patients.  We compared the mutational status of the NPM1, FLT3, CEBPA, MLL, and NRAS genes in leukemia cells with the clin. outcome in 872 adults younger than 60 years of age with cytogenetically normal AML.  Patients had been entered into one of four trials of therapy for AML.  In each study, patients with an HLA-matched related donor were assigned to undergo stem-cell transplantation.  A total of 53% of patients had NPM1 mutations, 31% had FLT3 internal tandem duplications (ITDs), 11% had FLT3 tyrosine kinase-domain mutations, 13% had CEBPA mutations, 7% had MLL partial tandem duplications (PTDs), and 13% had NRAS mutations.  The overall complete-remission rate was 77%.  The genotype of mutant NPM1 without FLT3-ITD, the mutant CEBPA genotype, and younger age were each significantly assocd. with complete remission.  Of the 663 patients who received postremission therapy, 150 underwent hematopoietic stem-cell transplantation from an HLA-matched related donor.  Significant assocns. were found between the risk of relapse or the risk of death during complete remission and the leukemia genotype of mutant NPM1 without FLT3-ITD (hazard ratio, 0.44; 95% confidence interval [CI], 0.32 to 0.61), the mutant CEBPA genotype (hazard ratio, 0.48; 95% CI, 0.30 to 0.75), and the MLL-PTD genotype (hazard ratio, 1.56; 95% CI, 1.00 to 2.43), as well as receipt of a transplant from an HLA-matched related donor (hazard ratio, 0.60; 95% CI, 0.44 to 0.82).  The benefit of the transplant was limited to the subgroup of patients with the prognostically adverse genotype FLT3-ITD or the genotype consisting of wild-type NPM1 and CEBPA without FLT3-ITD.  Genotypes defined by the mutational status of NPM1, FLT3, CEBPA, and MLL are assocd. with the outcome of treatment for patients with cytogenetically normal AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6JpbRc9OYmrVg90H21EOLACvtfcHk0li4ZJfQTOc5Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ggu70%253D&md5=4109ec9d7141f2405163dfc31a9dd660</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa074306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa074306%26sid%3Dliteratum%253Aachs%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DKrauter%26aufirst%3DJ.%26atitle%3DMutations%2520and%2520treatment%2520outcome%2520in%2520cytogenetically%2520normal%2520acute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D1909%26epage%3D1918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopeck, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliverman, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannah, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span> </span><span class="NLM_article-title">SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">801</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=795-801&author=F.+J.+Gilesauthor=A.+T.+Stopeckauthor=L.+R.+Slivermanauthor=J.+E.+Lancetauthor=M.+A.+Cooperauthor=A.+L.+Hannahauthor=J.+M.+Cherringtonauthor=A.+M.+O%E2%80%99Farrellauthor=H.+A.+Yuenauthor=S.+G.+Louieauthor=W.+Hongauthor=J.+E.+Cortesauthor=S.+Verstovsekauthor=M.+Albitarauthor=S.+M.+O%E2%80%99Brienauthor=H.+M.+Kantarjianauthor=J.+E.+Karp&title=SU5416%2C+a+small+molecule+tyrosine+kinase+receptor+inhibitor%2C+has+biologic+activity+in+patients+with+refractory+acute+myeloid+leukemia+or+myelodysplastic+syndromes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DStopeck%26aufirst%3DA.%2BT.%26aulast%3DSliverman%26aufirst%3DL.%2BR.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BM.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26atitle%3DSU5416%252C%2520a%2520small%2520molecule%2520tyrosine%2520kinase%2520receptor%2520inhibitor%252C%2520has%2520biologic%2520activity%2520in%2520patients%2520with%2520refractory%2520acute%2520myeloid%2520leukemia%2520or%2520myelodysplastic%2520syndromes%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D795%26epage%3D801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">O’Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngai, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, K. W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolich, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span> </span><span class="NLM_article-title">SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">3597</span><span class="NLM_x">–</span> <span class="NLM_lpage">3605</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=3597-3605&author=A.+M.+O%E2%80%99Farrellauthor=T.+J.+Abramsauthor=H.+A.+Yuenauthor=T.+J.+Ngaiauthor=S.+G.+Louieauthor=K.+W.+H.+Yeeauthor=L.+M.+Wongauthor=W.+Hongauthor=L.+B.+Leeauthor=A.+Townauthor=B.+D.+Smolichauthor=W.+C.+Manningauthor=L.+J.+Murrayauthor=M.+C.+Heinrichauthor=J.+M.+Cherrington&title=SU11248+is+a+novel+FLT3+tyrosine+kinase+inhibitor+with+potent+activity+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DNgai%26aufirst%3DT.%2BJ.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DYee%26aufirst%3DK.%2BW.%2BH.%26aulast%3DWong%26aufirst%3DL.%2BM.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DSmolich%26aufirst%3DB.%2BD.%26aulast%3DManning%26aufirst%3DW.%2BC.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26atitle%3DSU11248%2520is%2520a%2520novel%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%2520with%2520potent%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26spage%3D3597%26epage%3D3605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Menezes, D. E. L. d.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shephard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldbeck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aukerman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C.</span><span> </span><span class="NLM_article-title">CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5281</span><span class="NLM_x">–</span> <span class="NLM_lpage">5291</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1158%2F1078-0432.CCR-05-0358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=16033847" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=5281-5291&author=D.+E.+L.+d.+Menezesauthor=J.+Pengauthor=E.+N.+Garrettauthor=S.+G.+Louieauthor=S.+H.+Leeauthor=M.+Wiesmannauthor=Y.+Tangauthor=L.+Shephardauthor=C.+Goldbeckauthor=Y.+Oeiauthor=H.+Yeauthor=S.+L.+Aukermanauthor=C.+Heise&title=CHIR-258%3A+a+potent+inhibitor+of+FLT3+kinase+in+experimental+tumor+xenograft+models+of+human+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0358%26sid%3Dliteratum%253Aachs%26aulast%3DMenezes%26aufirst%3DD.%2BE.%2BL.%2Bd.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DGarrett%26aufirst%3DE.%2BN.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DShephard%26aufirst%3DL.%26aulast%3DGoldbeck%26aufirst%3DC.%26aulast%3DOei%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DAukerman%26aufirst%3DS.%2BL.%26aulast%3DHeise%26aufirst%3DC.%26atitle%3DCHIR-258%253A%2520a%2520potent%2520inhibitor%2520of%2520FLT3%2520kinase%2520in%2520experimental%2520tumor%2520xenograft%2520models%2520of%2520human%2520acute%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D5281%26epage%3D5291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klimek, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliand, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">PKC 412 Flt3 inhibitor therapy in AML: results of a phase II trial</span> <span class="citation_source-journal">Ann. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S80</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2004&pages=S80-90&issue=Suppl+1&author=R.+M.+Stoneauthor=J.+De+Angeloauthor=I.+Galinskyauthor=E.+Esteyauthor=V.+Klimekauthor=W.+Grandinauthor=D.+Lebwohlauthor=P.+Cohenauthor=E.+Foxauthor=D.+Neubergauthor=J.+Clarkauthor=D.+G.+Gilliandauthor=J.+D.+Griffin&title=PKC+412+Flt3+inhibitor+therapy+in+AML%3A+results+of+a+phase+II+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDe%2BAngelo%26aufirst%3DJ.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DKlimek%26aufirst%3DV.%26aulast%3DGrandin%26aufirst%3DW.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DFox%26aufirst%3DE.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGilliand%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DPKC%2520412%2520Flt3%2520inhibitor%2520therapy%2520in%2520AML%253A%2520results%2520of%2520a%2520phase%2520II%2520trial%26jtitle%3DAnn.%2520Hematol.%26date%3D2004%26volume%3D83%26issue%3DSuppl%25201%26spage%3DS80%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauses, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allebach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3669</span><span class="NLM_x">–</span> <span class="NLM_lpage">3676</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2004&pages=3669-3676&author=B.+D.+Smithauthor=M.+Levisauthor=M.+Beranauthor=F.+Gilesauthor=H.+Kantarjianauthor=K.+Bergauthor=K.+M.+Murphyauthor=T.+Dausesauthor=J.+Allebachauthor=D.+Small&title=Single-agent+CEP-701%2C+a+novel+FLT3+inhibitor%2C+shows+biologic+and+clinical+activity+in+patients+with+relapsed+or+refractory+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBerg%26aufirst%3DK.%26aulast%3DMurphy%26aufirst%3DK.%2BM.%26aulast%3DDauses%26aufirst%3DT.%26aulast%3DAllebach%26aufirst%3DJ.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DSingle-agent%2520CEP-701%252C%2520a%2520novel%2520FLT3%2520inhibitor%252C%2520shows%2520biologic%2520and%2520clinical%2520activity%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2004%26volume%3D103%26spage%3D3669%26epage%3D3676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaney, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klisovic, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecerf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karol, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holford, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3674</span><span class="NLM_x">–</span> <span class="NLM_lpage">3681</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1182%2Fblood-2006-02-005702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=16902153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3674-3681&author=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=M.+L.+Heaneyauthor=S.+D.+Nimerauthor=R.+L.+Paquetteauthor=R.+B.+Klisovicauthor=M.+A.+Caligiuriauthor=M.+R.+J.+Cooperauthor=M.+Lecerfauthor=M.+D.+Karolauthor=S.+Shengauthor=N.+Holfordauthor=P.+T.+Curtinauthor=B.+J.+Drukerauthor=M.+C.+Heinrich&title=Phase+1+clinical+results+with+tandutinib+%28MLN518%29%2C+a+novel+FLT3+antagonist%2C+in+patients+with+acute+myelogenous+leukemia+or+high-risk+myelodysplastic+syndrome%3A+safety%2C+pharmacokinetics%2C+and+pharmacodynamics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span></div><div class="casAuthors">DeAngelo, Daniel J.; Stone, Richard M.; Heaney, Mark L.; Nimer, Stephen D.; Paquette, Ronald L.; Klisovic, Rebecca B.; Caligiuri, Michael A.; Cooper, Michael R.; Lecerf, Jean-Michel; Karol, Michael D.; Sheng, Shihong; Holford, Nick; Curtin, Peter T.; Druker, Brian J.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3674-3681</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT.  Because of the correlation between FLT3 internal tandem duplication (ITD) mutations and poor prognosis in acute myelogenous leukemia (AML), we conducted a phase 1 trial of tandutinib in 40 patients with either AML or high-risk myelodysplastic syndrome (MDS).  Tandutinib was given orally in doses ranging from 50 mg to 700 mg twice daily The principal dose-limiting toxicity (DLT) of tandutinib was reversible generalized muscular weakness, fatigue, or both, occurring at doses of 525 mg and 700 mg twice daily.  Tandutinib's pharmacokinetics were characterized by slow elimination, with achievement of steady-state plasma concns. requiring greater than 1 wk of dosing.  Western blotting showed that tandutinib inhibited phosphorylation of FLT3 in circulating leukemic blasts.  Eight patients had FLT3-ITD mutations; 5 of these were evaluable for assessment of tandutinib's antileukemic effect.  Two of the 5 patients, treated at 525 mg and 700 mg twice daily, showed evidence of antileukemic activity, with decreases in both peripheral and bone marrow blasts.  Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraXRBv_Gv-TLVg90H21EOLACvtfcHk0ljFC4PyZREhPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM&md5=42c0b5a4c193955023198d6c6d12c463</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-02-005702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-02-005702%26sid%3Dliteratum%253Aachs%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DHeaney%26aufirst%3DM.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DCooper%26aufirst%3DM.%2BR.%2BJ.%26aulast%3DLecerf%26aufirst%3DM.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DSheng%26aufirst%3DS.%26aulast%3DHolford%26aufirst%3DN.%26aulast%3DCurtin%26aufirst%3DP.%2BT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DPhase%25201%2520clinical%2520results%2520with%2520tandutinib%2520%2528MLN518%2529%252C%2520a%2520novel%2520FLT3%2520antagonist%252C%2520in%2520patients%2520with%2520acute%2520myelogenous%2520leukemia%2520or%2520high-risk%2520myelodysplastic%2520syndrome%253A%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3674%26epage%3D3681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konopleva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQueen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintás-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span> </span><span class="NLM_article-title">Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">198</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1093%2Fjnci%2Fdjm328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=18230792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFygsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2008&pages=184-198&author=W.+Zhangauthor=M.+Konoplevaauthor=Y.+X.+Shiauthor=T.+McQueenauthor=D.+Harrisauthor=X.+Lingauthor=Z.+Estrovauthor=A.+Quint%C3%A1s-Cardamaauthor=D.+Smallauthor=J.+Cortesauthor=M.+Andreeff&title=Mutant+FLT3%3A+a+direct+target+of+sorafenib+in+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia</span></div><div class="casAuthors">Zhang, Weiguo; Konopleva, Marina; Shi, Yue-xi; McQueen, Teresa; Harris, David; Ling, Xiaoyang; Estrov, Zeev; Quintas-Cardama, Alfonso; Small, Donald; Cortes, Jorge; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">184-198</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Internal tandem duplication (ITD) mutations in the juxtamembrane domain-coding sequence of the Fms-like tyrosine kinase 3 (FLT3) gene have been identified in 30% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  The kinase inhibitor sorafenib induces growth arrest and apoptosis at much lower concns. in AML cell lines that harbor FLT3-ITD mutations than in AML cell lines with wild-type FLT3.  The antileukemic activity of sorafenib was investigated in isogenic murine Ba/F3 AML cell lines that expressed mutant (ITD, D835G, and D835Y) or wild-type human FLT3, in primary human AML cells, and in a mouse leukemia xenograft model.  Effects of sorafenib on apoptosis and signaling in AML cell lines were investigated by flow cytometry and immunoblot anal., resp., and the in vivo effects were detd. by monitoring the survival of leukemia xenograft-bearing mice treated with sorafenib (groups of 15 mice).  In a phase 1 clin. trial, 16 patients with refractory or relapsed AML were treated with sorafenib on different dose schedules.  We detd. their FLT3 mutation status by a polymerase chain reaction assay and analyzed clin. responses by std. criteria.  All statistical tests were two-sided.  Sorafenib was 1000- to 3000-fold more effective in inducing growth arrest and apoptosis in Ba/F3 cells with FLT3-ITD or D835G mutations than in Ba/F3 cells with FLT3-D835Y mutant or wild-type FLT3 and inhibited the phosphorylation of tyrosine residues in ITD mutant but not wild-type FLT3 protein.  In a mouse model, sorafenib decreased the leukemia burden and prolonged survival (median survival in the sorafenib-treated group vs the vehicle-treated group = 36.5 vs 16 days, difference = 20.5 days, 95% confidence interval = 20.3 to 21.3 days; P = .0018).  Sorafenib reduced the percentage of leukemia blasts in the peripheral blood and the bone marrow of AML patients with FLT3-ITD (median percentages before and after sorafenib: 81% vs. 7.5% [P = .016] and 75.5% vs. 34% [P = .05], resp.) but not in patients without this mutation.  Sorafenib may have therapeutic efficacy in AML patients whose cells harbor FLT3-ITD mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNBWJSPfrsN7Vg90H21EOLACvtfcHk0liHypilTa9e0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFygsrY%253D&md5=d747b1107866a0299c972c1bcd58c770</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjm328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjm328%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DY.%2BX.%26aulast%3DMcQueen%26aufirst%3DT.%26aulast%3DHarris%26aufirst%3DD.%26aulast%3DLing%26aufirst%3DX.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DMutant%2520FLT3%253A%2520a%2520direct%2520target%2520of%2520sorafenib%2520in%2520acute%2520myelogenous%2520leukemia%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2008%26volume%3D100%26spage%3D184%26epage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanizaki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozeki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1607</span><span class="NLM_x">–</span> <span class="NLM_lpage">1617</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=1607-1617&author=Y.+Shiotsuauthor=H.+Kiyoiauthor=Y.+Ishikawaauthor=R.+Tanizakiauthor=M.+Shimizuauthor=H.+Umeharaauthor=K.+Ishiiauthor=Y.+Moriauthor=K.+Ozekiauthor=Y.+Minamiauthor=A.+Abeauthor=H.+Maedaauthor=T.+Akiyamaauthor=Y.+Kandaauthor=Y.+Satoauthor=S.+Akinagaauthor=T.+Naoe&title=KW-2449%2C+a+novel+multikinase+inhibitor%2C+suppresses+the+growth+of+leukemia+cells+with+FLT3+mutations+or+T315I-mutated+BCR%2FABL+translocation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DTanizaki%26aufirst%3DR.%26aulast%3DShimizu%26aufirst%3DM.%26aulast%3DUmehara%26aufirst%3DH.%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DOzeki%26aufirst%3DK.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DA.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DAkiyama%26aufirst%3DT.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DKW-2449%252C%2520a%2520novel%2520multikinase%2520inhibitor%252C%2520suppresses%2520the%2520growth%2520of%2520leukemia%2520cells%2520with%2520FLT3%2520mutations%2520or%2520T315I-mutated%2520BCR%252FABL%2520translocation%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D1607%26epage%3D1617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20b"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghirdaladze, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foran, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVetten, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zodelava, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padre, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corringham, R.</span><span> </span><span class="NLM_article-title">Phase 1 AML study of AC220, a potent and selective second generation FLT3 receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">767</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=767&author=J.+Cortesauthor=D.+Ghirdaladzeauthor=J.+M.+Foranauthor=M.+P.+DeVettenauthor=M.+Zodelavaauthor=M.+J.+Levisauthor=N.+M.+Padreauthor=J.+Jamesauthor=P.+P.+Zarrinkarauthor=R.+Corringham&title=Phase+1+AML+study+of+AC220%2C+a+potent+and+selective+second+generation+FLT3+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DGhirdaladze%26aufirst%3DD.%26aulast%3DForan%26aufirst%3DJ.%2BM.%26aulast%3DDeVetten%26aufirst%3DM.%2BP.%26aulast%3DZodelava%26aufirst%3DM.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPadre%26aufirst%3DN.%2BM.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DCorringham%26aufirst%3DR.%26atitle%3DPhase%25201%2520AML%2520study%2520of%2520AC220%252C%2520a%2520potent%2520and%2520selective%2520second%2520generation%2520FLT3%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26spage%3D767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J .</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roboz, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arowojolu, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shudo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span> </span><span class="NLM_article-title">A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">3938</span><span class="NLM_x">–</span> <span class="NLM_lpage">3946</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=3938-3946&author=K.+W.+Pratzauthor=J+.+Cortesauthor=G.+J.+Robozauthor=N.+Raoauthor=O.+Arowojoluauthor=A.+Stineauthor=Y.+Shiotsuauthor=A.+Shudoauthor=S.+Akinagaauthor=D.+Smallauthor=J.+E.+Karpauthor=M.+Levis&title=A+pharmacodynamic+study+of+the+FLT3+inhibitor+KW-2449+yields+insight+into+the+basis+for+clinical+response"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DCortes%26aufirst%3DJ%2B.%26aulast%3DRoboz%26aufirst%3DG.%2BJ.%26aulast%3DRao%26aufirst%3DN.%26aulast%3DArowojolu%26aufirst%3DO.%26aulast%3DStine%26aufirst%3DA.%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DShudo%26aufirst%3DA.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DA%2520pharmacodynamic%2520study%2520of%2520the%2520FLT3%2520inhibitor%2520KW-2449%2520yields%2520insight%2520into%2520the%2520basis%2520for%2520clinical%2520response%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D3938%26epage%3D3946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaney, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klisovic, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecerf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karol, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holford, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3674</span><span class="NLM_x">–</span> <span class="NLM_lpage">3681</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1182%2Fblood-2006-02-005702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=16902153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3674-3681&author=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=M.+L.+Heaneyauthor=S.+D.+Nimerauthor=R.+L.+Paquetteauthor=R.+B.+Klisovicauthor=M.+A.+Caligiuriauthor=M.+R.+J.+Cooperauthor=M.+Lecerfauthor=M.+D.+Karolauthor=S.+Shengauthor=N.+Holfordauthor=P.+T.+Curtinauthor=B.+J.+Drukerauthor=M.+C.+Heinrich&title=Phase+1+clinical+results+with+tandutinib+%28MLN518%29%2C+a+novel+FLT3+antagonist%2C+in+patients+with+acute+myelogenous+leukemia+or+high-risk+myelodysplastic+syndrome%3A+safety%2C+pharmacokinetics%2C+and+pharmacodynamics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span></div><div class="casAuthors">DeAngelo, Daniel J.; Stone, Richard M.; Heaney, Mark L.; Nimer, Stephen D.; Paquette, Ronald L.; Klisovic, Rebecca B.; Caligiuri, Michael A.; Cooper, Michael R.; Lecerf, Jean-Michel; Karol, Michael D.; Sheng, Shihong; Holford, Nick; Curtin, Peter T.; Druker, Brian J.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3674-3681</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT.  Because of the correlation between FLT3 internal tandem duplication (ITD) mutations and poor prognosis in acute myelogenous leukemia (AML), we conducted a phase 1 trial of tandutinib in 40 patients with either AML or high-risk myelodysplastic syndrome (MDS).  Tandutinib was given orally in doses ranging from 50 mg to 700 mg twice daily The principal dose-limiting toxicity (DLT) of tandutinib was reversible generalized muscular weakness, fatigue, or both, occurring at doses of 525 mg and 700 mg twice daily.  Tandutinib's pharmacokinetics were characterized by slow elimination, with achievement of steady-state plasma concns. requiring greater than 1 wk of dosing.  Western blotting showed that tandutinib inhibited phosphorylation of FLT3 in circulating leukemic blasts.  Eight patients had FLT3-ITD mutations; 5 of these were evaluable for assessment of tandutinib's antileukemic effect.  Two of the 5 patients, treated at 525 mg and 700 mg twice daily, showed evidence of antileukemic activity, with decreases in both peripheral and bone marrow blasts.  Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraXRBv_Gv-TLVg90H21EOLACvtfcHk0ljKzJFYHnWuug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM&md5=42c0b5a4c193955023198d6c6d12c463</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-02-005702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-02-005702%26sid%3Dliteratum%253Aachs%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DHeaney%26aufirst%3DM.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DCooper%26aufirst%3DM.%2BR.%2BJ.%26aulast%3DLecerf%26aufirst%3DM.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DSheng%26aufirst%3DS.%26aulast%3DHolford%26aufirst%3DN.%26aulast%3DCurtin%26aufirst%3DP.%2BT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DPhase%25201%2520clinical%2520results%2520with%2520tandutinib%2520%2528MLN518%2529%252C%2520a%2520novel%2520FLT3%2520antagonist%252C%2520in%2520patients%2520with%2520acute%2520myelogenous%2520leukemia%2520or%2520high-risk%2520myelodysplastic%2520syndrome%253A%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3674%26epage%3D3681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Knapper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littlewood, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kell, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3262</span><span class="NLM_x">–</span> <span class="NLM_lpage">3270</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3262-3270&author=S.+Knapperauthor=A.+K.+Burnettauthor=T.+Littlewoodauthor=W.+J.+Kellauthor=S.+Agrawalauthor=R.+Chopraauthor=R.+Clarkauthor=M.+J.+Levisauthor=D.+Small&title=A+phase+2+trial+of+the+FLT3+inhibitor+lestaurtinib+%28CEP701%29+as+first-line+treatment+for+older+patients+with+acute+myeloid+leukemia+not+considered+fit+for+intensive+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKnapper%26aufirst%3DS.%26aulast%3DBurnett%26aufirst%3DA.%2BK.%26aulast%3DLittlewood%26aufirst%3DT.%26aulast%3DKell%26aufirst%3DW.%2BJ.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DClark%26aufirst%3DR.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DA%2520phase%25202%2520trial%2520of%2520the%2520FLT3%2520inhibitor%2520lestaurtinib%2520%2528CEP701%2529%2520as%2520first-line%2520treatment%2520for%2520older%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520not%2520considered%2520fit%2520for%2520intensive%2520chemotherapy%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3262%26epage%3D3270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Li, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qing, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">Taking quinazoline as a general support-Nog to design potent and selective kinase inhibitors: application to FMS-like tyrosine kinase 3</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=513-516&author=W.+W.+Liauthor=J.+J.+Chenauthor=R.+L.+Zhengauthor=W.+Q.+Zhangauthor=Z.+X.+Caoauthor=L.+L.+Yangauthor=X.+Y.+Qingauthor=L.+X.+Zhouauthor=L.+Yangauthor=L.+D.+Yuauthor=L.+J.+Chenauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=Taking+quinazoline+as+a+general+support-Nog+to+design+potent+and+selective+kinase+inhibitors%3A+application+to+FMS-like+tyrosine+kinase+3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%2BW.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DZheng%26aufirst%3DR.%2BL.%26aulast%3DZhang%26aufirst%3DW.%2BQ.%26aulast%3DCao%26aufirst%3DZ.%2BX.%26aulast%3DYang%26aufirst%3DL.%2BL.%26aulast%3DQing%26aufirst%3DX.%2BY.%26aulast%3DZhou%26aufirst%3DL.%2BX.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DL.%2BD.%26aulast%3DChen%26aufirst%3DL.%2BJ.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DTaking%2520quinazoline%2520as%2520a%2520general%2520support-Nog%2520to%2520design%2520potent%2520and%2520selective%2520kinase%2520inhibitors%253A%2520application%2520to%2520FMS-like%2520tyrosine%2520kinase%25203%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D513%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Duffel, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ing, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segarra, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barfknecht, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenwald, R. D.</span><span> </span><span class="NLM_article-title"><i>N-</i>Substituted sulfonamide carbonic anhydrase inhibitors with topical effects on intraocular pressure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1488</span><span class="NLM_x">–</span> <span class="NLM_lpage">1494</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00158a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1986&pages=1488-1494&author=M.+W.+Duffelauthor=I.+S.+Ingauthor=T.+M.+Segarraauthor=J.+A.+Dixsonauthor=C.+F.+Barfknechtauthor=R.+D.+Schoenwald&title=N-Substituted+sulfonamide+carbonic+anhydrase+inhibitors+with+topical+effects+on+intraocular+pressure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm00158a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00158a028%26sid%3Dliteratum%253Aachs%26aulast%3DDuffel%26aufirst%3DM.%2BW.%26aulast%3DIng%26aufirst%3DI.%2BS.%26aulast%3DSegarra%26aufirst%3DT.%2BM.%26aulast%3DDixson%26aufirst%3DJ.%2BA.%26aulast%3DBarfknecht%26aufirst%3DC.%2BF.%26aulast%3DSchoenwald%26aufirst%3DR.%2BD.%26atitle%3DN-Substituted%2520sulfonamide%2520carbonic%2520anhydrase%2520inhibitors%2520with%2520topical%2520effects%2520on%2520intraocular%2520pressure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1986%26volume%3D29%26spage%3D1488%26epage%3D1494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Zhong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, M. P.</span><span> </span><span class="NLM_article-title">Stereo-selective synthesis of (Z)-ketene selenothioacetals via hydrozirconation of alkylacetylenic selenides</span> <span class="citation_source-journal">J. Chem. Res. Synopses</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">370</span><span class="NLM_x">–</span> <span class="NLM_lpage">371</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1995&pages=370-371&author=P.+Zhongauthor=M.+P.+Guo&title=Stereo-selective+synthesis+of+%28Z%29-ketene+selenothioacetals+via+hydrozirconation+of+alkylacetylenic+selenides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DM.%2BP.%26atitle%3DStereo-selective%2520synthesis%2520of%2520%2528Z%2529-ketene%2520selenothioacetals%2520via%2520hydrozirconation%2520of%2520alkylacetylenic%2520selenides%26jtitle%3DJ.%2520Chem.%2520Res.%2520Synopses%26date%3D1995%26volume%3D9%26spage%3D370%26epage%3D371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Almajan, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innocenti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puccetti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manole, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbuceanu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saramet, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scozzafava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span> </span><span class="NLM_article-title">Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2347</span><span class="NLM_x">–</span> <span class="NLM_lpage">2352</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2347-2352&author=G.+L.+Almajanauthor=A.+Innocentiauthor=L.+Puccettiauthor=G.+Manoleauthor=S.+Barbuceanuauthor=I.+Sarametauthor=A.+Scozzafavaauthor=C.+T.+Supuran&title=Carbonic+anhydrase+inhibitors.+Inhibition+of+the+cytosolic+and+tumor-associated+carbonic+anhydrase+isozymes+I%2C+II%2C+and+IX+with+a+series+of+1%2C3%2C4-thiadiazole-+and+1%2C2%2C4-triazole-thiols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlmajan%26aufirst%3DG.%2BL.%26aulast%3DInnocenti%26aufirst%3DA.%26aulast%3DPuccetti%26aufirst%3DL.%26aulast%3DManole%26aufirst%3DG.%26aulast%3DBarbuceanu%26aufirst%3DS.%26aulast%3DSaramet%26aufirst%3DI.%26aulast%3DScozzafava%26aufirst%3DA.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26atitle%3DCarbonic%2520anhydrase%2520inhibitors.%2520Inhibition%2520of%2520the%2520cytosolic%2520and%2520tumor-associated%2520carbonic%2520anhydrase%2520isozymes%2520I%252C%2520II%252C%2520and%2520IX%2520with%2520a%2520series%2520of%25201%252C3%252C4-thiadiazole-%2520and%25201%252C2%252C4-triazole-thiols%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D2347%26epage%3D2352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misra, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlins, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursuker, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roongta, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulheron, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bol, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, K. R.</span><span> </span><span class="NLM_article-title">Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3905</span><span class="NLM_x">–</span> <span class="NLM_lpage">3927</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0201520" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3905-3927&author=K.+S.+Kimauthor=S.+D.+Kimballauthor=R.+N.+Misraauthor=D.+B.+Rawlinsauthor=J.+T.+Huntauthor=H.+Y.+Xiaoauthor=S.+Luauthor=L.+Qianauthor=W.+C.+Hanauthor=W.+Shanauthor=T.+Mittauthor=Z.+W.+Caiauthor=M.+A.+Possauthor=H.+Zhuauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=C.+Y.+Changauthor=N.+Pavletichauthor=A.+Kamathauthor=W.+G.+Humphreysauthor=P.+Maratheauthor=I.+Bursukerauthor=K.+A.+Kellarauthor=U.+Roongtaauthor=R.+Batorskyauthor=J.+G.+Mulheronauthor=D.+Bolauthor=C.+R.+Fairchildauthor=F.+Y.+Leeauthor=K.+R.+Webster&title=Discovery+of+aminothiazole+inhibitors+of+cyclin-dependent+kinase+2%3A+synthesis%2C+X-ray+crystallographic+analysis%2C+and+biological+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0201520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0201520%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DXiao%26aufirst%3DH.%2BY.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DW.%2BC.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DMitt%26aufirst%3DT.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DPavletich%26aufirst%3DN.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DBursuker%26aufirst%3DI.%26aulast%3DKellar%26aufirst%3DK.%2BA.%26aulast%3DRoongta%26aufirst%3DU.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DBol%26aufirst%3DD.%26aulast%3DFairchild%26aufirst%3DC.%2BR.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3DDiscovery%2520of%2520aminothiazole%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25202%253A%2520synthesis%252C%2520X-ray%2520crystallographic%2520analysis%252C%2520and%2520biological%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3905%26epage%3D3927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Smith, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakley, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainwright, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Womersley, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span> </span><span class="NLM_article-title">Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts</span> <span class="citation_source-journal">Mol. Cancer. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2198</span><span class="NLM_x">–</span> <span class="NLM_lpage">2208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1158%2F1535-7163.MCT-07-0142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=17699717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2198-2208&author=N.+R.+Smithauthor=N.+H.+Jamesauthor=I.+Oakleyauthor=A.+Wainwrightauthor=C.+Copleyauthor=J.+Kendrewauthor=L.+M.+Womersleyauthor=J.+M.+J%C3%BCrgensmeierauthor=S.+R.+Wedgeauthor=S.+T.+Barry&title=Acute+pharmacodynamic+and+antivascular+effects+of+the+vascular+endothelial+growth+factor+signaling+inhibitor+AZD2171+in+Calu-6+human+lung+tumor+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts</span></div><div class="casAuthors">Smith, Neil R.; James, Neil H.; Oakley, Ian; Wainwright, Anna; Copley, Clive; Kendrew, Jane; Womersley, Lynsey M.; Juergensmeier, Juliane M.; Wedge, Stephen R.; Barry, Simon T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2198-2208</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The vascular endothelial growth factor-A (VEGF-A) signaling pathway, a key stimulant of solid tumor vascularization, is primarily dependent on the activation of the endothelial cell surface receptor VEGF receptor-2 (VEGFR-2).  AZD2171 is an oral, highly potent small-mol. inhibitor of VEGFR tyrosine kinase activity that inhibits angiogenesis and the growth of human tumor xenografts in vivo.  Here, we show pharmacodynamic changes in VEGFR-2 phosphorylation induced by AZD2171.  In mouse lung tissue, a single dose of AZD2171 at 6 mg/kg inhibited VEGF-A-stimulated VEGFR-2 phosphorylation by 87% at 2 h with significant inhibition (≥60%) maintained to 24 h.  To examine inhibition of VEGFR-2 phosphorylation in tumor vasculature by immunohistochem., a comprehensive assessment of antibodies to various phosphorylation sites on the receptor was undertaken.  Antibodies to the phosphotyrosine epitopes pY1175/1173 and pY1214/1212 were found suitable for this application.  Calu-6 human lung tumor xenografts, from mice receiving AZD2171 or vehicle treatment (p.o., once daily), were examd. by immunohistochem.  A significant redn. in tumor vessel staining of phosphorylated VEGFR-2 (pVEGFR-2) was evident within 28 h of AZD2171 treatment (6 mg/kg).  This effect preceded a significant redn. in tumor microvessel d., which was detectable following 52 h of AZD2171 treatment.  These data show that AZD2171 is a potent inhibitor of VEGFR-2 activation in vivo and suggest that AZD2171 delivers therapeutic benefit in Calu-6 tumors by targeting vessels dependent on VEGFR-2 signaling for survival.  In addn., this work highlights the utility of measuring either pY1175/1173 or pY1214/1212 on VEGFR-2 as a pharmacodynamic marker of VEGFR-2 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSVvyqU1WR9bVg90H21EOLACvtfcHk0lg-OHoVCY_W7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltb4%253D&md5=a6bef539c30c6cefc41a8d0eb433e418</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0142%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DN.%2BR.%26aulast%3DJames%26aufirst%3DN.%2BH.%26aulast%3DOakley%26aufirst%3DI.%26aulast%3DWainwright%26aufirst%3DA.%26aulast%3DCopley%26aufirst%3DC.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DWomersley%26aufirst%3DL.%2BM.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26atitle%3DAcute%2520pharmacodynamic%2520and%2520antivascular%2520effects%2520of%2520the%2520vascular%2520endothelial%2520growth%2520factor%2520signaling%2520inhibitor%2520AZD2171%2520in%2520Calu-6%2520human%2520lung%2520tumor%2520xenografts%26jtitle%3DMol.%2520Cancer.%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2198%26epage%3D2208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Brave, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratcliffe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainwright, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadbent, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sproat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farnsworth, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennequin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibuya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span> </span><span class="NLM_article-title">Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family</span> <span class="citation_source-journal">Mol. Cancer. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">873</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1158%2F1535-7163.MCT-10-0976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=21441409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlslKgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=861-873&author=S.+R.+Braveauthor=K.+Ratcliffeauthor=Z.+Wilsonauthor=N.+H.+Jamesauthor=S.+Ashtonauthor=A.+Wainwrightauthor=J.+Kendrewauthor=P.+Dudleyauthor=N.+Broadbentauthor=G.+Sproatauthor=S.+Taylorauthor=C.+Barnesauthor=J.+C.+Silvaauthor=C.+L.+Farnsworthauthor=L.+Hennequinauthor=D.+J.+Ogilvieauthor=J.+M.+J%C3%BCrgensmeierauthor=M.+Shibuyaauthor=S.+R.+Wedgeauthor=S.+T.+Barry&title=Assessing+the+activity+of+cediranib%2C+a+VEGFR-2%2F3+tyrosine+kinase+inhibitor%2C+against+VEGFR-1+and+members+of+the+structurally+related+PDGFR+family"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family</span></div><div class="casAuthors">Brave, Sandra R.; Ratcliffe, Kirsty; Wilson, Zena; James, Neil H.; Ashton, Sue; Wainwright, Anna; Kendrew, Jane; Dudley, Philippa; Broadbent, Nicola; Sproat, Graham; Taylor, Sian; Barnes, Claire; Silva, Jeffrey C.; Farnsworth, Charles L.; Hennequin, Laurent; Ogilvie, Donald J.; Juergensmeier, Juliane M.; Shibuya, Masabumi; Wedge, Stephen R.; Barry, Simon T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">861-873</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cediranib is a potent inhibitor of the VEGF receptor (VEGFR)-2 and VEGFR-3 tyrosine kinases.  This study assessed the activity of cediranib against the VEGFR-1 tyrosine kinase and the platelet-derived growth factor receptor (PDGFR)-assocd. kinases c-Kit, PDGFR-α, and PDGFR-β.  Cediranib inhibited VEGF-A-stimulated VEGFR-1 activation in AG1-G1-Flt1 cells (IC50 = 1.2 nmol/L).  VEGF-A induced greatest phosphorylation of VEGFR-1 at tyrosine residues Y1048 and Y1053; this was reversed by cediranib.  Potency against VEGFR-1 was comparable with that previously obsd. vs. VEGFR-2 and VEGFR-3.  Cediranib also showed significant activity against wild-type c-Kit in cellular phosphorylation assays (IC50 = 1-3 nmol/L) and in a stem cell factor-induced proliferation assay (IC50 = 13 nmol/L).  Furthermore, phosphorylation of wild-type c-Kit in NCI-H526 tumor xenografts was reduced markedly following oral administration of cediranib (≥1.5 mg/kg/d) to tumor-bearing nude mice.  The activity of cediranib against PDGFR-β and PDGFR-α was studied in tumor cell lines, vascular smooth muscle cells (VSMC), and a fibroblast line using PDGF-AA and PDGF-BB ligands.  Both receptor phosphorylation (IC50 = 12-32 nmol/L) and PDGF-BB-stimulated cellular proliferation (IC50 = 32 nmol/L in human VSMCs; 64 nmol/L in osteosarcoma cells) were inhibited.  In vivo, ligand-induced PDGFR-β phosphorylation in murine lung tissue was inhibited by 55% following treatment with cediranib at 6 mg/kg but not at 3 mg/kg or less.  In contrast, in C6 rat glial tumor xenografts in mice, ligand-induced phosphorylation of both PDGFR-α and PDGFR-β was reduced by 46% to 61% with 0.75 mg/kg cediranib.  Addnl. selectivity was showed vs. Flt-3, CSF-1R, EGFR, FGFR1, and FGFR4.  Collectively, these data indicate that cediranib is a potent pan-VEGFR kinase inhibitor with similar activity against c-Kit but is significantly less potent than PDGFR-α and PDGFR-β.  Mol Cancer Ther; 10(5); 861-73.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTno6b8K1-qrVg90H21EOLACvtfcHk0lg-OHoVCY_W7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlslKgt7o%253D&md5=2d166c229ff2a012bff16fa7aead0b31</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0976%26sid%3Dliteratum%253Aachs%26aulast%3DBrave%26aufirst%3DS.%2BR.%26aulast%3DRatcliffe%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DJames%26aufirst%3DN.%2BH.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DWainwright%26aufirst%3DA.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DDudley%26aufirst%3DP.%26aulast%3DBroadbent%26aufirst%3DN.%26aulast%3DSproat%26aufirst%3DG.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DBarnes%26aufirst%3DC.%26aulast%3DSilva%26aufirst%3DJ.%2BC.%26aulast%3DFarnsworth%26aufirst%3DC.%2BL.%26aulast%3DHennequin%26aufirst%3DL.%26aulast%3DOgilvie%26aufirst%3DD.%2BJ.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DShibuya%26aufirst%3DM.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26atitle%3DAssessing%2520the%2520activity%2520of%2520cediranib%252C%2520a%2520VEGFR-2%252F3%2520tyrosine%2520kinase%2520inhibitor%252C%2520against%2520VEGFR-1%2520and%2520members%2520of%2520the%2520structurally%2520related%2520PDGFR%2520family%26jtitle%3DMol.%2520Cancer.%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D861%26epage%3D873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Pandey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkots, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seroogy, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambing, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchaleelaha, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenbach, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarborough, R. M.</span><span> </span><span class="NLM_article-title">Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3772</span><span class="NLM_x">–</span> <span class="NLM_lpage">3793</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020143r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3772-3793&author=A.+Pandeyauthor=D.+L.+Volkotsauthor=J.+M.+Seroogyauthor=J.+W.+Roseauthor=J.+C.+Yuauthor=J.+L.+Lambingauthor=A.+Hutchaleelahaauthor=S.+J.+Hollenbachauthor=K.+Abeauthor=N.+A.+Gieseauthor=R.+M.+Scarborough&title=Identification+of+orally+active%2C+potent%2C+and+selective+4-piperazinylquinazolines+as+antagonists+of+the+platelet-derived+growth+factor+receptor+tyrosine+kinase+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm020143r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020143r%26sid%3Dliteratum%253Aachs%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DVolkots%26aufirst%3DD.%2BL.%26aulast%3DSeroogy%26aufirst%3DJ.%2BM.%26aulast%3DRose%26aufirst%3DJ.%2BW.%26aulast%3DYu%26aufirst%3DJ.%2BC.%26aulast%3DLambing%26aufirst%3DJ.%2BL.%26aulast%3DHutchaleelaha%26aufirst%3DA.%26aulast%3DHollenbach%26aufirst%3DS.%2BJ.%26aulast%3DAbe%26aufirst%3DK.%26aulast%3DGiese%26aufirst%3DN.%2BA.%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26atitle%3DIdentification%2520of%2520orally%2520active%252C%2520potent%252C%2520and%2520selective%25204-piperazinylquinazolines%2520as%2520antagonists%2520of%2520the%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3772%26epage%3D3793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Mortlock, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foote, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heron, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, J. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savi, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dousson, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaton, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odedra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keen, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crafter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brightwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khatri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kearney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKillop, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhead, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span> </span><span class="NLM_article-title">Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of Aurora B kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2213</span><span class="NLM_x">–</span> <span class="NLM_lpage">2224</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061335f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2213-2224&author=A.+A.+Mortlockauthor=K.+M.+Footeauthor=N.+M.+Heronauthor=F.+H.+Jungauthor=G.+Pasquetauthor=J.+J.+M.+Lohmannauthor=N.+Warinauthor=F.+Renaudauthor=C.+D.+Saviauthor=N.+J.+Robertsauthor=T.+Johnsonauthor=C.+B.+Doussonauthor=G.+B.+Hillauthor=D.+Perkinsauthor=G.+Hatterauthor=R.+W.+Wilkinsonauthor=S.+R.+Wedgeauthor=S.+P.+Heatonauthor=R.+Odedraauthor=N.+J.+Keenauthor=C.+Crafterauthor=E.+Brownauthor=K.+Thompsonauthor=S.+Brightwellauthor=L.+Khatriauthor=M.+C.+Bradyauthor=S.+Kearneyauthor=D.+McKillopauthor=S.+Rheadauthor=T.+Parryauthor=S.+Green&title=Discovery%2C+synthesis%2C+and+in+vivo+activity+of+a+new+class+of+pyrazoloquinazolines+as+selective+inhibitors+of+Aurora+B+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm061335f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061335f%26sid%3Dliteratum%253Aachs%26aulast%3DMortlock%26aufirst%3DA.%2BA.%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DHeron%26aufirst%3DN.%2BM.%26aulast%3DJung%26aufirst%3DF.%2BH.%26aulast%3DPasquet%26aufirst%3DG.%26aulast%3DLohmann%26aufirst%3DJ.%2BJ.%2BM.%26aulast%3DWarin%26aufirst%3DN.%26aulast%3DRenaud%26aufirst%3DF.%26aulast%3DSavi%26aufirst%3DC.%2BD.%26aulast%3DRoberts%26aufirst%3DN.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DDousson%26aufirst%3DC.%2BB.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DHatter%26aufirst%3DG.%26aulast%3DWilkinson%26aufirst%3DR.%2BW.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DHeaton%26aufirst%3DS.%2BP.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DKeen%26aufirst%3DN.%2BJ.%26aulast%3DCrafter%26aufirst%3DC.%26aulast%3DBrown%26aufirst%3DE.%26aulast%3DThompson%26aufirst%3DK.%26aulast%3DBrightwell%26aufirst%3DS.%26aulast%3DKhatri%26aufirst%3DL.%26aulast%3DBrady%26aufirst%3DM.%2BC.%26aulast%3DKearney%26aufirst%3DS.%26aulast%3DMcKillop%26aufirst%3DD.%26aulast%3DRhead%26aufirst%3DS.%26aulast%3DParry%26aufirst%3DT.%26aulast%3DGreen%26aufirst%3DS.%26atitle%3DDiscovery%252C%2520synthesis%252C%2520and%2520in%2520vivo%2520activity%2520of%2520a%2520new%2520class%2520of%2520pyrazoloquinazolines%2520as%2520selective%2520inhibitors%2520of%2520Aurora%2520B%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2213%26epage%3D2224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Bemis, G. W.; Harbeson, S. L.; Ledeboer, M.</span><span> </span><span class="NLM_article-title">Inhibitors of JAK protein kinase</span>. US 20040038992 A120040226.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Bemis%2C+G.+W.%3B+Harbeson%2C+S.+L.%3B+Ledeboer%2C+M.+Inhibitors+of+JAK+protein+kinase.+US+20040038992+A120040226."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBemis%26aufirst%3DG.%2BW.%26atitle%3DInhibitors%2520of%2520JAK%2520protein%2520kinase" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20b'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 29 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Julakanti Satyanarayana Reddy, Chih-Ming Chen, Mohane Selvaraj Coumar, Hsu-Yi Sun, Na Sun, <span class="NLM_string-name hlFld-ContribAuthor">Hsing-Pang Hsieh</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Robust Scale-Up Synthetic Route for BPR1K871: A Clinical Candidate for the Treatment of Acute Myeloid Leukemia and Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2021,</strong> <em>25 </em>
                                    (4)
                                     , 817-830. <a href="https://doi.org/10.1021/acs.oprd.0c00515" title="DOI URL">https://doi.org/10.1021/acs.oprd.0c00515</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.0c00515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.0c00515%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ba%252BRobust%252BScale-Up%252BSynthetic%252BRoute%252Bfor%252BBPR1K871%25253A%252BA%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BAcute%252BMyeloid%252BLeukemia%252Band%252BSolid%252BTumors%26aulast%3DReddy%26aufirst%3DJulakanti%2BSatyanarayana%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D26112020%26date%3D18022021%26volume%3D25%26issue%3D4%26spage%3D817%26epage%3D830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mieko  Arisawa</span>, <span class="hlFld-ContribAuthor ">Takeru  Tazawa</span>, <span class="hlFld-ContribAuthor ">Saori  Tanii</span>, <span class="hlFld-ContribAuthor ">Kiyofumi  Horiuchi</span>, and <span class="hlFld-ContribAuthor ">Masahiko  Yamaguchi</span>  . </span><span class="cited-content_cbyCitation_article-title">Rhodium-Catalyzed Synthesis of Unsymmetric Di(heteroaryl) Sulfides Using Heteroaryl Ethers and S-Heteroaryl Thioesters via Heteroarylthio Exchange. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>82 </em>
                                    (1)
                                     , 804-810. <a href="https://doi.org/10.1021/acs.joc.6b02585" title="DOI URL">https://doi.org/10.1021/acs.joc.6b02585</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.6b02585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.6b02585%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DRhodium-Catalyzed%252BSynthesis%252Bof%252BUnsymmetric%252BDi%252528heteroaryl%252529%252BSulfides%252BUsing%252BHeteroaryl%252BEthers%252Band%252BS-Heteroaryl%252BThioesters%252Bvia%252BHeteroarylthio%252BExchange%26aulast%3DArisawa%26aufirst%3DMieko%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D31102016%26date%3D20122016%26date%3D06012017%26date%3D12122016%26volume%3D82%26issue%3D1%26spage%3D804%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Hu</span>, <span class="hlFld-ContribAuthor ">Cui-Yun  Li</span>, <span class="hlFld-ContribAuthor ">Xiao-Ming  Wang</span>, <span class="hlFld-ContribAuthor ">Yong-Hua  Yang</span>, and <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>  . </span><span class="cited-content_cbyCitation_article-title">1,3,4-Thiadiazole: Synthesis, Reactions, and Applications in Medicinal, Agricultural, and Materials Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2014,</strong> <em>114 </em>
                                    (10)
                                     , 5572-5610. <a href="https://doi.org/10.1021/cr400131u" title="DOI URL">https://doi.org/10.1021/cr400131u</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cr400131u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcr400131u%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3D1%25252C3%25252C4-Thiadiazole%25253A%252BSynthesis%25252C%252BReactions%25252C%252Band%252BApplications%252Bin%252BMedicinal%25252C%252BAgricultural%25252C%252Band%252BMaterials%252BChemistry%26aulast%3DHu%26aufirst%3DYang%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D27022013%26date%3D09042014%26date%3D28052014%26volume%3D114%26issue%3D10%26spage%3D5572%26epage%3D5610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhongyan  Chen</span>, <span class="hlFld-ContribAuthor ">Jiuxi  Chen</span>, <span class="hlFld-ContribAuthor ">Miaochang  Liu</span>, <span class="hlFld-ContribAuthor ">Jinchang  Ding</span>, <span class="hlFld-ContribAuthor ">Wenxia  Gao</span>, <span class="hlFld-ContribAuthor ">Xiaobo  Huang</span>, and <span class="hlFld-ContribAuthor ">Huayue  Wu</span>  . </span><span class="cited-content_cbyCitation_article-title">Unexpected Copper-Catalyzed Cascade Synthesis of Quinazoline Derivatives. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2013,</strong> <em>78 </em>
                                    (22)
                                     , 11342-11348. <a href="https://doi.org/10.1021/jo401908g" title="DOI URL">https://doi.org/10.1021/jo401908g</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jo401908g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjo401908g%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DUnexpected%252BCopper-Catalyzed%252BCascade%252BSynthesis%252Bof%252BQuinazoline%252BDerivatives%26aulast%3DChen%26aufirst%3DZhongyan%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D28082013%26date%3D30102013%26date%3D15112013%26date%3D17102013%26volume%3D78%26issue%3D22%26spage%3D11342%26epage%3D11348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling-Ling  Yang</span>, <span class="hlFld-ContribAuthor ">Guo-Bo  Li</span>, <span class="hlFld-ContribAuthor ">Shuang  Ma</span>, <span class="hlFld-ContribAuthor ">Chan  Zou</span>, <span class="hlFld-ContribAuthor ">Shu  Zhou</span>, <span class="hlFld-ContribAuthor ">Qi-Zheng  Sun</span>, <span class="hlFld-ContribAuthor ">Chuan  Cheng</span>, <span class="hlFld-ContribAuthor ">Xin  Chen</span>, <span class="hlFld-ContribAuthor ">Li-Jiao  Wang</span>, <span class="hlFld-ContribAuthor ">Shan  Feng</span>, <span class="hlFld-ContribAuthor ">Lin-Li  Li</span>, and <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure–Activity Relationship Studies of Pyrazolo[3,4-d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (4)
                                     , 1641-1655. <a href="https://doi.org/10.1021/jm301537p" title="DOI URL">https://doi.org/10.1021/jm301537p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301537p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301537p%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%2525E2%252580%252593Activity%252BRelationship%252BStudies%252Bof%252BPyrazolo%25255B3%25252C4-d%25255Dpyrimidine%252BDerivatives%252BLeading%252Bto%252Bthe%252BDiscovery%252Bof%252Ba%252BNovel%252BMultikinase%252BInhibitor%252BThat%252BPotently%252BInhibits%252BFLT3%252Band%252BVEGFR2%252Band%252BEvaluation%252Bof%252BIts%252BActivity%252Bagainst%252BAcute%252BMyeloid%252BLeukemia%252Bin%252BVitro%252Band%252Bin%252BVivo%26aulast%3DYang%26aufirst%3DLing-Ling%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D20102012%26date%3D19022013%26date%3D28022013%26date%3D30012013%26volume%3D56%26issue%3D4%26spage%3D1641%26epage%3D1655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shilong  Zheng</span>, <span class="hlFld-ContribAuthor ">Qiu  Zhong</span>, <span class="hlFld-ContribAuthor ">Quan  Jiang</span>, <span class="hlFld-ContribAuthor ">Madhusoodanan  Mottamal</span>, <span class="hlFld-ContribAuthor ">Qiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Naijue  Zhu</span>, <span class="hlFld-ContribAuthor ">Matthew E.  Burow</span>, <span class="hlFld-ContribAuthor ">Rebecca A.  Worthylake</span>, and <span class="hlFld-ContribAuthor ">Guangdi  Wang</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Series of Thiazole Derivatives as Novel Inhibitors of Metastatic Cancer Cell Migration and Invasion. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>4 </em>
                                    (2)
                                     , 191-196. <a href="https://doi.org/10.1021/ml300322n" title="DOI URL">https://doi.org/10.1021/ml300322n</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml300322n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml300322n%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BSeries%252Bof%252BThiazole%252BDerivatives%252Bas%252BNovel%252BInhibitors%252Bof%252BMetastatic%252BCancer%252BCell%252BMigration%252Band%252BInvasion%26aulast%3DZheng%26aufirst%3DShilong%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D05102012%26date%3D15012013%26date%3D22012013%26date%3D14022013%26date%3D15012013%26volume%3D4%26issue%3D2%26spage%3D191%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andris  Jeminejs</span>, <span class="hlFld-ContribAuthor ">Svetlana M.  Goliškina</span>, <span class="hlFld-ContribAuthor ">Irina  Novosjolova</span>, <span class="hlFld-ContribAuthor ">Dmitrijs  Stepanovs</span>, <span class="hlFld-ContribAuthor ">Ērika  Bizdēna</span>, <span class="hlFld-ContribAuthor ">Māris  Turks</span>. </span><span class="cited-content_cbyCitation_article-title">Application of Azide-Tetrazole Tautomerism and Arylsulfanyl Group Dance in the Synthesis of Thiosubstituted Tetrazoloquinazolines. </span><span class="cited-content_cbyCitation_journal-name">Synthesis</span><span> <strong>2021,</strong> <em>53 </em>
                                    (08)
                                     , 1443-1456. <a href="https://doi.org/10.1055/s-0040-1706568" title="DOI URL">https://doi.org/10.1055/s-0040-1706568</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0040-1706568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0040-1706568%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthesis%26atitle%3DApplication%252Bof%252BAzide-Tetrazole%252BTautomerism%252Band%252BArylsulfanyl%252BGroup%252BDance%252Bin%252Bthe%252BSynthesis%252Bof%252BThiosubstituted%252BTetrazoloquinazolines%26aulast%3DJeminejs%26aufirst%3DAndris%26date%3D2021%26date%3D2020%26volume%3D53%26issue%3D08%26spage%3D1443%26epage%3D1456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rajkumar Romeshkumar  Singh</span>, <span class="hlFld-ContribAuthor ">Thokchom Prasanta  Singh</span>, <span class="hlFld-ContribAuthor ">Thangjam Linda  Devi</span>, <span class="hlFld-ContribAuthor ">Thokchom Jeeta  Devi</span>, <span class="hlFld-ContribAuthor ">Okram Mukherjee  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 2,4-disubstituted quinazolines promoted by deep eutectic solvent. </span><span class="cited-content_cbyCitation_journal-name">Current Research in Green and Sustainable Chemistry</span><span> <strong>2021,</strong> <em>4 </em>, 100130. <a href="https://doi.org/10.1016/j.crgsc.2021.100130" title="DOI URL">https://doi.org/10.1016/j.crgsc.2021.100130</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.crgsc.2021.100130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.crgsc.2021.100130%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Research%2520in%2520Green%2520and%2520Sustainable%2520Chemistry%26atitle%3DSynthesis%252Bof%252B2%25252C4-disubstituted%252Bquinazolines%252Bpromoted%252Bby%252Bdeep%252Beutectic%252Bsolvent%26aulast%3DSingh%26aufirst%3DRajkumar%2BRomeshkumar%26date%3D2021%26volume%3D4%26spage%3D100130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayoub  Aghcheli</span>, <span class="hlFld-ContribAuthor ">Mahsa  Toolabi</span>, <span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Loghman  Firoozpour</span>, <span class="hlFld-ContribAuthor ">Tayebeh Oghabi  Bakhshaiesh</span>, <span class="hlFld-ContribAuthor ">Elahe  Nazeri</span>, <span class="hlFld-ContribAuthor ">Maryam  Norouzbahari</span>, <span class="hlFld-ContribAuthor ">Rezvan  Esmaeili</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of 1-(5-(benzylthio)-1,3,4-thiadiazol-2-yl)-3-phenylurea derivatives as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2020,</strong> <em>29 </em>
                                    (11)
                                     , 2000-2010. <a href="https://doi.org/10.1007/s00044-020-02616-2" title="DOI URL">https://doi.org/10.1007/s00044-020-02616-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-020-02616-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-020-02616-2%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252B1-%2525285-%252528benzylthio%252529-1%25252C3%25252C4-thiadiazol-2-yl%252529-3-phenylurea%252Bderivatives%252Bas%252Banticancer%252Bagents%26aulast%3DAghcheli%26aufirst%3DAyoub%26date%3D2020%26date%3D2020%26volume%3D29%26issue%3D11%26spage%3D2000%26epage%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guo  Zhang</span>, <span class="hlFld-ContribAuthor ">Wenqing  Zhang</span>, <span class="hlFld-ContribAuthor ">Chenjian  Shen</span>, <span class="hlFld-ContribAuthor ">Jinshan  Nan</span>, <span class="hlFld-ContribAuthor ">Ming  Chen</span>, <span class="hlFld-ContribAuthor ">Shusheng  Lai</span>, <span class="hlFld-ContribAuthor ">Jiemin  Zhong</span>, <span class="hlFld-ContribAuthor ">Bolin  Li</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Yifei  Wang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>, <span class="hlFld-ContribAuthor ">Linli  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of small molecule FLT3 inhibitors that are able to overcome drug-resistant mutations. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (22)
                                     , 127532. <a href="https://doi.org/10.1016/j.bmcl.2020.127532" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127532</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127532%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bsmall%252Bmolecule%252BFLT3%252Binhibitors%252Bthat%252Bare%252Bable%252Bto%252Bovercome%252Bdrug-resistant%252Bmutations%26aulast%3DZhang%26aufirst%3DGuo%26date%3D2020%26volume%3D30%26issue%3D22%26spage%3D127532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qing  Li</span>, <span class="hlFld-ContribAuthor ">Ran  An</span>, <span class="hlFld-ContribAuthor ">Yaochun  Xu</span>, <span class="hlFld-ContribAuthor ">Mi  Zhou</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Chun  Guo</span>, <span class="hlFld-ContribAuthor ">Renxiao  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of (1,3,4-thiadiazol-2-yl)-acrylamide derivatives as potential antitumor agents against acute leukemia cells. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (10)
                                     , 127114. <a href="https://doi.org/10.1016/j.bmcl.2020.127114" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127114%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Bof%252B%2525281%25252C3%25252C4-thiadiazol-2-yl%252529-acrylamide%252Bderivatives%252Bas%252Bpotential%252Bantitumor%252Bagents%252Bagainst%252Bacute%252Bleukemia%252Bcells%26aulast%3DLi%26aufirst%3DQing%26date%3D2020%26volume%3D30%26issue%3D10%26spage%3D127114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reem F.  Abutayeh</span>, <span class="hlFld-ContribAuthor ">Jehad  Almaliti</span>, <span class="hlFld-ContribAuthor ">Mutasem O.  Taha</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of New Sulfonamides-Based Flt3 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry</span><span> <strong>2020,</strong> <em>16 </em>
                                    (3)
                                     , 403-412. <a href="https://doi.org/10.2174/1573406415666190401144053" title="DOI URL">https://doi.org/10.2174/1573406415666190401144053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1573406415666190401144053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1573406415666190401144053%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BNew%252BSulfonamides-Based%252BFlt3%252BInhibitors%26aulast%3DAbutayeh%26aufirst%3DReem%2BF.%26date%3D2020%26volume%3D16%26issue%3D3%26spage%3D403%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vikas  Patil</span>, <span class="hlFld-ContribAuthor ">Nagaiyan  Sekar</span>, <span class="hlFld-ContribAuthor ">Vikas S.  Padalkar</span>, <span class="hlFld-ContribAuthor ">Jamatsing  Rajput</span>, <span class="hlFld-ContribAuthor ">Sharad R.  Patil</span>, <span class="hlFld-ContribAuthor ">Satish V.  Patil</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular properties of 5-(1H-Benzo[D]Oxa, thia, imid azole-2-Yl)-2-methyl quinazolin-4-ol fluorescent brighteners: Theoretical and experimental approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2020,</strong> <em>1199 </em>, 126984. <a href="https://doi.org/10.1016/j.molstruc.2019.126984" title="DOI URL">https://doi.org/10.1016/j.molstruc.2019.126984</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2019.126984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2019.126984%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DMolecular%252Bproperties%252Bof%252B5-%2525281H-Benzo%25255BD%25255DOxa%25252C%252Bthia%25252C%252Bimid%252Bazole-2-Yl%252529-2-methyl%252Bquinazolin-4-ol%252Bfluorescent%252Bbrighteners%25253A%252BTheoretical%252Band%252Bexperimental%252Bapproach%26aulast%3DPatil%26aufirst%3DVikas%26date%3D2020%26volume%3D1199%26spage%3D126984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Govindan  Subramanian</span>, <span class="hlFld-ContribAuthor ">Yaqi  Zhu</span>, <span class="hlFld-ContribAuthor ">Scott J.  Bowen</span>, <span class="hlFld-ContribAuthor ">Nicole  Roush</span>, <span class="hlFld-ContribAuthor ">Julie A.  White</span>, <span class="hlFld-ContribAuthor ">Dennis  Huczek</span>, <span class="hlFld-ContribAuthor ">Theresa  Zachary</span>, <span class="hlFld-ContribAuthor ">Christopher  Javens</span>, <span class="hlFld-ContribAuthor ">Tracey  Williams</span>, <span class="hlFld-ContribAuthor ">Ann  Janssen</span>, <span class="hlFld-ContribAuthor ">Andrea  Gonzales</span>. </span><span class="cited-content_cbyCitation_article-title">Lead identification and characterization of hTrkA type 2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (22)
                                     , 126680. <a href="https://doi.org/10.1016/j.bmcl.2019.126680" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126680</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126680%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DLead%252Bidentification%252Band%252Bcharacterization%252Bof%252BhTrkA%252Btype%252B2%252Binhibitors%26aulast%3DSubramanian%26aufirst%3DGovindan%26date%3D2019%26volume%3D29%26issue%3D22%26spage%3D126680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Heng</span>, <span class="hlFld-ContribAuthor ">Zhijie  Wang</span>, <span class="hlFld-ContribAuthor ">Hongmei  Li</span>, <span class="hlFld-ContribAuthor ">Yatian  Huang</span>, <span class="hlFld-ContribAuthor ">Qingyuan  Lan</span>, <span class="hlFld-ContribAuthor ">Xiaoxing  Guo</span>, <span class="hlFld-ContribAuthor ">Liang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yanle  Zhi</span>, <span class="hlFld-ContribAuthor ">Jiongheng  Cai</span>, <span class="hlFld-ContribAuthor ">Tianren  Qin</span>, <span class="hlFld-ContribAuthor ">Li  Xiang</span>, <span class="hlFld-ContribAuthor ">Shuxian  Wang</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>176 </em>, 248-267. <a href="https://doi.org/10.1016/j.ejmech.2019.05.021" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.05.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.05.021%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCombining%252Bstructure-%252Band%252Bproperty-based%252Boptimization%252Bto%252Bidentify%252Bselective%252BFLT3-ITD%252Binhibitors%252Bwith%252Bgood%252Bantitumor%252Befficacy%252Bin%252BAML%252Bcell%252Binoculated%252Bmouse%252Bxenograft%252Bmodel%26aulast%3DHeng%26aufirst%3DHao%26date%3D2019%26volume%3D176%26spage%3D248%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reem Fawaz  Abutayeh</span>, <span class="hlFld-ContribAuthor ">Mutasem O.  Taha</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel Flt3 inhibitory chemotypes through extensive ligand-based and new structure-based pharmacophore modelling methods. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2019,</strong> <em>88 </em>, 128-151. <a href="https://doi.org/10.1016/j.jmgm.2019.01.011" title="DOI URL">https://doi.org/10.1016/j.jmgm.2019.01.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2019.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2019.01.011%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DDiscovery%252Bof%252Bnovel%252BFlt3%252Binhibitory%252Bchemotypes%252Bthrough%252Bextensive%252Bligand-based%252Band%252Bnew%252Bstructure-based%252Bpharmacophore%252Bmodelling%252Bmethods%26aulast%3DAbutayeh%26aufirst%3DReem%2BFawaz%26date%3D2019%26volume%3D88%26spage%3D128%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Longjia  Yan</span>, <span class="hlFld-ContribAuthor ">Minggao  Deng</span>, <span class="hlFld-ContribAuthor ">Anchao  Chen</span>, <span class="hlFld-ContribAuthor ">Yongliang  Li</span>, <span class="hlFld-ContribAuthor ">Wanzheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhi-yun  Du</span>, <span class="hlFld-ContribAuthor ">Chang-zhi  Dong</span>, <span class="hlFld-ContribAuthor ">Bernard  Meunier</span>, <span class="hlFld-ContribAuthor ">Huixiong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of N-pyrimidin[1,3,4]oxadiazoles and N-pyrimidin[1,3,4]-thiadiazoles from 1,3,4-oxadiazol-2-amines and 1,3,4-thiadiazol-2-amines via Pd-catalyzed heteroarylamination. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2019,</strong> <em>60 </em>
                                    (20)
                                     , 1359-1362. <a href="https://doi.org/10.1016/j.tetlet.2019.04.022" title="DOI URL">https://doi.org/10.1016/j.tetlet.2019.04.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2019.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2019.04.022%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DSynthesis%252Bof%252BN-pyrimidin%25255B1%25252C3%25252C4%25255Doxadiazoles%252Band%252BN-pyrimidin%25255B1%25252C3%25252C4%25255D-thiadiazoles%252Bfrom%252B1%25252C3%25252C4-oxadiazol-2-amines%252Band%252B1%25252C3%25252C4-thiadiazol-2-amines%252Bvia%252BPd-catalyzed%252Bheteroarylamination%26aulast%3DYan%26aufirst%3DLongjia%26date%3D2019%26volume%3D60%26issue%3D20%26spage%3D1359%26epage%3D1362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah  Diab</span>, <span class="hlFld-ContribAuthor ">Ahmad M.  Abdelaziz</span>, <span class="hlFld-ContribAuthor ">Peng  Li</span>, <span class="hlFld-ContribAuthor ">Theodosia  Teo</span>, <span class="hlFld-ContribAuthor ">Sunita K.C.  Basnet</span>, <span class="hlFld-ContribAuthor ">Ben  Noll</span>, <span class="hlFld-ContribAuthor ">Muhammed H.  Rahaman</span>, <span class="hlFld-ContribAuthor ">Jingfeng  Lu</span>, <span class="hlFld-ContribAuthor ">Jinqiang  Hou</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Yu</span>, <span class="hlFld-ContribAuthor ">Bich T.  Le</span>, <span class="hlFld-ContribAuthor ">Hugo  Albrecht</span>, <span class="hlFld-ContribAuthor ">Robert W.  Milne</span>, <span class="hlFld-ContribAuthor ">Shudong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>139 </em>, 762-772. <a href="https://doi.org/10.1016/j.ejmech.2017.08.006" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.006%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252BInhibition%252Bof%252BMnk2%252Band%252BFLT3%252Bfor%252Bpotential%252Btreatment%252Bof%252Bacute%252Bmyeloid%252Bleukaemia%26aulast%3DDiab%26aufirst%3DSarah%26date%3D2017%26volume%3D139%26spage%3D762%26epage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kamal M.  Dawood</span>, <span class="hlFld-ContribAuthor ">Thoraya A.  Farghaly</span>. </span><span class="cited-content_cbyCitation_article-title">Thiadiazole inhibitors: a patent review. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2017,</strong> <em>27 </em>
                                    (4)
                                     , 477-505. <a href="https://doi.org/10.1080/13543776.2017.1272575" title="DOI URL">https://doi.org/10.1080/13543776.2017.1272575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2017.1272575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2017.1272575%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DThiadiazole%252Binhibitors%25253A%252Ba%252Bpatent%252Breview%26aulast%3DDawood%26aufirst%3DKamal%2BM.%26date%3D2017%26date%3D2017%26volume%3D27%26issue%3D4%26spage%3D477%26epage%3D505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mieko  Arisawa</span>, <span class="hlFld-ContribAuthor ">Masahiko  Yamaguchi</span>, <span class="hlFld-ContribAuthor ">Saori  Tanii</span>, <span class="hlFld-ContribAuthor ">Takeru  Tazawa</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Unsymmetric HetAr–X–HetAr’ Compounds by Rhodium-Catalyzed Heteroaryl Exchange Reactions. </span><span class="cited-content_cbyCitation_journal-name">HETEROCYCLES</span><span> <strong>2017,</strong> <em>94 </em>
                                    (12)
                                     , 2179. <a href="https://doi.org/10.3987/REV-17-869" title="DOI URL">https://doi.org/10.3987/REV-17-869</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3987/REV-17-869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3987%2FREV-17-869%26sid%3Dliteratum%253Aachs%26jtitle%3DHETEROCYCLES%26atitle%3DSynthesis%252Bof%252BUnsymmetric%252BHetAr%2525E2%252580%252593X%2525E2%252580%252593HetAr%2525E2%252580%252599%252BCompounds%252Bby%252BRhodium-Catalyzed%252BHeteroaryl%252BExchange%252BReactions%26aulast%3DArisawa%26aufirst%3DMieko%26date%3D2017%26volume%3D94%26issue%3D12%26spage%3D2179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M. V.  Madhubabu</span>, <span class="hlFld-ContribAuthor ">R.  Shankar</span>, <span class="hlFld-ContribAuthor ">Satish. S.  More</span>, <span class="hlFld-ContribAuthor ">Mandava V.  Basaveswara Rao</span>, <span class="hlFld-ContribAuthor ">U. K. Syam  Kumar</span>, <span class="hlFld-ContribAuthor ">A.  Raghunadh</span>. </span><span class="cited-content_cbyCitation_article-title">An efficient and convenient protocol for the synthesis of tetracyclic isoindolo[1,2-a]quinazoline derivatives. </span><span class="cited-content_cbyCitation_journal-name">RSC Adv.</span><span> <strong>2016,</strong> <em>6 </em>
                                    (43)
                                     , 36599-36601. <a href="https://doi.org/10.1039/C5RA28097D" title="DOI URL">https://doi.org/10.1039/C5RA28097D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5RA28097D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5RA28097D%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Adv.%26atitle%3DAn%252Befficient%252Band%252Bconvenient%252Bprotocol%252Bfor%252Bthe%252Bsynthesis%252Bof%252Btetracyclic%252Bisoindolo%25255B1%25252C2-a%25255Dquinazoline%252Bderivatives%26aulast%3DMadhubabu%26aufirst%3DM.%2BV.%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D43%26spage%3D36599%26epage%3D36601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xing-Dong  Lin</span>, <span class="hlFld-ContribAuthor ">Hui-Wen  Yang</span>, <span class="hlFld-ContribAuthor ">Shuang  Ma</span>, <span class="hlFld-ContribAuthor ">Wei-Wei  Li</span>, <span class="hlFld-ContribAuthor ">Chun-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Wen-Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>, <span class="hlFld-ContribAuthor ">Lin-Li  Li</span>, <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (20)
                                     , 4534-4538. <a href="https://doi.org/10.1016/j.bmcl.2015.08.068" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.08.068</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.08.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.08.068%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B6-phenylimidazo%25255B2%25252C1-b%25255Dthiazole%252Bderivatives%252Bas%252Ba%252Bnew%252Btype%252Bof%252BFLT3%252Binhibitors%26aulast%3DLin%26aufirst%3DXing-Dong%26date%3D2015%26volume%3D25%26issue%3D20%26spage%3D4534%26epage%3D4538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jin  Xu</span>, <span class="hlFld-ContribAuthor ">Esther H.Q.  Ong</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Hill</span>, <span class="hlFld-ContribAuthor ">Anqi  Chen</span>, <span class="hlFld-ContribAuthor ">Christina L.L.  Chai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2014,</strong> <em>22 </em>
                                    (23)
                                     , 6625-6637. <a href="https://doi.org/10.1016/j.bmc.2014.10.006" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.10.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.10.006%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252BFLT3%252Bcovalent%252Binhibitors%252Bwith%252Ba%252Bresorcylic%252Bacid%252Bcore%26aulast%3DXu%26aufirst%3DJin%26date%3D2014%26volume%3D22%26issue%3D23%26spage%3D6625%26epage%3D6637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heng-Xiu  Yan</span>, <span class="hlFld-ContribAuthor ">Wei-Wei  Li</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Xia-Wei  Wei</span>, <span class="hlFld-ContribAuthor ">Li-Xin  Fu</span>, <span class="hlFld-ContribAuthor ">Guo-Bo  Shen</span>, <span class="hlFld-ContribAuthor ">Tao  Yin</span>, <span class="hlFld-ContribAuthor ">Xiu-Ying  Li</span>, <span class="hlFld-ContribAuthor ">Hua-Shan  Shi</span>, <span class="hlFld-ContribAuthor ">Yang  Wan</span>, <span class="hlFld-ContribAuthor ">Qing-Yin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiong  Li</span>, <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>, <span class="hlFld-ContribAuthor ">Yu-Quan  Wei</span>. </span><span class="cited-content_cbyCitation_article-title">Accumulation of FLT3+ CD11c+ dendritic cells in psoriatic lesions and the anti-psoriatic effect of a selective FLT3 inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Immunologic Research</span><span> <strong>2014,</strong> <em>60 </em>
                                    (1)
                                     , 112-126. <a href="https://doi.org/10.1007/s12026-014-8521-4" title="DOI URL">https://doi.org/10.1007/s12026-014-8521-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12026-014-8521-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12026-014-8521-4%26sid%3Dliteratum%253Aachs%26jtitle%3DImmunologic%2520Research%26atitle%3DAccumulation%252Bof%252BFLT3%25252B%252BCD11c%25252B%252Bdendritic%252Bcells%252Bin%252Bpsoriatic%252Blesions%252Band%252Bthe%252Banti-psoriatic%252Beffect%252Bof%252Ba%252Bselective%252BFLT3%252Binhibitor%26aulast%3DYan%26aufirst%3DHeng-Xiu%26date%3D2014%26date%3D2014%26volume%3D60%26issue%3D1%26spage%3D112%26epage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianbin  Chen</span>, <span class="hlFld-ContribAuthor ">Kishore  Natte</span>, <span class="hlFld-ContribAuthor ">Helfried  Neumann</span>, <span class="hlFld-ContribAuthor ">Xiao-Feng  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">A convenient palladium-catalyzed carbonylative synthesis of quinazolines from 2-aminobenzylamine and aryl bromides. </span><span class="cited-content_cbyCitation_journal-name">RSC Adv.</span><span> <strong>2014,</strong> <em>4 </em>
                                    (99)
                                     , 56502-56505. <a href="https://doi.org/10.1039/C4RA11303A" title="DOI URL">https://doi.org/10.1039/C4RA11303A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4RA11303A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4RA11303A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Adv.%26atitle%3DA%252Bconvenient%252Bpalladium-catalyzed%252Bcarbonylative%252Bsynthesis%252Bof%252Bquinazolines%252Bfrom%252B2-aminobenzylamine%252Band%252Baryl%252Bbromides%26aulast%3DChen%26aufirst%3DJianbin%26date%3D2014%26date%3D2014%26volume%3D4%26issue%3D99%26spage%3D56502%26epage%3D56505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hai-Chuan  Zhao</span>, <span class="hlFld-ContribAuthor ">Yan-Ping  Shi</span>, <span class="hlFld-ContribAuthor ">Yu-Ming  Liu</span>, <span class="hlFld-ContribAuthor ">Cai-Wen  Li</span>, <span class="hlFld-ContribAuthor ">Li-Na  Xuan</span>, <span class="hlFld-ContribAuthor ">Peng  Wang</span>, <span class="hlFld-ContribAuthor ">Kai  Zhang</span>, <span class="hlFld-ContribAuthor ">Bao-Quan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antitumor-evaluation of 1,3-selenazole-containing 1,3,4-thiadiazole derivatives. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (24)
                                     , 6577-6579. <a href="https://doi.org/10.1016/j.bmcl.2013.10.062" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.10.062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.10.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.10.062%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bantitumor-evaluation%252Bof%252B1%25252C3-selenazole-containing%252B1%25252C3%25252C4-thiadiazole%252Bderivatives%26aulast%3DZhao%26aufirst%3DHai-Chuan%26date%3D2013%26volume%3D23%26issue%3D24%26spage%3D6577%26epage%3D6579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leping  Ye</span>, <span class="hlFld-ContribAuthor ">Lin  Yu</span>, <span class="hlFld-ContribAuthor ">Lijun  Zhu</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Xia</span>. </span><span class="cited-content_cbyCitation_article-title">One-Pot Tandem Synthesis of 2-Arylquinazolines by a Multicomponent Cyclization Reaction. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2013,</strong> <em>18 </em>
                                    (11)
                                     , 13860-13869. <a href="https://doi.org/10.3390/molecules181113860" title="DOI URL">https://doi.org/10.3390/molecules181113860</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules181113860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules181113860%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DOne-Pot%252BTandem%252BSynthesis%252Bof%252B2-Arylquinazolines%252Bby%252Ba%252BMulticomponent%252BCyclization%252BReaction%26aulast%3DYe%26aufirst%3DLeping%26date%3D2013%26date%3D2013%26volume%3D18%26issue%3D11%26spage%3D13860%26epage%3D13869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A Y H  Leung</span>, <span class="hlFld-ContribAuthor ">C-H  Man</span>, <span class="hlFld-ContribAuthor ">Y-L  Kwong</span>. </span><span class="cited-content_cbyCitation_article-title">FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. </span><span class="cited-content_cbyCitation_journal-name">Leukemia</span><span> <strong>2013,</strong> <em>27 </em>
                                    (2)
                                     , 260-268. <a href="https://doi.org/10.1038/leu.2012.195" title="DOI URL">https://doi.org/10.1038/leu.2012.195</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/leu.2012.195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fleu.2012.195%26sid%3Dliteratum%253Aachs%26jtitle%3DLeukemia%26atitle%3DFLT3%252Binhibition%25253A%252Ba%252Bmoving%252Band%252Bevolving%252Btarget%252Bin%252Bacute%252Bmyeloid%252Bleukaemia%26aulast%3DLeung%26aufirst%3DA%2BY%2BH%26date%3D2013%26date%3D2012%26volume%3D27%26issue%3D2%26spage%3D260%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sanghee  Lee</span>, <span class="hlFld-ContribAuthor ">Ala  Jo</span>, <span class="hlFld-ContribAuthor ">Seung Bum  Park</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a highly selective FLT3 kinase inhibitor from phenotypic cell viability profiling. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2013,</strong> <em>4 </em>
                                    (1)
                                     , 228-232. <a href="https://doi.org/10.1039/C2MD20169K" title="DOI URL">https://doi.org/10.1039/C2MD20169K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C2MD20169K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC2MD20169K%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDiscovery%252Bof%252Ba%252Bhighly%252Bselective%252BFLT3%252Bkinase%252Binhibitor%252Bfrom%252Bphenotypic%252Bcell%252Bviability%252Bprofiling%26aulast%3DLee%26aufirst%3DSanghee%26date%3D2013%26date%3D2013%26volume%3D4%26issue%3D1%26spage%3D228%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) thiazole-2-thiol, [1,3,4]thiadiazole-2-thiol, or 4-methylthiazole-2-thiol, K<sub>2</sub>CO<sub>3</sub>, 2-butanone, 80 °C, 2–4 h.</p></p></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0013.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) phosphorus oxychloride, toluene, <i>N,N-</i>diethylaniline, reflux, 3 h; (b) thiazole-2-thiol, K<sub>2</sub>CO<sub>3</sub>, 2-butanone, 80 °C, 2–4 h; (c) NH<sub>3</sub>·H<sub>2</sub>O, MeOH, rt, 5 h; (d) alkyl halides, K<sub>2</sub>CO<sub>3</sub>, 2-butanone, 85 °C, 6 h.</p></p></figure><figure data-id="sch3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0015.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) phosphorus oxychloride, chloroform, Et<sub>3</sub>N, reflux, overnight; (b) thiazole-2-thiol, K<sub>2</sub>CO<sub>3</sub>, 2-butanone, 80 °C, 4 h; (c) NH<sub>3</sub>·H<sub>2</sub>O, MeOH, rt, 5 h; (d) alkyl halides, K<sub>2</sub>CO<sub>3</sub>, 2-butanone, 85 °C, 6 h.</p></p></figure><figure data-id="sch4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0014.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 2-(2-mercapto-4-methylthiazol-5-yl)acetic acid or 2-(2-mercaptothiazol-4-yl)acetic acid, 2-butanone, K<sub>2</sub>CO<sub>3</sub>, reflux, overnight; (b) anilines or amines, HOBT, EDCI, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, reflux, 12–24 h.</p></p></figure><figure data-id="sch5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0016.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>N,N</i>-dimethylformamide, K<sub>2</sub>CO<sub>3</sub>, 100 °C, overnight.</p></p></figure><figure data-id="sch6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0017.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3-morpholinopropan-1-ol, NaH (60%), <i>N,N</i>-dimethylformamide, 100 °C, overnight; (b) (i) phosphorus oxychloride, <i>N,N-</i>diethylaniline, reflux, 3 h; (ii) <b>16</b>, <i>N,N</i>-dimethylformamide, K<sub>2</sub>CO<sub>3</sub>, 100 °C, overnight.</p></p></figure><figure data-id="fig1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Dose–response relationship of <b>20c</b> inhibition against the human FLT3 kinase (ATP concentration: 200 μM). (b) Western blot analysis showing that <b>20c</b> inhibits FLT3 autophosphorylation and the phosphorylation of downstream signaling proteins STAT5 and ERK1/2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/medium/jm-2012-00042x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Antitumor efficacy of <b>20c</b> at different doses in an <i>in vivo</i> MV4-11 xenograft model. (b) Average body weights for <b>20c</b>-treated mice groups at different doses (20 mg/kg, 40 mg/kg, and 100 mg/kg) and vehicle group in an <i>in vivo</i> MV4-11 xenograft model. (c) Ki67 and TUNEL staining of tumor tissues showing the inhibition of cell proliferation and the induction of apoptosis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-8/jm300042x/production/images/large/jm-2012-00042x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300042x&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i74">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64545" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64545" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 33 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Lyman, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zappone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleath, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckmann, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bird, T.</span><span> </span><span class="NLM_article-title">Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">815</span><span class="NLM_x">–</span> <span class="NLM_lpage">822</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1993&pages=815-822&author=S.+D.+Lymanauthor=L.+Jamesauthor=J.+Zapponeauthor=P.+R.+Sleathauthor=M.+P.+Beckmannauthor=T.+Bird&title=Characterization+of+the+protein+encoded+by+the+flt3+%28flk2%29+receptor-like+tyrosine+kinase+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLyman%26aufirst%3DS.%2BD.%26aulast%3DJames%26aufirst%3DL.%26aulast%3DZappone%26aufirst%3DJ.%26aulast%3DSleath%26aufirst%3DP.%2BR.%26aulast%3DBeckmann%26aufirst%3DM.%2BP.%26aulast%3DBird%26aufirst%3DT.%26atitle%3DCharacterization%2520of%2520the%2520protein%2520encoded%2520by%2520the%2520flt3%2520%2528flk2%2529%2520receptor-like%2520tyrosine%2520kinase%2520gene%26jtitle%3DOncogene%26date%3D1993%26volume%3D8%26spage%3D815%26epage%3D822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Rosnet, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pebusque, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchetto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonnelle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toiron, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birnbaum, D.</span><span> </span><span class="NLM_article-title">Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">1110</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1993&pages=1110-1119&author=O.+Rosnetauthor=C.+Schiffauthor=M.+J.+Pebusqueauthor=S.+Marchettoauthor=C.+Tonnelleauthor=Y.+Toironauthor=F.+Birgauthor=D.+Birnbaum&title=Human+FLT3%2FFLK2+gene%3A+cDNA+cloning+and+expression+in+hematopoietic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosnet%26aufirst%3DO.%26aulast%3DSchiff%26aufirst%3DC.%26aulast%3DPebusque%26aufirst%3DM.%2BJ.%26aulast%3DMarchetto%26aufirst%3DS.%26aulast%3DTonnelle%26aufirst%3DC.%26aulast%3DToiron%26aufirst%3DY.%26aulast%3DBirg%26aufirst%3DF.%26aulast%3DBirnbaum%26aufirst%3DD.%26atitle%3DHuman%2520FLT3%252FFLK2%2520gene%253A%2520cDNA%2520cloning%2520and%2520expression%2520in%2520hematopoietic%2520cells%26jtitle%3DBlood%26date%3D1993%26volume%3D82%26spage%3D1110%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Lyman, S. D.</span><span> </span><span class="NLM_article-title">Biology of Xt3 ligand and receptor</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1016%2F0925-5710%2895%2900389-A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=8590775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADyaK2MXptl2qsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1995&pages=63-73&author=S.+D.+Lyman&title=Biology+of+Xt3+ligand+and+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Biology of flt3 ligand and receptor</span></div><div class="casAuthors">Lyman, Stewart D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">63-73</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review, with 42 refs., on the discovery of the flt3 ligand and its receptor, its biol. activities, and some potential clin. uses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouQkW9M_ml7rVg90H21EOLACvtfcHk0ljAB4r0IITgaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptl2qsLs%253D&md5=18590831d0db14fe9b6f5767db528a40</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2F0925-5710%2895%2900389-A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0925-5710%252895%252900389-A%26sid%3Dliteratum%253Aachs%26aulast%3DLyman%26aufirst%3DS.%2BD.%26atitle%3DBiology%2520of%2520Xt3%2520ligand%2520and%2520receptor%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D1995%26volume%3D62%26spage%3D63%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">The roles of FLT3 in hematopoiesis and leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1532</span><span class="NLM_x">–</span> <span class="NLM_lpage">1542</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1182%2Fblood-2002-02-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=12176867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=1532-1542&author=D.+G.+Gillilandauthor=J.+D.+Griffin&title=The+roles+of+FLT3+in+hematopoiesis+and+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of FLT3 in hematopoiesis and leukemia</span></div><div class="casAuthors">Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1532-1542</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system.  The ligand for FLT3 is expressed by marrow stromal cells and other cells and synergized with other growth factors to stimulate proliferation of stem cells, progenitor cells, dendritic cells, and natural killer cells.  Mutations of FLT3 have been detected in about 30% of patients with acute myelogenous leukemia and a small no. of patients with acute lymphocytic leukemia or myelodysplastic syndrome.  Patients with FLT3 mutations tend to have a poor prognosis.  The mutations most often involve small tandem duplications of amino acids within the juxtamembrane domain of the receptor and result in constitutive tyrosine kinase activity.  Expression of a mutant FLT3 receptor in murine marrow cells results in a lethal myeloproliferative syndrome and preliminary studies suggest that mutant FLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype.  Taken together, these results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQc2WkC8EQbVg90H21EOLACvtfcHk0ljAB4r0IITgaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D&md5=f6d04b227f5c5baf5c22cfba6e693ff1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-02-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-02-0492%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520roles%2520of%2520FLT3%2520in%2520hematopoiesis%2520and%2520leukemia%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D1532%26epage%3D1542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">FLT3 tyrosine kinase inhibitors</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1532%2FIJH97.05079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=16146839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2005&pages=100-107&author=M.+Levisauthor=D.+Small&title=FLT3+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 tyrosine kinase inhibitors</span></div><div class="casAuthors">Levis, Mark; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">100-107</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Carden Jennings Publishing</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase FLT3 is an important regulatory mol. in hematopoiesis and is expressed on the blasts in most cases of acute leukemia.  Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are assocd. with a distinctly worse clin. outcome.  Efforts to target this mutation and improve outcomes in this subgroup of AML patients have led to the investigation of several novel small-mol. FLT3 tyrosine kinase inhibitors.  These compds. derive from a wide variety of chem. classes and differ significantly, both in their potency and in their selectivity.  In this review, we discuss the results of preclin., clin., and correlative lab. studies of FLT3 inhibitors in demonstrating how this field represents a truly translational enterprise with multiple ongoing interactions between the lab. and the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF4BnW93Jv2rVg90H21EOLACvtfcHk0lijJMz6A9dqwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN&md5=75bdd31913d422c3a42551ee048e4f1e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1532%2FIJH97.05079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1532%252FIJH97.05079%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DFLT3%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2005%26volume%3D82%26spage%3D100%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Cloos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goemans, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, C. J.</span><span> </span><span class="NLM_article-title">Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1217</span><span class="NLM_x">–</span> <span class="NLM_lpage">1220</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=1217-1220&author=J.+Cloosauthor=B.+F.+Goemansauthor=C.+J.+Hess&title=Stability+and+prognostic+influence+of+FLT3+mutations+in+paired+initial+and+relapsed+AML+samples"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3DGoemans%26aufirst%3DB.%2BF.%26aulast%3DHess%26aufirst%3DC.%2BJ.%26atitle%3DStability%2520and%2520prognostic%2520influence%2520of%2520FLT3%2520mutations%2520in%2520paired%2520initial%2520and%2520relapsed%2520AML%2520samples%26jtitle%3DLeukemia%26date%3D2006%26volume%3D20%26spage%3D1217%26epage%3D1220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Gale, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, C.</span><span> </span><span class="NLM_article-title">The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">2776</span><span class="NLM_x">–</span> <span class="NLM_lpage">2784</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=2776-2784&author=R.+E.+Galeauthor=C.+Greenauthor=C.+Allen&title=The+impact+of+FLT3+internal+tandem+duplication+mutant+level%2C+number%2C+size%2C+and+interaction+with+NPM1+mutations+in+a+large+cohort+of+young+adult+patients+with+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGale%26aufirst%3DR.%2BE.%26aulast%3DGreen%26aufirst%3DC.%26aulast%3DAllen%26aufirst%3DC.%26atitle%3DThe%2520impact%2520of%2520FLT3%2520internal%2520tandem%2520duplication%2520mutant%2520level%252C%2520number%252C%2520size%252C%2520and%2520interaction%2520with%2520NPM1%2520mutations%2520in%2520a%2520large%2520cohort%2520of%2520young%2520adult%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D2776%26epage%3D2784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Meshinchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonzo, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirewalt, D. L.</span><span> </span><span class="NLM_article-title">Clinical implications of FLT3 mutations in pediatric AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3654</span><span class="NLM_x">–</span> <span class="NLM_lpage">3661</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3654-3661&author=S.+Meshinchiauthor=T.+A.+Alonzoauthor=D.+L.+Stirewalt&title=Clinical+implications+of+FLT3+mutations+in+pediatric+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeshinchi%26aufirst%3DS.%26aulast%3DAlonzo%26aufirst%3DT.%2BA.%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26atitle%3DClinical%2520implications%2520of%2520FLT3%2520mutations%2520in%2520pediatric%2520AML%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3654%26epage%3D3661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozekia, K.</span><span> </span><span class="NLM_article-title">Clinical significance of FLT3 in leukemia</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">85</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1532%2FIJH97.05066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=16146837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2005&pages=85-92&author=H.+Kiyoiauthor=M.+Yanadaauthor=K.+Ozekia&title=Clinical+significance+of+FLT3+in+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of FLT3 in leukemia</span></div><div class="casAuthors">Kiyoi, Hitoshi; Yanada, Masamitsu; Ozeki, Kazutaka</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-92</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Carden Jennings Publishing</span>)
        </div><div class="casAbstract">A review.  FLT3 is a class III receptor tyrosine kinase together with KIT, FMS and PDGFR.  FLT3 mutations were first reported as internal tandem duplication (FLT3/ITD) of the juxtamembrane domain-coding sequence, and subsequently as a missense mutation of D835 (FLT3/KDM) within a kinase domain.  Furthermore, point mutations, deletions, and insertions in the codons surrounding D835 have also been found.  FLT3/ITD and FLT3/KDM occur in 15% to 35% and 5% to 10%, resp., of patients with AML.  FLT3 mutations are, therefore, the most frequent genetic alterations so far reported in AML.  Several large-scale studies have confirmed that FLT3/ITD is strongly assocd. with leukocytosis and a poor prognosis.  Although the clin. significance of FLT3/KDM is controversial, the meta-anal. suggests its adverse effect on the outcome.  FLT3/ITD is far less common in patients with ALL, whereas FLT3/KDM is recurrently found in patients with ALL, esp. in those harboring an MLL gene rearrangement or hyperdiploidy.  The overexpression of FLT3 transcripts has been demonstrated in a proportion of the AML patients without FLT3 mutations, which are assocd. with a poor prognosis for overall survival.  Routine screening of FLT3 mutations is recommended to stratify the patients into distinct risk groups, while the optimal treatment strategy for patients with FLT3 mutations should be further evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8m_krDfgYdbVg90H21EOLACvtfcHk0lijJMz6A9dqwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL7E&md5=f7a532cc6aa951bb754f64bd3163cb1f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1532%2FIJH97.05066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1532%252FIJH97.05066%26sid%3Dliteratum%253Aachs%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DYanada%26aufirst%3DM.%26aulast%3DOzekia%26aufirst%3DK.%26atitle%3DClinical%2520significance%2520of%2520FLT3%2520in%2520leukemia%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2005%26volume%3D82%26spage%3D85%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Meshinchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonzo, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirewalt, D. L.</span><span> </span><span class="NLM_article-title">Clinical implications of FLT3 mutations in pediatric AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3654</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3654-366&author=S.+Meshinchiauthor=T.+A.+Alonzoauthor=D.+L.+Stirewalt&title=Clinical+implications+of+FLT3+mutations+in+pediatric+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeshinchi%26aufirst%3DS.%26aulast%3DAlonzo%26aufirst%3DT.%2BA.%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26atitle%3DClinical%2520implications%2520of%2520FLT3%2520mutations%2520in%2520pediatric%2520AML%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3654%26epage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Schlenk, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauter, J.</span><span> </span><span class="NLM_article-title">Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">1909</span><span class="NLM_x">–</span> <span class="NLM_lpage">1918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1056%2FNEJMoa074306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=18450602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ggu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1909-1918&author=R.+F.+Schlenkauthor=K.+Dohnerauthor=J.+Krauter&title=Mutations+and+treatment+outcome+in+cytogenetically+normal+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia</span></div><div class="casAuthors">Schlenk, Richard F.; Doehner, Konstanze; Krauter, Jurgen; Frohling, Stefan; Corbacioglu, Andrea; Bullinger, Lars; Habdank, Marianne; Spith, Daniela; Morgan, Michael; Benner, Axel; Schlegelberger, Brigitte; Heil, Gerhard; Ganser, Arnold; Doehner, Hartmut; Schlimok, G.; Arnold, R.; Pezzutto, A.; Glasmacher, A.; Germing, U.; Heit, W.; Hoelzer, D.; Derigs, H. G.; Luebbert, M.; Pralle, H.; Runde, V.; Griesinger, F.; Fiedler, W.; Salwender, H.; Kirchner, H.; Hensel, M.; Hartmann, F.; Fischer, J. T.; Kneba, M.; Hinke, A.; Kremers, S.; Goetze, K.; Waterhouse, C.; del Valle, F.; Matzdorff, A.; Grimminger, W.; Mergenthaler, H. G.; Kirchen, H.; Brossart, P.; Bergmann, L.; Raghavachar, Aruna; Petzer, A.; Koller, E.; Neons, L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1909-1918</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations occur in several genes in cytogenetically normal acute myeloid leukemia (AML) cells: the nucleophosmin gene (NPM1), the fms-related tyrosine kinase 3 gene (FLT3), the CCAAT/enhancer binding protein a gene (CEPBA), the myeloid-lymphoid or mixed-lineage leukemia gene (MLL), and the neuroblastoma RAS viral oncogene homolog (NRAS).  We evaluated the assocns. of these mutations with clin. outcomes in patients.  We compared the mutational status of the NPM1, FLT3, CEBPA, MLL, and NRAS genes in leukemia cells with the clin. outcome in 872 adults younger than 60 years of age with cytogenetically normal AML.  Patients had been entered into one of four trials of therapy for AML.  In each study, patients with an HLA-matched related donor were assigned to undergo stem-cell transplantation.  A total of 53% of patients had NPM1 mutations, 31% had FLT3 internal tandem duplications (ITDs), 11% had FLT3 tyrosine kinase-domain mutations, 13% had CEBPA mutations, 7% had MLL partial tandem duplications (PTDs), and 13% had NRAS mutations.  The overall complete-remission rate was 77%.  The genotype of mutant NPM1 without FLT3-ITD, the mutant CEBPA genotype, and younger age were each significantly assocd. with complete remission.  Of the 663 patients who received postremission therapy, 150 underwent hematopoietic stem-cell transplantation from an HLA-matched related donor.  Significant assocns. were found between the risk of relapse or the risk of death during complete remission and the leukemia genotype of mutant NPM1 without FLT3-ITD (hazard ratio, 0.44; 95% confidence interval [CI], 0.32 to 0.61), the mutant CEBPA genotype (hazard ratio, 0.48; 95% CI, 0.30 to 0.75), and the MLL-PTD genotype (hazard ratio, 1.56; 95% CI, 1.00 to 2.43), as well as receipt of a transplant from an HLA-matched related donor (hazard ratio, 0.60; 95% CI, 0.44 to 0.82).  The benefit of the transplant was limited to the subgroup of patients with the prognostically adverse genotype FLT3-ITD or the genotype consisting of wild-type NPM1 and CEBPA without FLT3-ITD.  Genotypes defined by the mutational status of NPM1, FLT3, CEBPA, and MLL are assocd. with the outcome of treatment for patients with cytogenetically normal AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6JpbRc9OYmrVg90H21EOLACvtfcHk0li-BbEsyAd9cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ggu70%253D&md5=4109ec9d7141f2405163dfc31a9dd660</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa074306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa074306%26sid%3Dliteratum%253Aachs%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DKrauter%26aufirst%3DJ.%26atitle%3DMutations%2520and%2520treatment%2520outcome%2520in%2520cytogenetically%2520normal%2520acute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D1909%26epage%3D1918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopeck, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliverman, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannah, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span> </span><span class="NLM_article-title">SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">801</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=795-801&author=F.+J.+Gilesauthor=A.+T.+Stopeckauthor=L.+R.+Slivermanauthor=J.+E.+Lancetauthor=M.+A.+Cooperauthor=A.+L.+Hannahauthor=J.+M.+Cherringtonauthor=A.+M.+O%E2%80%99Farrellauthor=H.+A.+Yuenauthor=S.+G.+Louieauthor=W.+Hongauthor=J.+E.+Cortesauthor=S.+Verstovsekauthor=M.+Albitarauthor=S.+M.+O%E2%80%99Brienauthor=H.+M.+Kantarjianauthor=J.+E.+Karp&title=SU5416%2C+a+small+molecule+tyrosine+kinase+receptor+inhibitor%2C+has+biologic+activity+in+patients+with+refractory+acute+myeloid+leukemia+or+myelodysplastic+syndromes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DStopeck%26aufirst%3DA.%2BT.%26aulast%3DSliverman%26aufirst%3DL.%2BR.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BM.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26atitle%3DSU5416%252C%2520a%2520small%2520molecule%2520tyrosine%2520kinase%2520receptor%2520inhibitor%252C%2520has%2520biologic%2520activity%2520in%2520patients%2520with%2520refractory%2520acute%2520myeloid%2520leukemia%2520or%2520myelodysplastic%2520syndromes%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D795%26epage%3D801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">O’Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngai, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, K. W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolich, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span> </span><span class="NLM_article-title">SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">3597</span><span class="NLM_x">–</span> <span class="NLM_lpage">3605</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=3597-3605&author=A.+M.+O%E2%80%99Farrellauthor=T.+J.+Abramsauthor=H.+A.+Yuenauthor=T.+J.+Ngaiauthor=S.+G.+Louieauthor=K.+W.+H.+Yeeauthor=L.+M.+Wongauthor=W.+Hongauthor=L.+B.+Leeauthor=A.+Townauthor=B.+D.+Smolichauthor=W.+C.+Manningauthor=L.+J.+Murrayauthor=M.+C.+Heinrichauthor=J.+M.+Cherrington&title=SU11248+is+a+novel+FLT3+tyrosine+kinase+inhibitor+with+potent+activity+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DNgai%26aufirst%3DT.%2BJ.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DYee%26aufirst%3DK.%2BW.%2BH.%26aulast%3DWong%26aufirst%3DL.%2BM.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DSmolich%26aufirst%3DB.%2BD.%26aulast%3DManning%26aufirst%3DW.%2BC.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26atitle%3DSU11248%2520is%2520a%2520novel%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%2520with%2520potent%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26spage%3D3597%26epage%3D3605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Menezes, D. E. L. d.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shephard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldbeck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aukerman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C.</span><span> </span><span class="NLM_article-title">CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5281</span><span class="NLM_x">–</span> <span class="NLM_lpage">5291</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1158%2F1078-0432.CCR-05-0358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=16033847" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=5281-5291&author=D.+E.+L.+d.+Menezesauthor=J.+Pengauthor=E.+N.+Garrettauthor=S.+G.+Louieauthor=S.+H.+Leeauthor=M.+Wiesmannauthor=Y.+Tangauthor=L.+Shephardauthor=C.+Goldbeckauthor=Y.+Oeiauthor=H.+Yeauthor=S.+L.+Aukermanauthor=C.+Heise&title=CHIR-258%3A+a+potent+inhibitor+of+FLT3+kinase+in+experimental+tumor+xenograft+models+of+human+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0358%26sid%3Dliteratum%253Aachs%26aulast%3DMenezes%26aufirst%3DD.%2BE.%2BL.%2Bd.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DGarrett%26aufirst%3DE.%2BN.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DShephard%26aufirst%3DL.%26aulast%3DGoldbeck%26aufirst%3DC.%26aulast%3DOei%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DAukerman%26aufirst%3DS.%2BL.%26aulast%3DHeise%26aufirst%3DC.%26atitle%3DCHIR-258%253A%2520a%2520potent%2520inhibitor%2520of%2520FLT3%2520kinase%2520in%2520experimental%2520tumor%2520xenograft%2520models%2520of%2520human%2520acute%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D5281%26epage%3D5291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klimek, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliand, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">PKC 412 Flt3 inhibitor therapy in AML: results of a phase II trial</span> <span class="citation_source-journal">Ann. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S80</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2004&pages=S80-90&issue=Suppl+1&author=R.+M.+Stoneauthor=J.+De+Angeloauthor=I.+Galinskyauthor=E.+Esteyauthor=V.+Klimekauthor=W.+Grandinauthor=D.+Lebwohlauthor=P.+Cohenauthor=E.+Foxauthor=D.+Neubergauthor=J.+Clarkauthor=D.+G.+Gilliandauthor=J.+D.+Griffin&title=PKC+412+Flt3+inhibitor+therapy+in+AML%3A+results+of+a+phase+II+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDe%2BAngelo%26aufirst%3DJ.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DKlimek%26aufirst%3DV.%26aulast%3DGrandin%26aufirst%3DW.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DFox%26aufirst%3DE.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGilliand%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DPKC%2520412%2520Flt3%2520inhibitor%2520therapy%2520in%2520AML%253A%2520results%2520of%2520a%2520phase%2520II%2520trial%26jtitle%3DAnn.%2520Hematol.%26date%3D2004%26volume%3D83%26issue%3DSuppl%25201%26spage%3DS80%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauses, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allebach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3669</span><span class="NLM_x">–</span> <span class="NLM_lpage">3676</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2004&pages=3669-3676&author=B.+D.+Smithauthor=M.+Levisauthor=M.+Beranauthor=F.+Gilesauthor=H.+Kantarjianauthor=K.+Bergauthor=K.+M.+Murphyauthor=T.+Dausesauthor=J.+Allebachauthor=D.+Small&title=Single-agent+CEP-701%2C+a+novel+FLT3+inhibitor%2C+shows+biologic+and+clinical+activity+in+patients+with+relapsed+or+refractory+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBerg%26aufirst%3DK.%26aulast%3DMurphy%26aufirst%3DK.%2BM.%26aulast%3DDauses%26aufirst%3DT.%26aulast%3DAllebach%26aufirst%3DJ.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DSingle-agent%2520CEP-701%252C%2520a%2520novel%2520FLT3%2520inhibitor%252C%2520shows%2520biologic%2520and%2520clinical%2520activity%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2004%26volume%3D103%26spage%3D3669%26epage%3D3676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaney, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klisovic, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecerf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karol, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holford, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3674</span><span class="NLM_x">–</span> <span class="NLM_lpage">3681</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1182%2Fblood-2006-02-005702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=16902153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3674-3681&author=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=M.+L.+Heaneyauthor=S.+D.+Nimerauthor=R.+L.+Paquetteauthor=R.+B.+Klisovicauthor=M.+A.+Caligiuriauthor=M.+R.+J.+Cooperauthor=M.+Lecerfauthor=M.+D.+Karolauthor=S.+Shengauthor=N.+Holfordauthor=P.+T.+Curtinauthor=B.+J.+Drukerauthor=M.+C.+Heinrich&title=Phase+1+clinical+results+with+tandutinib+%28MLN518%29%2C+a+novel+FLT3+antagonist%2C+in+patients+with+acute+myelogenous+leukemia+or+high-risk+myelodysplastic+syndrome%3A+safety%2C+pharmacokinetics%2C+and+pharmacodynamics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span></div><div class="casAuthors">DeAngelo, Daniel J.; Stone, Richard M.; Heaney, Mark L.; Nimer, Stephen D.; Paquette, Ronald L.; Klisovic, Rebecca B.; Caligiuri, Michael A.; Cooper, Michael R.; Lecerf, Jean-Michel; Karol, Michael D.; Sheng, Shihong; Holford, Nick; Curtin, Peter T.; Druker, Brian J.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3674-3681</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT.  Because of the correlation between FLT3 internal tandem duplication (ITD) mutations and poor prognosis in acute myelogenous leukemia (AML), we conducted a phase 1 trial of tandutinib in 40 patients with either AML or high-risk myelodysplastic syndrome (MDS).  Tandutinib was given orally in doses ranging from 50 mg to 700 mg twice daily The principal dose-limiting toxicity (DLT) of tandutinib was reversible generalized muscular weakness, fatigue, or both, occurring at doses of 525 mg and 700 mg twice daily.  Tandutinib's pharmacokinetics were characterized by slow elimination, with achievement of steady-state plasma concns. requiring greater than 1 wk of dosing.  Western blotting showed that tandutinib inhibited phosphorylation of FLT3 in circulating leukemic blasts.  Eight patients had FLT3-ITD mutations; 5 of these were evaluable for assessment of tandutinib's antileukemic effect.  Two of the 5 patients, treated at 525 mg and 700 mg twice daily, showed evidence of antileukemic activity, with decreases in both peripheral and bone marrow blasts.  Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraXRBv_Gv-TLVg90H21EOLACvtfcHk0lgpGmEpTpqzgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM&md5=42c0b5a4c193955023198d6c6d12c463</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-02-005702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-02-005702%26sid%3Dliteratum%253Aachs%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DHeaney%26aufirst%3DM.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DCooper%26aufirst%3DM.%2BR.%2BJ.%26aulast%3DLecerf%26aufirst%3DM.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DSheng%26aufirst%3DS.%26aulast%3DHolford%26aufirst%3DN.%26aulast%3DCurtin%26aufirst%3DP.%2BT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DPhase%25201%2520clinical%2520results%2520with%2520tandutinib%2520%2528MLN518%2529%252C%2520a%2520novel%2520FLT3%2520antagonist%252C%2520in%2520patients%2520with%2520acute%2520myelogenous%2520leukemia%2520or%2520high-risk%2520myelodysplastic%2520syndrome%253A%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3674%26epage%3D3681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konopleva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQueen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintás-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span> </span><span class="NLM_article-title">Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">198</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1093%2Fjnci%2Fdjm328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=18230792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFygsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2008&pages=184-198&author=W.+Zhangauthor=M.+Konoplevaauthor=Y.+X.+Shiauthor=T.+McQueenauthor=D.+Harrisauthor=X.+Lingauthor=Z.+Estrovauthor=A.+Quint%C3%A1s-Cardamaauthor=D.+Smallauthor=J.+Cortesauthor=M.+Andreeff&title=Mutant+FLT3%3A+a+direct+target+of+sorafenib+in+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia</span></div><div class="casAuthors">Zhang, Weiguo; Konopleva, Marina; Shi, Yue-xi; McQueen, Teresa; Harris, David; Ling, Xiaoyang; Estrov, Zeev; Quintas-Cardama, Alfonso; Small, Donald; Cortes, Jorge; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">184-198</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Internal tandem duplication (ITD) mutations in the juxtamembrane domain-coding sequence of the Fms-like tyrosine kinase 3 (FLT3) gene have been identified in 30% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  The kinase inhibitor sorafenib induces growth arrest and apoptosis at much lower concns. in AML cell lines that harbor FLT3-ITD mutations than in AML cell lines with wild-type FLT3.  The antileukemic activity of sorafenib was investigated in isogenic murine Ba/F3 AML cell lines that expressed mutant (ITD, D835G, and D835Y) or wild-type human FLT3, in primary human AML cells, and in a mouse leukemia xenograft model.  Effects of sorafenib on apoptosis and signaling in AML cell lines were investigated by flow cytometry and immunoblot anal., resp., and the in vivo effects were detd. by monitoring the survival of leukemia xenograft-bearing mice treated with sorafenib (groups of 15 mice).  In a phase 1 clin. trial, 16 patients with refractory or relapsed AML were treated with sorafenib on different dose schedules.  We detd. their FLT3 mutation status by a polymerase chain reaction assay and analyzed clin. responses by std. criteria.  All statistical tests were two-sided.  Sorafenib was 1000- to 3000-fold more effective in inducing growth arrest and apoptosis in Ba/F3 cells with FLT3-ITD or D835G mutations than in Ba/F3 cells with FLT3-D835Y mutant or wild-type FLT3 and inhibited the phosphorylation of tyrosine residues in ITD mutant but not wild-type FLT3 protein.  In a mouse model, sorafenib decreased the leukemia burden and prolonged survival (median survival in the sorafenib-treated group vs the vehicle-treated group = 36.5 vs 16 days, difference = 20.5 days, 95% confidence interval = 20.3 to 21.3 days; P = .0018).  Sorafenib reduced the percentage of leukemia blasts in the peripheral blood and the bone marrow of AML patients with FLT3-ITD (median percentages before and after sorafenib: 81% vs. 7.5% [P = .016] and 75.5% vs. 34% [P = .05], resp.) but not in patients without this mutation.  Sorafenib may have therapeutic efficacy in AML patients whose cells harbor FLT3-ITD mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNBWJSPfrsN7Vg90H21EOLACvtfcHk0lgpGmEpTpqzgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFygsrY%253D&md5=d747b1107866a0299c972c1bcd58c770</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjm328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjm328%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DY.%2BX.%26aulast%3DMcQueen%26aufirst%3DT.%26aulast%3DHarris%26aufirst%3DD.%26aulast%3DLing%26aufirst%3DX.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DMutant%2520FLT3%253A%2520a%2520direct%2520target%2520of%2520sorafenib%2520in%2520acute%2520myelogenous%2520leukemia%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2008%26volume%3D100%26spage%3D184%26epage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanizaki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozeki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1607</span><span class="NLM_x">–</span> <span class="NLM_lpage">1617</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=1607-1617&author=Y.+Shiotsuauthor=H.+Kiyoiauthor=Y.+Ishikawaauthor=R.+Tanizakiauthor=M.+Shimizuauthor=H.+Umeharaauthor=K.+Ishiiauthor=Y.+Moriauthor=K.+Ozekiauthor=Y.+Minamiauthor=A.+Abeauthor=H.+Maedaauthor=T.+Akiyamaauthor=Y.+Kandaauthor=Y.+Satoauthor=S.+Akinagaauthor=T.+Naoe&title=KW-2449%2C+a+novel+multikinase+inhibitor%2C+suppresses+the+growth+of+leukemia+cells+with+FLT3+mutations+or+T315I-mutated+BCR%2FABL+translocation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DTanizaki%26aufirst%3DR.%26aulast%3DShimizu%26aufirst%3DM.%26aulast%3DUmehara%26aufirst%3DH.%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DOzeki%26aufirst%3DK.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DA.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DAkiyama%26aufirst%3DT.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DKW-2449%252C%2520a%2520novel%2520multikinase%2520inhibitor%252C%2520suppresses%2520the%2520growth%2520of%2520leukemia%2520cells%2520with%2520FLT3%2520mutations%2520or%2520T315I-mutated%2520BCR%252FABL%2520translocation%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D1607%26epage%3D1617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghirdaladze, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foran, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVetten, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zodelava, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padre, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corringham, R.</span><span> </span><span class="NLM_article-title">Phase 1 AML study of AC220, a potent and selective second generation FLT3 receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">767</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=767&author=J.+Cortesauthor=D.+Ghirdaladzeauthor=J.+M.+Foranauthor=M.+P.+DeVettenauthor=M.+Zodelavaauthor=M.+J.+Levisauthor=N.+M.+Padreauthor=J.+Jamesauthor=P.+P.+Zarrinkarauthor=R.+Corringham&title=Phase+1+AML+study+of+AC220%2C+a+potent+and+selective+second+generation+FLT3+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DGhirdaladze%26aufirst%3DD.%26aulast%3DForan%26aufirst%3DJ.%2BM.%26aulast%3DDeVetten%26aufirst%3DM.%2BP.%26aulast%3DZodelava%26aufirst%3DM.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPadre%26aufirst%3DN.%2BM.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DCorringham%26aufirst%3DR.%26atitle%3DPhase%25201%2520AML%2520study%2520of%2520AC220%252C%2520a%2520potent%2520and%2520selective%2520second%2520generation%2520FLT3%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26spage%3D767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J .</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roboz, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arowojolu, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shudo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span> </span><span class="NLM_article-title">A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">3938</span><span class="NLM_x">–</span> <span class="NLM_lpage">3946</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=3938-3946&author=K.+W.+Pratzauthor=J+.+Cortesauthor=G.+J.+Robozauthor=N.+Raoauthor=O.+Arowojoluauthor=A.+Stineauthor=Y.+Shiotsuauthor=A.+Shudoauthor=S.+Akinagaauthor=D.+Smallauthor=J.+E.+Karpauthor=M.+Levis&title=A+pharmacodynamic+study+of+the+FLT3+inhibitor+KW-2449+yields+insight+into+the+basis+for+clinical+response"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DCortes%26aufirst%3DJ%2B.%26aulast%3DRoboz%26aufirst%3DG.%2BJ.%26aulast%3DRao%26aufirst%3DN.%26aulast%3DArowojolu%26aufirst%3DO.%26aulast%3DStine%26aufirst%3DA.%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DShudo%26aufirst%3DA.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DA%2520pharmacodynamic%2520study%2520of%2520the%2520FLT3%2520inhibitor%2520KW-2449%2520yields%2520insight%2520into%2520the%2520basis%2520for%2520clinical%2520response%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D3938%26epage%3D3946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaney, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klisovic, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecerf, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karol, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holford, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3674</span><span class="NLM_x">–</span> <span class="NLM_lpage">3681</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1182%2Fblood-2006-02-005702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=16902153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3674-3681&author=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=M.+L.+Heaneyauthor=S.+D.+Nimerauthor=R.+L.+Paquetteauthor=R.+B.+Klisovicauthor=M.+A.+Caligiuriauthor=M.+R.+J.+Cooperauthor=M.+Lecerfauthor=M.+D.+Karolauthor=S.+Shengauthor=N.+Holfordauthor=P.+T.+Curtinauthor=B.+J.+Drukerauthor=M.+C.+Heinrich&title=Phase+1+clinical+results+with+tandutinib+%28MLN518%29%2C+a+novel+FLT3+antagonist%2C+in+patients+with+acute+myelogenous+leukemia+or+high-risk+myelodysplastic+syndrome%3A+safety%2C+pharmacokinetics%2C+and+pharmacodynamics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span></div><div class="casAuthors">DeAngelo, Daniel J.; Stone, Richard M.; Heaney, Mark L.; Nimer, Stephen D.; Paquette, Ronald L.; Klisovic, Rebecca B.; Caligiuri, Michael A.; Cooper, Michael R.; Lecerf, Jean-Michel; Karol, Michael D.; Sheng, Shihong; Holford, Nick; Curtin, Peter T.; Druker, Brian J.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3674-3681</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT.  Because of the correlation between FLT3 internal tandem duplication (ITD) mutations and poor prognosis in acute myelogenous leukemia (AML), we conducted a phase 1 trial of tandutinib in 40 patients with either AML or high-risk myelodysplastic syndrome (MDS).  Tandutinib was given orally in doses ranging from 50 mg to 700 mg twice daily The principal dose-limiting toxicity (DLT) of tandutinib was reversible generalized muscular weakness, fatigue, or both, occurring at doses of 525 mg and 700 mg twice daily.  Tandutinib's pharmacokinetics were characterized by slow elimination, with achievement of steady-state plasma concns. requiring greater than 1 wk of dosing.  Western blotting showed that tandutinib inhibited phosphorylation of FLT3 in circulating leukemic blasts.  Eight patients had FLT3-ITD mutations; 5 of these were evaluable for assessment of tandutinib's antileukemic effect.  Two of the 5 patients, treated at 525 mg and 700 mg twice daily, showed evidence of antileukemic activity, with decreases in both peripheral and bone marrow blasts.  Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraXRBv_Gv-TLVg90H21EOLACvtfcHk0lh2qT2c3lyhpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM&md5=42c0b5a4c193955023198d6c6d12c463</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-02-005702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-02-005702%26sid%3Dliteratum%253Aachs%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DHeaney%26aufirst%3DM.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DCooper%26aufirst%3DM.%2BR.%2BJ.%26aulast%3DLecerf%26aufirst%3DM.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DSheng%26aufirst%3DS.%26aulast%3DHolford%26aufirst%3DN.%26aulast%3DCurtin%26aufirst%3DP.%2BT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DPhase%25201%2520clinical%2520results%2520with%2520tandutinib%2520%2528MLN518%2529%252C%2520a%2520novel%2520FLT3%2520antagonist%252C%2520in%2520patients%2520with%2520acute%2520myelogenous%2520leukemia%2520or%2520high-risk%2520myelodysplastic%2520syndrome%253A%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3674%26epage%3D3681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Knapper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littlewood, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kell, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3262</span><span class="NLM_x">–</span> <span class="NLM_lpage">3270</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3262-3270&author=S.+Knapperauthor=A.+K.+Burnettauthor=T.+Littlewoodauthor=W.+J.+Kellauthor=S.+Agrawalauthor=R.+Chopraauthor=R.+Clarkauthor=M.+J.+Levisauthor=D.+Small&title=A+phase+2+trial+of+the+FLT3+inhibitor+lestaurtinib+%28CEP701%29+as+first-line+treatment+for+older+patients+with+acute+myeloid+leukemia+not+considered+fit+for+intensive+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKnapper%26aufirst%3DS.%26aulast%3DBurnett%26aufirst%3DA.%2BK.%26aulast%3DLittlewood%26aufirst%3DT.%26aulast%3DKell%26aufirst%3DW.%2BJ.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DClark%26aufirst%3DR.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DA%2520phase%25202%2520trial%2520of%2520the%2520FLT3%2520inhibitor%2520lestaurtinib%2520%2528CEP701%2529%2520as%2520first-line%2520treatment%2520for%2520older%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520not%2520considered%2520fit%2520for%2520intensive%2520chemotherapy%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3262%26epage%3D3270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Li, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qing, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">Taking quinazoline as a general support-Nog to design potent and selective kinase inhibitors: application to FMS-like tyrosine kinase 3</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">516</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=513-516&author=W.+W.+Liauthor=J.+J.+Chenauthor=R.+L.+Zhengauthor=W.+Q.+Zhangauthor=Z.+X.+Caoauthor=L.+L.+Yangauthor=X.+Y.+Qingauthor=L.+X.+Zhouauthor=L.+Yangauthor=L.+D.+Yuauthor=L.+J.+Chenauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=Taking+quinazoline+as+a+general+support-Nog+to+design+potent+and+selective+kinase+inhibitors%3A+application+to+FMS-like+tyrosine+kinase+3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%2BW.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DZheng%26aufirst%3DR.%2BL.%26aulast%3DZhang%26aufirst%3DW.%2BQ.%26aulast%3DCao%26aufirst%3DZ.%2BX.%26aulast%3DYang%26aufirst%3DL.%2BL.%26aulast%3DQing%26aufirst%3DX.%2BY.%26aulast%3DZhou%26aufirst%3DL.%2BX.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DL.%2BD.%26aulast%3DChen%26aufirst%3DL.%2BJ.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DTaking%2520quinazoline%2520as%2520a%2520general%2520support-Nog%2520to%2520design%2520potent%2520and%2520selective%2520kinase%2520inhibitors%253A%2520application%2520to%2520FMS-like%2520tyrosine%2520kinase%25203%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D513%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Duffel, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ing, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segarra, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barfknecht, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenwald, R. D.</span><span> </span><span class="NLM_article-title"><i>N-</i>Substituted sulfonamide carbonic anhydrase inhibitors with topical effects on intraocular pressure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1488</span><span class="NLM_x">–</span> <span class="NLM_lpage">1494</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00158a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1986&pages=1488-1494&author=M.+W.+Duffelauthor=I.+S.+Ingauthor=T.+M.+Segarraauthor=J.+A.+Dixsonauthor=C.+F.+Barfknechtauthor=R.+D.+Schoenwald&title=N-Substituted+sulfonamide+carbonic+anhydrase+inhibitors+with+topical+effects+on+intraocular+pressure"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm00158a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00158a028%26sid%3Dliteratum%253Aachs%26aulast%3DDuffel%26aufirst%3DM.%2BW.%26aulast%3DIng%26aufirst%3DI.%2BS.%26aulast%3DSegarra%26aufirst%3DT.%2BM.%26aulast%3DDixson%26aufirst%3DJ.%2BA.%26aulast%3DBarfknecht%26aufirst%3DC.%2BF.%26aulast%3DSchoenwald%26aufirst%3DR.%2BD.%26atitle%3DN-Substituted%2520sulfonamide%2520carbonic%2520anhydrase%2520inhibitors%2520with%2520topical%2520effects%2520on%2520intraocular%2520pressure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1986%26volume%3D29%26spage%3D1488%26epage%3D1494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Zhong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, M. P.</span><span> </span><span class="NLM_article-title">Stereo-selective synthesis of (Z)-ketene selenothioacetals via hydrozirconation of alkylacetylenic selenides</span> <span class="citation_source-journal">J. Chem. Res. Synopses</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">370</span><span class="NLM_x">–</span> <span class="NLM_lpage">371</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1995&pages=370-371&author=P.+Zhongauthor=M.+P.+Guo&title=Stereo-selective+synthesis+of+%28Z%29-ketene+selenothioacetals+via+hydrozirconation+of+alkylacetylenic+selenides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DM.%2BP.%26atitle%3DStereo-selective%2520synthesis%2520of%2520%2528Z%2529-ketene%2520selenothioacetals%2520via%2520hydrozirconation%2520of%2520alkylacetylenic%2520selenides%26jtitle%3DJ.%2520Chem.%2520Res.%2520Synopses%26date%3D1995%26volume%3D9%26spage%3D370%26epage%3D371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Almajan, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innocenti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puccetti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manole, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbuceanu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saramet, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scozzafava, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supuran, C. T.</span><span> </span><span class="NLM_article-title">Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2347</span><span class="NLM_x">–</span> <span class="NLM_lpage">2352</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2347-2352&author=G.+L.+Almajanauthor=A.+Innocentiauthor=L.+Puccettiauthor=G.+Manoleauthor=S.+Barbuceanuauthor=I.+Sarametauthor=A.+Scozzafavaauthor=C.+T.+Supuran&title=Carbonic+anhydrase+inhibitors.+Inhibition+of+the+cytosolic+and+tumor-associated+carbonic+anhydrase+isozymes+I%2C+II%2C+and+IX+with+a+series+of+1%2C3%2C4-thiadiazole-+and+1%2C2%2C4-triazole-thiols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlmajan%26aufirst%3DG.%2BL.%26aulast%3DInnocenti%26aufirst%3DA.%26aulast%3DPuccetti%26aufirst%3DL.%26aulast%3DManole%26aufirst%3DG.%26aulast%3DBarbuceanu%26aufirst%3DS.%26aulast%3DSaramet%26aufirst%3DI.%26aulast%3DScozzafava%26aufirst%3DA.%26aulast%3DSupuran%26aufirst%3DC.%2BT.%26atitle%3DCarbonic%2520anhydrase%2520inhibitors.%2520Inhibition%2520of%2520the%2520cytosolic%2520and%2520tumor-associated%2520carbonic%2520anhydrase%2520isozymes%2520I%252C%2520II%252C%2520and%2520IX%2520with%2520a%2520series%2520of%25201%252C3%252C4-thiadiazole-%2520and%25201%252C2%252C4-triazole-thiols%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D2347%26epage%3D2352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misra, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlins, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursuker, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roongta, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulheron, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bol, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, K. R.</span><span> </span><span class="NLM_article-title">Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3905</span><span class="NLM_x">–</span> <span class="NLM_lpage">3927</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0201520" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3905-3927&author=K.+S.+Kimauthor=S.+D.+Kimballauthor=R.+N.+Misraauthor=D.+B.+Rawlinsauthor=J.+T.+Huntauthor=H.+Y.+Xiaoauthor=S.+Luauthor=L.+Qianauthor=W.+C.+Hanauthor=W.+Shanauthor=T.+Mittauthor=Z.+W.+Caiauthor=M.+A.+Possauthor=H.+Zhuauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=C.+Y.+Changauthor=N.+Pavletichauthor=A.+Kamathauthor=W.+G.+Humphreysauthor=P.+Maratheauthor=I.+Bursukerauthor=K.+A.+Kellarauthor=U.+Roongtaauthor=R.+Batorskyauthor=J.+G.+Mulheronauthor=D.+Bolauthor=C.+R.+Fairchildauthor=F.+Y.+Leeauthor=K.+R.+Webster&title=Discovery+of+aminothiazole+inhibitors+of+cyclin-dependent+kinase+2%3A+synthesis%2C+X-ray+crystallographic+analysis%2C+and+biological+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0201520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0201520%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DXiao%26aufirst%3DH.%2BY.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DW.%2BC.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DMitt%26aufirst%3DT.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DPavletich%26aufirst%3DN.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DBursuker%26aufirst%3DI.%26aulast%3DKellar%26aufirst%3DK.%2BA.%26aulast%3DRoongta%26aufirst%3DU.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DBol%26aufirst%3DD.%26aulast%3DFairchild%26aufirst%3DC.%2BR.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3DDiscovery%2520of%2520aminothiazole%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25202%253A%2520synthesis%252C%2520X-ray%2520crystallographic%2520analysis%252C%2520and%2520biological%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3905%26epage%3D3927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Smith, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakley, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainwright, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Womersley, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span> </span><span class="NLM_article-title">Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts</span> <span class="citation_source-journal">Mol. Cancer. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2198</span><span class="NLM_x">–</span> <span class="NLM_lpage">2208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1158%2F1535-7163.MCT-07-0142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=17699717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2198-2208&author=N.+R.+Smithauthor=N.+H.+Jamesauthor=I.+Oakleyauthor=A.+Wainwrightauthor=C.+Copleyauthor=J.+Kendrewauthor=L.+M.+Womersleyauthor=J.+M.+J%C3%BCrgensmeierauthor=S.+R.+Wedgeauthor=S.+T.+Barry&title=Acute+pharmacodynamic+and+antivascular+effects+of+the+vascular+endothelial+growth+factor+signaling+inhibitor+AZD2171+in+Calu-6+human+lung+tumor+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts</span></div><div class="casAuthors">Smith, Neil R.; James, Neil H.; Oakley, Ian; Wainwright, Anna; Copley, Clive; Kendrew, Jane; Womersley, Lynsey M.; Juergensmeier, Juliane M.; Wedge, Stephen R.; Barry, Simon T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2198-2208</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The vascular endothelial growth factor-A (VEGF-A) signaling pathway, a key stimulant of solid tumor vascularization, is primarily dependent on the activation of the endothelial cell surface receptor VEGF receptor-2 (VEGFR-2).  AZD2171 is an oral, highly potent small-mol. inhibitor of VEGFR tyrosine kinase activity that inhibits angiogenesis and the growth of human tumor xenografts in vivo.  Here, we show pharmacodynamic changes in VEGFR-2 phosphorylation induced by AZD2171.  In mouse lung tissue, a single dose of AZD2171 at 6 mg/kg inhibited VEGF-A-stimulated VEGFR-2 phosphorylation by 87% at 2 h with significant inhibition (≥60%) maintained to 24 h.  To examine inhibition of VEGFR-2 phosphorylation in tumor vasculature by immunohistochem., a comprehensive assessment of antibodies to various phosphorylation sites on the receptor was undertaken.  Antibodies to the phosphotyrosine epitopes pY1175/1173 and pY1214/1212 were found suitable for this application.  Calu-6 human lung tumor xenografts, from mice receiving AZD2171 or vehicle treatment (p.o., once daily), were examd. by immunohistochem.  A significant redn. in tumor vessel staining of phosphorylated VEGFR-2 (pVEGFR-2) was evident within 28 h of AZD2171 treatment (6 mg/kg).  This effect preceded a significant redn. in tumor microvessel d., which was detectable following 52 h of AZD2171 treatment.  These data show that AZD2171 is a potent inhibitor of VEGFR-2 activation in vivo and suggest that AZD2171 delivers therapeutic benefit in Calu-6 tumors by targeting vessels dependent on VEGFR-2 signaling for survival.  In addn., this work highlights the utility of measuring either pY1175/1173 or pY1214/1212 on VEGFR-2 as a pharmacodynamic marker of VEGFR-2 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSVvyqU1WR9bVg90H21EOLACvtfcHk0ljqi1SwVppJgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGltb4%253D&md5=a6bef539c30c6cefc41a8d0eb433e418</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0142%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DN.%2BR.%26aulast%3DJames%26aufirst%3DN.%2BH.%26aulast%3DOakley%26aufirst%3DI.%26aulast%3DWainwright%26aufirst%3DA.%26aulast%3DCopley%26aufirst%3DC.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DWomersley%26aufirst%3DL.%2BM.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26atitle%3DAcute%2520pharmacodynamic%2520and%2520antivascular%2520effects%2520of%2520the%2520vascular%2520endothelial%2520growth%2520factor%2520signaling%2520inhibitor%2520AZD2171%2520in%2520Calu-6%2520human%2520lung%2520tumor%2520xenografts%26jtitle%3DMol.%2520Cancer.%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2198%26epage%3D2208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Brave, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratcliffe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainwright, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broadbent, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sproat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farnsworth, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennequin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jürgensmeier, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibuya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, S. T.</span><span> </span><span class="NLM_article-title">Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family</span> <span class="citation_source-journal">Mol. Cancer. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">861</span><span class="NLM_x">–</span> <span class="NLM_lpage">873</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm300042x&amp;key=10.1158%2F1535-7163.MCT-10-0976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm300042x&amp;key=21441409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm300042x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlslKgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=861-873&author=S.+R.+Braveauthor=K.+Ratcliffeauthor=Z.+Wilsonauthor=N.+H.+Jamesauthor=S.+Ashtonauthor=A.+Wainwrightauthor=J.+Kendrewauthor=P.+Dudleyauthor=N.+Broadbentauthor=G.+Sproatauthor=S.+Taylorauthor=C.+Barnesauthor=J.+C.+Silvaauthor=C.+L.+Farnsworthauthor=L.+Hennequinauthor=D.+J.+Ogilvieauthor=J.+M.+J%C3%BCrgensmeierauthor=M.+Shibuyaauthor=S.+R.+Wedgeauthor=S.+T.+Barry&title=Assessing+the+activity+of+cediranib%2C+a+VEGFR-2%2F3+tyrosine+kinase+inhibitor%2C+against+VEGFR-1+and+members+of+the+structurally+related+PDGFR+family"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family</span></div><div class="casAuthors">Brave, Sandra R.; Ratcliffe, Kirsty; Wilson, Zena; James, Neil H.; Ashton, Sue; Wainwright, Anna; Kendrew, Jane; Dudley, Philippa; Broadbent, Nicola; Sproat, Graham; Taylor, Sian; Barnes, Claire; Silva, Jeffrey C.; Farnsworth, Charles L.; Hennequin, Laurent; Ogilvie, Donald J.; Juergensmeier, Juliane M.; Shibuya, Masabumi; Wedge, Stephen R.; Barry, Simon T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">861-873</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cediranib is a potent inhibitor of the VEGF receptor (VEGFR)-2 and VEGFR-3 tyrosine kinases.  This study assessed the activity of cediranib against the VEGFR-1 tyrosine kinase and the platelet-derived growth factor receptor (PDGFR)-assocd. kinases c-Kit, PDGFR-α, and PDGFR-β.  Cediranib inhibited VEGF-A-stimulated VEGFR-1 activation in AG1-G1-Flt1 cells (IC50 = 1.2 nmol/L).  VEGF-A induced greatest phosphorylation of VEGFR-1 at tyrosine residues Y1048 and Y1053; this was reversed by cediranib.  Potency against VEGFR-1 was comparable with that previously obsd. vs. VEGFR-2 and VEGFR-3.  Cediranib also showed significant activity against wild-type c-Kit in cellular phosphorylation assays (IC50 = 1-3 nmol/L) and in a stem cell factor-induced proliferation assay (IC50 = 13 nmol/L).  Furthermore, phosphorylation of wild-type c-Kit in NCI-H526 tumor xenografts was reduced markedly following oral administration of cediranib (≥1.5 mg/kg/d) to tumor-bearing nude mice.  The activity of cediranib against PDGFR-β and PDGFR-α was studied in tumor cell lines, vascular smooth muscle cells (VSMC), and a fibroblast line using PDGF-AA and PDGF-BB ligands.  Both receptor phosphorylation (IC50 = 12-32 nmol/L) and PDGF-BB-stimulated cellular proliferation (IC50 = 32 nmol/L in human VSMCs; 64 nmol/L in osteosarcoma cells) were inhibited.  In vivo, ligand-induced PDGFR-β phosphorylation in murine lung tissue was inhibited by 55% following treatment with cediranib at 6 mg/kg but not at 3 mg/kg or less.  In contrast, in C6 rat glial tumor xenografts in mice, ligand-induced phosphorylation of both PDGFR-α and PDGFR-β was reduced by 46% to 61% with 0.75 mg/kg cediranib.  Addnl. selectivity was showed vs. Flt-3, CSF-1R, EGFR, FGFR1, and FGFR4.  Collectively, these data indicate that cediranib is a potent pan-VEGFR kinase inhibitor with similar activity against c-Kit but is significantly less potent than PDGFR-α and PDGFR-β.  Mol Cancer Ther; 10(5); 861-73.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTno6b8K1-qrVg90H21EOLACvtfcHk0lhZHgvXwJ6R5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlslKgt7o%253D&md5=2d166c229ff2a012bff16fa7aead0b31</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0976%26sid%3Dliteratum%253Aachs%26aulast%3DBrave%26aufirst%3DS.%2BR.%26aulast%3DRatcliffe%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DJames%26aufirst%3DN.%2BH.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DWainwright%26aufirst%3DA.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DDudley%26aufirst%3DP.%26aulast%3DBroadbent%26aufirst%3DN.%26aulast%3DSproat%26aufirst%3DG.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DBarnes%26aufirst%3DC.%26aulast%3DSilva%26aufirst%3DJ.%2BC.%26aulast%3DFarnsworth%26aufirst%3DC.%2BL.%26aulast%3DHennequin%26aufirst%3DL.%26aulast%3DOgilvie%26aufirst%3DD.%2BJ.%26aulast%3DJ%25C3%25BCrgensmeier%26aufirst%3DJ.%2BM.%26aulast%3DShibuya%26aufirst%3DM.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26atitle%3DAssessing%2520the%2520activity%2520of%2520cediranib%252C%2520a%2520VEGFR-2%252F3%2520tyrosine%2520kinase%2520inhibitor%252C%2520against%2520VEGFR-1%2520and%2520members%2520of%2520the%2520structurally%2520related%2520PDGFR%2520family%26jtitle%3DMol.%2520Cancer.%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D861%26epage%3D873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Pandey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volkots, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seroogy, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambing, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchaleelaha, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollenbach, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarborough, R. M.</span><span> </span><span class="NLM_article-title">Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3772</span><span class="NLM_x">–</span> <span class="NLM_lpage">3793</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020143r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3772-3793&author=A.+Pandeyauthor=D.+L.+Volkotsauthor=J.+M.+Seroogyauthor=J.+W.+Roseauthor=J.+C.+Yuauthor=J.+L.+Lambingauthor=A.+Hutchaleelahaauthor=S.+J.+Hollenbachauthor=K.+Abeauthor=N.+A.+Gieseauthor=R.+M.+Scarborough&title=Identification+of+orally+active%2C+potent%2C+and+selective+4-piperazinylquinazolines+as+antagonists+of+the+platelet-derived+growth+factor+receptor+tyrosine+kinase+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm020143r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020143r%26sid%3Dliteratum%253Aachs%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DVolkots%26aufirst%3DD.%2BL.%26aulast%3DSeroogy%26aufirst%3DJ.%2BM.%26aulast%3DRose%26aufirst%3DJ.%2BW.%26aulast%3DYu%26aufirst%3DJ.%2BC.%26aulast%3DLambing%26aufirst%3DJ.%2BL.%26aulast%3DHutchaleelaha%26aufirst%3DA.%26aulast%3DHollenbach%26aufirst%3DS.%2BJ.%26aulast%3DAbe%26aufirst%3DK.%26aulast%3DGiese%26aufirst%3DN.%2BA.%26aulast%3DScarborough%26aufirst%3DR.%2BM.%26atitle%3DIdentification%2520of%2520orally%2520active%252C%2520potent%252C%2520and%2520selective%25204-piperazinylquinazolines%2520as%2520antagonists%2520of%2520the%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3772%26epage%3D3793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Mortlock, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foote, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heron, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, J. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savi, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dousson, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaton, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odedra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keen, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crafter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brightwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khatri, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kearney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKillop, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhead, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span> </span><span class="NLM_article-title">Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of Aurora B kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2213</span><span class="NLM_x">–</span> <span class="NLM_lpage">2224</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061335f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2213-2224&author=A.+A.+Mortlockauthor=K.+M.+Footeauthor=N.+M.+Heronauthor=F.+H.+Jungauthor=G.+Pasquetauthor=J.+J.+M.+Lohmannauthor=N.+Warinauthor=F.+Renaudauthor=C.+D.+Saviauthor=N.+J.+Robertsauthor=T.+Johnsonauthor=C.+B.+Doussonauthor=G.+B.+Hillauthor=D.+Perkinsauthor=G.+Hatterauthor=R.+W.+Wilkinsonauthor=S.+R.+Wedgeauthor=S.+P.+Heatonauthor=R.+Odedraauthor=N.+J.+Keenauthor=C.+Crafterauthor=E.+Brownauthor=K.+Thompsonauthor=S.+Brightwellauthor=L.+Khatriauthor=M.+C.+Bradyauthor=S.+Kearneyauthor=D.+McKillopauthor=S.+Rheadauthor=T.+Parryauthor=S.+Green&title=Discovery%2C+synthesis%2C+and+in+vivo+activity+of+a+new+class+of+pyrazoloquinazolines+as+selective+inhibitors+of+Aurora+B+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm061335f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061335f%26sid%3Dliteratum%253Aachs%26aulast%3DMortlock%26aufirst%3DA.%2BA.%26aulast%3DFoote%26aufirst%3DK.%2BM.%26aulast%3DHeron%26aufirst%3DN.%2BM.%26aulast%3DJung%26aufirst%3DF.%2BH.%26aulast%3DPasquet%26aufirst%3DG.%26aulast%3DLohmann%26aufirst%3DJ.%2BJ.%2BM.%26aulast%3DWarin%26aufirst%3DN.%26aulast%3DRenaud%26aufirst%3DF.%26aulast%3DSavi%26aufirst%3DC.%2BD.%26aulast%3DRoberts%26aufirst%3DN.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DDousson%26aufirst%3DC.%2BB.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DHatter%26aufirst%3DG.%26aulast%3DWilkinson%26aufirst%3DR.%2BW.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DHeaton%26aufirst%3DS.%2BP.%26aulast%3DOdedra%26aufirst%3DR.%26aulast%3DKeen%26aufirst%3DN.%2BJ.%26aulast%3DCrafter%26aufirst%3DC.%26aulast%3DBrown%26aufirst%3DE.%26aulast%3DThompson%26aufirst%3DK.%26aulast%3DBrightwell%26aufirst%3DS.%26aulast%3DKhatri%26aufirst%3DL.%26aulast%3DBrady%26aufirst%3DM.%2BC.%26aulast%3DKearney%26aufirst%3DS.%26aulast%3DMcKillop%26aufirst%3DD.%26aulast%3DRhead%26aufirst%3DS.%26aulast%3DParry%26aufirst%3DT.%26aulast%3DGreen%26aufirst%3DS.%26atitle%3DDiscovery%252C%2520synthesis%252C%2520and%2520in%2520vivo%2520activity%2520of%2520a%2520new%2520class%2520of%2520pyrazoloquinazolines%2520as%2520selective%2520inhibitors%2520of%2520Aurora%2520B%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2213%26epage%3D2224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Bemis, G. W.; Harbeson, S. L.; Ledeboer, M.</span><span> </span><span class="NLM_article-title">Inhibitors of JAK protein kinase</span>. US 20040038992 A120040226.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Bemis%2C+G.+W.%3B+Harbeson%2C+S.+L.%3B+Ledeboer%2C+M.+Inhibitors+of+JAK+protein+kinase.+US+20040038992+A120040226."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBemis%26aufirst%3DG.%2BW.%26atitle%3DInhibitors%2520of%2520JAK%2520protein%2520kinase" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i70"><a href="/doi/suppl/10.1021/jm300042x">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_06418"></div></div></div></div></div><hr /></hr><p class="last">IC<sub>50</sub> values of <b>1</b> against human FLT3 and pharmacokinetic properties of <b>20c</b> and <b>20e</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300042x/suppl_file/jm300042x_si_001.pdf">jm300042x_si_001.pdf (210.07 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm300042x&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-8%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm300042x%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm300042x" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b3e02ca003c5e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
